

UNIVERSITÀ DEGLI STUDI DI MILANO

DIPARTIMENTO DI SCIENZE FARMACOLOGICHE E BIOMOLECOLARI

CORSO DI DOTTORATO IN

SCIENZE FARMACOLOGICHE SPERIMENTALI E CLINICHE

XXX Ciclo



PhD THESIS

**DIET, OXIDATIVE STRESS STATUS AND INFLAMMATION IN  
PATIENTS WITH CARDIOVASCULAR DISEASE: IN SEARCH FOR  
A LINK**

Alessandro Di Minno, Pharm. D.

Matricola R11108

**TUTOR**

Professor Marina Camera

**COORDINATORE DEL DOTTORATO**

Professor Alberico L. Catapano

**ANNO ACCADEMICO 2016/2017**

## Contents

Abstract .....	5
Introduction.....	9
<b>History</b> .....	10
Ancel Keys' initiative.....	10
Studies supporting Ancel Keys' observation .....	12
<b>MD scores</b> .....	17
<b>The protective role of the individual components of the MD: current evidence.</b> .....	20
<b>Single food components</b> .....	21
<b>Clinical Vascular Diseases</b> .....	31
Athrothrombosis. ....	31
Cardiovascular Disease .....	31
Ischemic Heart Disease.....	32
Congestive Heart Failure .....	32
Atrial Fibrillation .....	33
Rheumatic Heart Disease .....	33
Cerebrovascular disease.....	34
Subarachnoid haemorrhage .....	34
Peripheral vascular disease .....	35
<b>Subclinical Vascular Diseases: Methods of Detection</b> .....	37
Carotid Intima media thickness (c-IMT) .....	37
High resolution B-Mode Eco-tomography.....	37
Ultrasound anatomy of carotid arteries.....	37
Thickness of the intramammary complex (or extracranial carotids IMT) .....	38
<b>MD and subclinical disease</b> .....	40
MD and c-IMT .....	40
MD and Carotid Plaques .....	40
MD and Vascular Stiffness .....	41
MD and FMD.....	42
<b>MD and Conventional Vascular Risk Factors for CAD</b> .....	44
Blood pressure.....	44
Physical activity.....	45
Glucose control.....	46
Total cholesterol.....	47

LDL-cholesterol .....	48
HDL-cholesterol .....	48
Triglycerides.....	50
Smoking habit .....	50
Obesity.....	51
Sex.....	52
Aging .....	53
<b>MD and Emerging Vascular Risk Factors</b> .....	54
Fatty acids profile .....	54
Inflammation .....	55
Oxidative stress. ....	57
Rationale.....	61
Aims of the present study .....	63
Methods .....	64
<b>The IMPROVE Study</b> .....	64
Study design. ....	64
Ultrasonographic protocol. ....	65
Laboratory analyses.....	68
Nutrition variables, physical activity, smoking habits, and psychosocial variables. ...	69
Quality control.....	69
The Mediterranean-Like Dietary Pattern (MLDP) score.....	70
<b>The RISMED Study</b> .....	72
Study objectives.....	72
Study design .....	72
Nutritional advice. ....	72
Laboratory analyses.....	73
FAs profile determination.....	74
Measurement of GSH and GSSG.....	75
Method development and validation.....	76
Calibration standards and quality controls .....	76
Linearity, calibration, and matrix effects evaluation.....	76
Precision, accuracy and recovery. ....	77
Lower limit of detection (LOD) and quantification (LLOQ).....	77
<b>Statistical analyses</b> .....	78

The IMPROVE study.....	78
The RISMED study.....	78
Results .....	80
<b>The IMPROVE Study</b> .....	80
Adherence to MLDP.....	82
Validation analysis (MLDP score vs VEs).....	88
MLDP score and c-IMT.....	90
MLDP score and indices of inflammation.....	97
<b>The RISMED Study</b> .....	99
Correlation between inflammatory markers and MD adherence.....	100
MD and FAs profile .....	100
MD and Oxidative stress status .....	103
Correlation between oxidative stress and single items of the MD .....	104
Correlation between oxidative stress and FAs profile .....	105
Discussion .....	107
<b>MLDP adherence and c-IMT or c-IMT change over time.</b> .....	107
<b>MLDP score adherence, vascular events and latitude.</b> .....	109
<b>MD and inflammation.</b> .....	111
<b>MD and Oxidative stress.</b> .....	113
<b>MD and FAs profile</b> .....	115
Limitations .....	116
Conclusions.....	117
References.....	119

## **Abstract**

**BACKGROUND.** Previous studies have provided a rationale for understanding the health benefits of Mediterranean Diet (MD) against a variety of chronic diseases.

**OBJECTIVES AND EVIDENCE ANALYZED.** We have used new data from the IMPROVE Study -a multicenter, longitudinal, observational study, carried out in five European countries- and fresh information from the RISMED, a study carried out in our Institution in subjects with a recent history of coronary revascularization to address: 1) the relationship between MD adherence and carotid intima-media thickness (c-IMT) progression; 2) whether such relationship is similar in populations with different nutritional patterns, and 3) whether the relationship between MD, baseline carotid IMT, and clinical events involves changes in inflammation, oxidative stress, and fatty acid [FA] composition.

**FINDINGS.** In the analysis of the IMPROVE Study we have found: 1) a significant negative trend between most of the c-IMT-progression variables and a new relatively simple food frequency questionnaire to evaluate a Mediterranean-like dietary pattern (MLPD) score, validated *a priori* vs VEs in different European Countries; 2) that the significant association between MLDP adherence and VEs is independent of baseline c-IMT and c-IMT progression, and 3) that MLDP score adherence is associated to changes both in inflammatory markers and white blood cells counts. Information from the RISMED Study documented that: 1) MD adherence significantly affects indices of inflammation and oxidative stress balance; 2) blood FA profile is an index of the quality of food intake which might be used to estimate diet quality and compliance with nutritional advices; 3) it is possible to favorably modify patients' plasma FA profiles by consuming a MD, and 4) a relationship exists between inflammatory markers/oxidative stress status and modifications of the blood FA pattern.

**CONCLUSIONS AND RELEVANCE.** MD adherence is key to reduce oxidative stress, inflammation and VEs in subjects at risk of cardiovascular events. Since common approaches that simultaneously target old and new risk factors for cardiovascular

disease enhance cardio-protection and longevity, the need for evaluating MD as a strategy for a better health at older ages should be explored thoroughly.

## **Riassunto.**

**STATO DELL'ARTE.** Studi precedenti hanno fornito una spiegazione degli effetti benefici della dieta mediterranea (MD) nei confronti di varie malattie croniche.

**OBIETTIVI E DATI ANALIZZATI.** Abbiamo utilizzato nuovi dati dallo studio IMPROVE - uno studio multicentrico, longitudinale e osservazionale, svolto in cinque paesi europei - e informazioni preliminari dal RISMED, uno studio condotto presso il nostro Istituto in soggetti con una recente storia di rivascolarizzazione coronarica per valutare : 1) la correlazione: aderenza ad una MD e progressione dello spessore medio-intimale della carotide (c-IMT); 2) se tale correlazione sia simile in popolazioni con differenti modelli nutrizionali, e 3) se la relazione tra MD, c-IMT al basale ed eventi clinici (VEs), si accompagni a cambiamenti negli indici di infiammazione, di stress ossidativo e di composizione ematica in acidi grassi [FA].

**RISULTATI.** Dalle nuove analisi dello studio IMPROVE è emerso: 1) un significativo trend negativo di associazione tra la maggior parte delle variabili di progressione del c-IMT e il punteggio derivante da un nuovo score nutrizionale (MLPD), generato da un questionario relativamente semplice di frequenza di assunzione di 7 alimenti tipici di una dieta mediterranea. Tale score è stato in precedenza validato contro l'insorgenza di eventi vascolari (VEs) nelle diverse popolazioni europee coinvolte nello studio IMPROVE; 2) che l'associazione significativa tra l'aderenza allo score MLDP e i VEs è indipendente dalla progressione del c-IMT e dal c-IMT al basale, e 3) che l'aderenza allo score MLDP è associata a cambiamenti sia nei marcatori di infiammazione che nella conta dei globuli bianchi. I risultati dello studio RISMED documentarono che: 1) l'aderenza alla DM influenza in maniera significativa gli indici di infiammazione e di stress ossidativo; 2) che il profilo dei FA del sangue è un indice della qualità del cibo assunto e che tale indice può servire a stimare la qualità degli alimenti ingeriti e la conformità dei pazienti ai consigli nutrizionali; 3) che il consumo di una DM può modificare favorevolmente il profilo in FA del plasma dei pazienti, e 4) che esiste una correlazione tra marcatori dello stato infiammatorio e di stress ossidativo e modifiche del pattern di FA.

**CONCLUSIONI E RILEVANZA.** In soggetti a rischio di eventi cardiovascolari, l'adesione ad una MD è fondamentale per ridurre lo stress ossidativo, l'infiammazione e gli VEs. Poiché gli approcci che contemporaneamente modificano vecchi e nuovi fattori di rischio per la malattia cardiovascolare aumentano la protezione cardiaca e la longevità, occorre esplorare in modo approfondito la MD come strategia per una migliore salute nell'anziano.



## Introduction

In 2013, UNESCO recognized the Mediterranean Diet (MD) as an “Intangible Cultural Heritage of Italy, Portugal, Spain, Morocco, Greece, Cyprus and Croatia”. Despite different habits in the area, common characteristics prevail in the dietary patterns in the Mediterranean basin: high consumption of olive oil, legumes, unrefined cereals, fruits, and vegetables, moderate/high fish consumption, moderate consumption of dairy products (mostly as cheese and yogurt), moderate wine consumption (especially during meals), and low consumption of meat and meat products. Olive oil –that has a central position in all such dietary patterns-, is important not only for its own health benefits, but also because it is often consumed with large quantities of vegetables in the form of salads and large quantities of legumes in the form of cooked foods. In addition to olive oil and olives, other essential components of the MD are wheat, grapes, and their derivatives (**Figure 1**). The Italian variant of MD is characterized by high pasta consumption, whereas fish consumption is particularly high in Spain. <sup>1, 2</sup> Total fat content is generally  $\geq 40\%$  (Greece), or  $\geq 30\%$  (Italy) of total energy intake. <sup>1</sup> However, the monounsaturated to saturated fats ratio of MD in Southern European countries is much higher than in other regions of the world, including northern Europe and North America. Thus, it is appropriate to consider these patterns as variants of a single entity, and to define MD as a modern dietary approach inspired by the traditional diets of the countries bordering the Mediterranean Sea. <sup>3</sup>

**Figure 1** Mediterranean Diet: geographical distribution and major components



Historically, it might be convenient to define MD as the dietary pattern in the olive-growing areas of the Mediterranean regions in the late 1950s and early 1960s, when the consequences of World War II were over and the fast-food culture had not yet invaded the basin.<sup>1</sup>

### **History**

In the Greek medical tradition, first 'rational' medical treatises were written in the fifth century BC by a series of authors associated with Hippocrates and his thought over a period of more than 150 years. In the thought of the Hippocratic doctors, food was absorbed into the body to be broken down into nutritional substances to sustain the body and to guarantee the body's heat. How these products acted within the body, however, was not clear.

In his adaptation of the Hippocratic system, Galen (second century AD) extended and refined the Hippocratic system and identified nutrition, drug therapy and surgery as three branches of medicine. Accordingly, many doctors, including Galen wrote cookery books.<sup>4</sup> Galen wrote extensive treatises on nutrition, and clarified that diet might also have drug-based outcomes. Whether and to what extent diet was an integral entity or the sum of identifiable components (e.g., olive oil, fruits, vegetables) to be evaluated separately, or whether the beneficial effects of a diet (e.g. the MD) or of its major components were reproduced in different populations (e.g. in people living far from the Mediterranean region) was not addressed by Galen.<sup>1</sup>

### **Ancel Keys' initiative.**

Ancel Keys developed the concept that, at the population level, "rich" diets might be linked to higher plasma cholesterol and to a higher than normal tendency to coronary artery disease (CAD).<sup>5</sup> This observation was pursued during his long-stay in Italy (Pioppi), where he highlighted that the rate of ischemic heart disease was lower in Mediterranean regions.

This was tested in the "Seven Countries Study", a longitudinal survey of population samples from Finland, Greece, Italy, Japan, The Netherlands, U.S. and Yugoslavia, with at least 5-year follow-up. Medical records; ECGs at rest and after exercise, and a blood sample were obtained from population-based men 40-59 years old. The basic concept of a 3-way relationship between dietary lipids, serum cholesterol, and CAD emerged from the results of the Seven Countries Study<sup>6, 7</sup>. In cross-population analyses, 10-yr coronary mortality rate was strongly related to average dietary saturated fatty acid intake. Higher values were found in Finnish, Dutch, and American samples, intermediate intake levels in the Mediterranean population samples, and low values in Japanese men. Similar findings were found for serum cholesterol: the highest the sample average cholesterol level, the highest the coronary mortality rate. In addition, dietary saturated fatty acids were closely related to serum cholesterol. Overall, these data argued for serum cholesterol as a major CAD risk factor, and for the need of a population-wide prevention of epidemic cardiovascular (CV) disease (CVD)<sup>8</sup>.

## **Studies supporting Ancel Keys' observation**

**The Lyon Diet Heart Study** is a prospective, randomized single-blinded secondary prevention multicenter trial -death and nonfatal AMI being its primary endpoints-, designed to test the hypothesis that a MD enriched with  $\alpha$ -linoleic acid (ALA) might improve the prognosis of survivors of a first acute myocardial infarction (AMI).<sup>9-12</sup> Of the 600 survivors enlisted, half adopted a prudent diet and as many adopted a Mediterranean-type of diet, with no more butter, cream and delicatessen (which were replaced by poultry); less meat (beef, lamb, pork), and more bread, more cereals, more legumes and beans, more fresh vegetables and fruits, more fish, and more olive oil. Olive oil was recommended for salad and food preparations. For subjects who did not like it, olive oil was replaced by an experimental canola oil-based margarine (erucid acid free rapeseed oil). All dietary instructions were detailed and customized to each patient.<sup>9-12</sup> This strategy was well accepted by the patients who, at the end of the trial, were still following dietary patterns superimposable to those of the protocol.<sup>9-12</sup>

The whole protocol stemmed from the lowest rates in the world of cardiovascular diseases (and of vascular complications in patients with established CAD) in populations either following a MD or a diet low in n-6 fatty acids and rich in n-3 fatty acids (a major component of fish and fish oil).<sup>9-12</sup> In addition to a low n-6/ n-3 fatty acid ratio, and to the high oleic acid intake (and the low saturated fat intake) of the traditional MD, patients were instructed to lower animal fat consumption and to use vegetable oils such as olive oil (that does not contain ALA) and/or canola oil (that contains ALA and moderate amounts of LA).<sup>12</sup> The experimental MD tested in the trial supplied less than 30% of energy from fats and less than 8% of energy from saturated fats. As to essential fatty acids, the intake of LA, the main n-6 fatty acid, was restricted to 4% of energy and the intake of ALA, the main n-3 fatty acid, made up more than 0.6% of energy.<sup>13</sup>

The subjects were followed up for 5 years starting 6 months after the ischemic event.

At the 2-year follow-up, there were 16 CV deaths in the control group and 3 in the experimental one. After correction for other factors, a surprisingly high (76%) reduction in the risk of cardiac death was found during the observation period.<sup>12</sup> Consistent with the protective effect of the diet, a striking 50 to 70% reduction of the risk of recurrence was reported after four years of follow-up.<sup>9-12</sup> Such reduction was associated with enhanced plasma levels of eicosapentaenoic acid (EPA) and its parent fatty acid, ALA. In keeping with this, plasma arachidonic acid (the fatty acid precursor of the 2 series of prostaglandins and thromboxane), was significantly ( $p < 0.005$ ) reduced in subjects who had received the experimental diet. In addition, vitamin E, which has been previously reported to reduce the risk of CAD<sup>14</sup>, was significantly ( $p < 0.005$ ) increased while granulocyte count was lowered. On the other hand, high-normal white cells counts have been related with cerebral thrombosis and re-infarction, maximal association being found with granulocyte counts.<sup>15-17</sup> The involvement of white cells in blood rheology, endothelial cell injury (free radical generation), and blood coagulation (generation of tissue factor) provides a biological plausibility for this association. Thus, mechanisms other than polyunsaturated fatty acids changes should be considered in the cardio-protective effects of this diet.<sup>18-20</sup>

**European Prospective Investigation into Cancer and Nutrition (EPIC).** This is an ongoing multi-center prospective cohort study designed to investigate the relationship between nutrition and cancer, with the potential for studying other diseases.<sup>21</sup> EPIC is the largest single resource available today world-wide for prospective investigations on the etiology of cancers (and other diseases) that can integrate questionnaire data on lifestyle and diet, biomarkers of diet and of endogenous metabolism (e.g. hormones and growth factors) and genetic polymorphisms.<sup>21</sup> The study currently includes 519, 978 participants (366, 521 women and 153, 457 men, mostly aged 35–70 years) in 23 centers located in 10 European countries, to be followed for cancer incidence and cause-specific mortality for several decades. At enrolment, which took place between 1992 and

2000 at each of the different centers, information addressing usual diet was collected through a dietary questionnaire and information on lifestyle variables through a non-dietary questionnaire. Anthropometric measurements were performed and blood samples taken; plasma, serum, red cells and buffy coat fractions were separated and aliquoted were stored mostly in liquid nitrogen for long-term evaluations.<sup>21</sup> The usual dietary intake during the year preceding enrollment was assessed with the use of a semi-quantitative validated food-frequency questionnaire including approximately 150 commonly consumed foods and beverages and the questionnaire was administered by specially trained interviewers.<sup>22, 23</sup> For each of the items, individuals were asked to report their frequency of consumption and portion size, the latter being calculated based on information provided on household units and 76 photographs of usual portion sizes. Standard portion sizes were used for the estimation of consumed quantities,<sup>23</sup> and nutrient intakes were calculated by means of a food-composition data base modified to accommodate dietary specificities of individual Countries.<sup>24</sup> Eventually, 14 all-inclusive food groups or nutrients were considered: meat, fish, eggs, dairy products, potatoes, vegetables, legumes, fruits and nuts, cereals, sugar and sweets, nonalcoholic beverages, saturated lipids and margarines, and monounsaturated (mainly olive oil), and polyunsaturated lipids (vegetable-seed oils). For each participant, intake (g/day) of each of the indicated groups and total energy intake were calculated.<sup>22</sup> To calibrate dietary measurements, a standardized, computer-assisted 24-hour dietary recall was implemented at each center on stratified random samples of the participants, for a total of 36,900 subjects.

On 22,043 Greek adults from the Greek cohort, Trichopoulou et al. carried out an observational prospective study to investigate the capacity of a 10-point scale Mediterranean (MD) score to predict the overall and CAD mortality. During a median of 44 months of follow-up, there were 275 deaths. A high adherence to the MD was associated with a lower total mortality (adjusted hazard ratio [HR] for death associated with a two-point increment in the MD score, 0.75 [95 %

confidence interval [CI], 0.64 to 0.87]). An inverse association with high adherence to MD diet was true for both death due to CAD (HR, 0.67 [95% CI, 0.47 to 0.94]) and death due to cancer (HR, 0.76 [95% CI, 0.59 to 0.98]).<sup>a</sup> The association with the MD score appeared to be slightly stronger for mortality from CAD than for mortality from cancer, although mortality from cancer was reduced significantly. The inverse association between the Mediterranean-diet score and total mortality was independent of sex, body-mass index (BMI), waist-to-hip ratio, smoking, level of education and of physical activity. In analyses stratified according to age, the relation between the MD score and mortality was significant among participants 55 years of age or older but not among participants younger than 55 years of age (P=0.34).<sup>24</sup> In analyses adjusted for age, sex, BMI, smoking habits, waist to-hip ratio, energy-expenditure score, total energy intake, and years of education, the only individual measures that were predictive of total mortality were the intake of fruits and nuts and the ratio of monounsaturated/saturated lipids.

**PREDIMED Study** was a multicenter nutritional primary prevention randomized clinical trial (RCT) carried out in Spain between 2003 and 2011 which tested the long-term effects of the MD on incident CVD in men and women at high CVD risk (but no history of previous CVD episodes at enrolment) aged 55-75 years (men) or 60- 80 years (women). Participants were selected from >200 primary care facilities affiliated with 11 recruiting sites. The presence of either type 2 diabetes mellitus (T2DM) or ≥3 risk factors (smoking, overweight or obesity, hypertension/HTN, dyslipidemia/DLP, and family history of early-onset CVD) were major criteria for recruitment. Participants were randomized into one of three diets: 1) MD supplemented with extra-virgin olive oil (EVOO); 2) MD supplemented with nuts; and 3) control diet (advice on a low-fat diet). Trained dietitians delivered the intervention. Throughout the study, participants attended individual visits and group sessions in which they were instructed to follow their diets. Participants also

---

<sup>a</sup> An example of dietary changes resulting in such an increment would be a substantial increase in the intake of monounsaturated lipids relative to saturated lipids and a substantial reduction in the intake of meat.

attended quarterly group sessions where they received written material with information on key Mediterranean foods and seasonal shopping lists, menus and specific recipes for a typical week. of EVOO (1 L per week, including a minimum of 50 mL/day for participants and the rest for family needs) or mixed nuts (30 g/day: 15 g walnuts, 7.5 g almonds and 7.5 g hazelnuts plus extra allocations for the family) were supplied at no cost to each participant randomly assigned to the MD groups on a quarterly basis during the group sessions with dietitians. Participants in the control diet group attended similar quarterly sessions with explanations and written material on the low-fat diet and they received non-food gifts in these sessions. The three diets were energy-unrestricted and no intervention on physical activity was carried out. Validated food frequency questionnaires covering 137 foods were collected yearly by the dietitians.<sup>25</sup> Fasting blood and spot urine were obtained and serum, plasma and DNA samples were stored. Urinary hydroxytyrosol and plasma ALA measurements were determined in random sub-samples and were employed as objective biomarkers of adherence to EVOO and walnut consumption, respectively. The pre-specified primary end-point of the trial was incident CVD (a composite of non-fatal myocardial infarction/MI, non-fatal stroke or CVD death). The trial was neither powered nor designed to independently assess each of the three components of the combined end-point. Secondary outcomes included total mortality, T2DM, metabolic syndrome (MetS), peripheral arterial disease (PAD), atrial fibrillation (AF), neurodegenerative diseases and major cancers. An event adjudication committee, whose members were blinded to group allocation, was responsible for event ascertainment. As many as 7,447 participants were randomized into the three intervention groups that were well balanced with respect to their baseline characteristics and pharmacologic treatments. The mean age of participants was 67 years, 57% were women and the mean body mass index was 30 kg/m<sup>2</sup>. The baseline prevalence of diabetes was nearly 50% and the prevalence of DLP and HTN was higher than 70% and 80%, respectively. Compliance with the intervention in the two MD groups was adequate.<sup>26</sup> There were no between-group differences in physical activity during



the study. The effect of baseline adherence to the 14-point score with respect to the subsequent incidence of the primary CVD end-point during follow-up was assessed.<sup>27</sup> The multivariable-adjusted HR for participants with a baseline 14-item screener in the 2nd-3rd quintile who scored between 8-9 points was 0.72 (95% CI: 0.55-0.94), and for those with the highest adherence (two upper quintiles, scoring 10-14 points), it was 0.47 (CI: 0.35-0.65). The observed rates per 1,000 person-years for the primary end-point were 8.1, 8.0, and 11.2 in the MD+EVOO, MD+nuts, and control groups, respectively. The unadjusted HRs were 0.70 (CI, 0.53-0.91) for the MD+EVOO and 0.70 (CI, 0.53-0.94) for the MD+nuts. The pre-specified primary end-point of the trial occurred in 288 participants during a median follow-up of 4.8 years. No effect on all-cause mortality was apparent. Significant disease risk reductions were observed for incident T2DM (in the subset of participants initially free of T2DM)<sup>28, 29</sup> and for other CVD outcomes, such as PAD<sup>30</sup> and AF<sup>31</sup>. In comparison with the control group, participants randomized to either MD were more likely to show reversion of MetS, with HR 1.35 (CI 1.15–1.58) for the MD+EVOO, and HR 1.28 (CI 1.08–1.51) for the MD+nuts. Similarly, the MD interventions reduced blood pressure (BP) and the risk of HTN<sup>32, 33</sup>, and slowed the progression of subclinical atherosclerosis, as determined by changes in ultrasound-assessed carotid intima-media thickness (c-IMT) and plaque measurements.<sup>34, 35</sup>

### **MD scores**

The need to measure dietary intake without error, propose food frequency questionnaires (FFQs) as the gold-standard technique to reach this goal being FFQs low-cost and easy-to-use tools.<sup>36, 37</sup> Traditionally, they are used to describe habitual dietary intake, particularly in epidemiologic studies. However, in the last 10 years, they were also used to stratify patients according to their healthy dietary habit and, moreover to better characterize they risk to develop different pathology (e.g. cancer, CVD). Among them 2 are the most widely used and

accepted FFQs: European Prospective Investigation into Cancer and Nutrition (EPIC)<sup>24</sup> and the Prevención con Dieta Mediterránea (PREDIMED).<sup>38</sup>

**EPIC Score.** The Mediterranean food pattern of EPIC score was evaluated by developing an a priori 10-point score.<sup>24, 39</sup> A value of 0 or 1 was assigned to each of nine components, with the sex-specific medians used as the cut-off points. For beneficial components (vegetables, legumes, fruits and nuts, cereal, and fish), persons whose consumption was below the median were assigned a value of 0, and all others were assigned a value of 1. For detrimental components (meat and dairy products), persons whose consumption was below the median were assigned a value of 1, and all others were assigned a value of 0. A value of 1 was given to men consuming 10–<50 g of alcohol per day and to women consuming 5–25 g. For lipid intake, the ratio of monounsaturated fatty acids [MUFAs] to saturated fatty acids [SFA] was calculated. Those above the sex-specific median in the MUFA/SFA ratio were given 1 point. Thus, the total Mediterranean diet score ranged from 0 (minimal adherence to the traditional MD) to 9 (maximal adherence)

**PREDIMED Score.** The PREDIMED SCORE is a validated 14-point MD screener<sup>40</sup> used by dietitians as a tool to both assess actual adherence to the MD and enhance future adherence. These 14 items are:

1. Use of olive oil as the main culinary fat
2. Consumption of  $\geq 4$  tablespoons/d of olive oil (including oil used for frying, salads, out-of-house meals, etc.)
3. Consumption of  $\geq 2$  servings/d of vegetables
4. Consumption of  $\geq 3$  servings/d of fruits
5. Consumption of  $< 1$  serving/d of red meat, hamburger or meat products (ham, sausage, etc.)
6. Consumption of  $< 1$  serving/d of butter, margarine, or cream
7. Consumption of  $< 1$  serving/d of sweetened and/or carbonated beverages

8. Consumption of  $\geq 1$  serving/d of wine
9. Consumption of  $\geq 3$  servings/week of legumes
10. Consumption of  $\geq 3$  servings/week of fish or shellfish
11. Consumption of  $< 3$  servings/week of commercial sweets or pastries (not homemade), such as cakes, cookies, biscuits or custard
12. Consumption of  $\geq 3$  servings/week of nuts (including peanuts)
13. Preferential consumption of chicken, turkey or rabbit meat instead of veal, pork, hamburger or sausage
14. Consumption of  $\geq 2$  servings/week of sofrito, a sauce made with tomato and onion, leek or garlic and simmered with olive oil.

Dietitians collected yearly food frequency questionnaires covering 137 foods.<sup>41</sup>

### **The protective role of the individual components of the MD: current evidence.**

Biochemical, clinical, and epidemiologic research during the last 15 years has provided a rationale for the health benefits of the MD against a wide range of chronic diseases.<sup>42, 43</sup> Although the responsible compounds/mechanisms of such protection have not been established, an inverse relation of vegetables and fruits consumption with cancer having been shown in Italy, France, Spain, and Greece.<sup>44-51</sup> Four recently reviewed epidemiologic studies<sup>52, 53</sup> show that olive oil conveys some form of protection against breast cancer, and limited data suggest that olive oil may reduce the risk of endometrial and ovarian cancer.<sup>46, 54</sup> Vitamin E, which exists in abundance in olive oil, is associated with a statistically significant decrease in the risk of sporadic colorectal cancer in carriers of wild-type ki-ras genotype.<sup>55</sup> Moreover, an olive oil compound, 2-(3,4-dihydroxyphenyl) ethanol (DPE), is a potent specific inhibitor of lipoxygenase activities.<sup>56</sup> MD is associated with high intakes of Ca<sup>2+</sup> Mg<sup>2+</sup> and K<sup>1+</sup>, which exert major beneficial effects on a wide range of physiologic processes.<sup>57</sup> Moderate daily consumption of wine during meals is a characteristic of the MD.<sup>58</sup> Moderate drinking of alcoholic beverages reduces the risk of CAD probably by increasing levels of serum high-density lipoprotein (HDL) cholesterol. The latter levels are probably as important for the prevention of CAD as low levels of serum low-density lipoprotein (LDL) and total cholesterol.<sup>59, 60</sup> Moreover, monounsaturated fat, including olive oil, increases HDL cholesterol more than does polyunsaturated fat<sup>61</sup> and carbohydrates<sup>61-63</sup> making it an optimal energy-generating nutrient.<sup>42, 43</sup> Olive oil and complex carbohydrates derived from legumes, whole-wheat bread, and cereals, prevent/modulate postprandial hyperglycemia, which could be important in MetS. Finally, consumption of olive oil-derived monounsaturated fat may increase bone mineral density thus reducing the risk of osteoporosis.<sup>3</sup> Details of individual components of the MD will be provided below.

## Single food components

**Fats.** Both the AHA/ACC and ESC guidelines strongly endorse replacing saturated and trans-fatty acids with monounsaturated and polyunsaturated fats for both primary and secondary prevention.<sup>64, 65</sup> In addition to recent RCT data,<sup>38</sup> early meta-analyses primarily evaluating the effects of fatty acids on surrogate markers of CV disease, indicated that MUFA intake increases lipid levels, including HDL.<sup>66</sup> A large meta-analysis suggests an inverse correlation between blood pressure and MUFAs intake.<sup>67</sup> The cardioprotective effects of olive oil are accounted for by the presence of its phenolic compounds obtained from the water-soluble fraction and include mostly the low-molecular-weight molecule hydroxytyrosol and oleuropein, which are both potent antioxidants, free radical scavengers, and enzyme modulators.<sup>68</sup> Two randomized, blinded crossover trials have assessed the antioxidant effect of dietary supplementation of extra virgin olive oil in humans: EUROLIVE<sup>69</sup> and the Virgin Olive Oil Study (VOLOS).<sup>70</sup> The Italian VOLOS trial<sup>70</sup> studied the inflammatory protective potential of olive oil in 22 mildly dyslipidemic patients. After a 7-week treatment period, no change in overall serum lipid profiles were found. In contrast, total antioxidant capacity of plasma and circulating levels of serum thromboxane B<sub>2</sub> (an index of maximal platelet activation) were both reduced by the administration of olive oil. In the Effect of Olive Oil on Oxidative Damage in European Populations (EUROLIVE) study,<sup>69</sup> a randomized, crossover controlled trial performed at 6 research centers across 5 European Countries, patients received olive oil with low, medium, or high phenolic content for 3 weeks, with intervening 2-week washout periods. Markers of oxidative stress, (e.g. conjugated dienes, hydroxy fatty acids, and circulating oxidized LDL) linearly decreased with increasing phenolic content of the diet. In contrast to butter and walnut-rich meals, no effect of olive oil-rich meal does not influence postprandial activation of NF (nuclear factor)-κB pathway in monocytes of healthy volunteers,<sup>71</sup> thus arguing for an anti-inflammatory effect of olive oil.

Finally, some data indicate a beneficial effect of olive oil supplementation on endothelial function in low- to moderate-risk patients.<sup>72</sup> In keeping with this, a randomized crossover trial in a small group of healthy patients showed MD (rich with olive oil) improves endothelial function; reduces systemic inflammation and lowers the endothelial progenitor cell numbers, a marker of increased endothelial repair.<sup>73</sup>

**Fruits and Vegetables.** The ESC<sup>64</sup> and the AHA<sup>65</sup> strongly endorse the use of fruits and vegetables to reduce CV disease risk. In addition, the AHA has strongly recommended the intake of a variety of phytochemicals very abundant in fruits and vegetables.<sup>74</sup> These recommendations are based upon a broad base of observational studies, and subsequent meta-analyses. Although the results were slightly skewed by heterogeneity and publication bias, a meta-analysis of nearly 200,000 patients showed a 4% relative risk reduction in CV disease with each serving of vegetables, with a 7% relative risk reduction in CV disease with each daily increase in servings of fruit.<sup>75</sup> Another large (over 200,000 patients) meta-analysis of observational studies showed a 17% reduction in CV disease events with 3-5 servings of fruits and vegetables daily as the primary endpoint.<sup>76</sup> A 3.0-mm Hg decrease in systolic blood pressure among women (with no difference in men) who consumed a higher amount of fruits, vegetables, or vitamin C has been reported.<sup>77</sup> A cross-sectional analysis of the SUN prospective cohort<sup>78</sup> showed that fruit and vegetable consumption is inversely associated with blood pressure in a Mediterranean population with a high vegetable-fat intake. Increased fruit and vegetable intake has also been linked with a low BMI in a cross-sectional study.<sup>79</sup> Finally, the prospective Chicago Western Electric Study showed a slight benefit on blood pressure, over a 7-year period of time, in middle-aged men with an increased fruit and vegetable intake compared with those with a higher red meat intake.<sup>80</sup> Population-based evidence from the EPIC-Heart study showed, after an 8-year follow up of 313,074 patients without overt atherosclerosis, a 22% lower risk of coronary death in those consuming 8 portions of fruits and vegetables a day, as compared with 3 portions or less.<sup>81</sup> RCT data only

address the CV disease benefits of fruits and vegetables by using CV disease surrogates as endpoints. A 2001 RCT showed a strong trend for increased fruits and vegetables consumption as to lowering in lipid or blood pressure profiles.<sup>82</sup> A subsequent RCT showed a significant effect of fruit and vegetable consumption on both plasma antioxidant concentrations and blood pressure.<sup>83</sup> In addition to the evidence relating the antioxidant properties<sup>84</sup> and the health benefits of a high flavonol intake,<sup>85</sup> effects on nitric oxide (NO) species and/or on weight loss are also associated with the beneficial effects of diets high in fruits and vegetables<sup>86</sup>.

**Whole Grain.** The AHA guidelines indicate that diets high in fiber (e.g. whole grains, oats, and barley), reduce CV disease morbidity and mortality through lipid lowering, and recommend a total dietary fiber intake of 25-30 g per day from whole foods.<sup>87</sup> Likewise, the ESC endorses intake of foods high in dietary fiber to promote CV disease health.<sup>64</sup> RCTs show data on surrogate markers of CV disease such as blood pressure, cholesterol, and markers of inflammation. However, no information is available on hard CV disease endpoints. A small RCT showed beneficial effects on BMI and waist circumference in the group randomized to hypocaloric whole grains as compared to that receiving hypocaloric refined grains.<sup>88</sup> Cholesterol level lowering, the group obtaining all carbohydrates from 12-week whole grains had a significant improvement in C-reactive protein (CRP). A larger, subsequent, RCT confirmed these results in 230 participants randomized to 3 daily servings of whole grains ± whole oats vs refined carbohydrates, the former serving exhibiting a significant reduction in blood pressure and lipid profiles.<sup>89</sup> However, in over 300 overweight individuals in whom normal carbohydrate intake was randomly replaced with control, intermediate whole grain, or high whole grain diets for 4 months, no significant differences in surrogate markers of CV were observed after 4 months.<sup>90</sup> In spite of this, a 21% reduction in CV events and mortality in prospective cohort studies has been documented in a meta-analysis devoted to whole grains merits.<sup>91</sup> Larger observational studies such as the Iowa Women's Study and the Nurse Health Study<sup>92, 93</sup> show a reduction in CV disease

morbidity with increased intake of whole grain sources. Finally, observational data show improved all-cause and CV disease mortality in women with T2DM who consume whole grains.<sup>94</sup> Mechanisms<sup>95</sup> of the benefit of whole grains on CV disease include reduced inflammation, lower reactive oxidation species generation and improved antioxidant capabilities.<sup>96</sup> High-fiber whole grain diets inhibit absorption of fats, simple carbohydrates, or toxins. improved lipid profiles, and improved blood pressure control,<sup>97</sup> and improved glucose metabolism<sup>98,99</sup>, and weight loss<sup>100</sup> have also been reported. Yet the recommendation promoting whole grains has no RCT data behind it to show a reduction in CV disease morbidity or mortality. As such, increased whole grain intake for CV disease prevention should be pursued in the frame of a MD to maximize its cardioprotective potential.

**Nuts.** An early evaluation of observational studies showed that replacing walnuts, peanuts, almonds, or other nuts for a serving of carbohydrates or saturated fats reduced blood lipids as well as the risk for CV disease by 30% and 45%, respectively.<sup>101, 102</sup> Almost 10 years later, it has been argued that nut consumption leads to a 0.67 risk reduction on CV disease.<sup>103</sup> Furthermore, a 2009 meta-analysis showed a significant reduction in LDL cholesterol, inflammatory and oxidants mediators with increased walnut consumption,<sup>104</sup> without any evidence of reduction in risk factors or CV disease mortality. A more recent meta-analysis, however, pointed out benefits of nuts<sup>105</sup> on weight loss. A meta-analysis of 4 observational studies, showed an inverse relationship between nut consumption and CV disease (primary endpoint), and documented ≈40% decrease in the incidence of primary CV disease with consumption of at least 4 nut servings per week and up to 10% reduction with a single serving per week.<sup>106</sup> Due to the small sample size of the studies and the large variety of nuts studied, old RCT data are less convincing with respect to this issue. Recent RCT data provide evidence that the MD supplemented with nuts provides primary CV disease-prevention benefits.<sup>38</sup> Being these benefits seen in the frame of a MD, it would be



inappropriate to ascribe the benefit solely to nuts. In keeping with their ability to improving CV morbidity and mortality, several cohort studies and few small RCTs have shown a benefit of nuts as to improving lipid profiles and reducing blood pressure and reactive oxygen species (ROS) generation, and improving vascular function. Such evidence on CV disease prevention argues for increased nut consumption as being able *per se* to provide CV benefits, greater benefits being observed when added to the MD.<sup>107</sup>

**Legumes.** Legumes, the seeds of plants that contain roots which use nitrogen-fixing bacteria, are considered a low-glycemic useful dietary source of protein and fiber. Initial observational studies showed legume and soy intake to be beneficial to prevent CV disease (11% reduction in CV disease in women who consumed legumes 4 or more times weekly over those who consumed legumes one or fewer times weekly).<sup>108</sup> Similar observational data have been reported in Japan<sup>109</sup> and China.<sup>110</sup> However, RCT data seldom address hard CV disease endpoints, and the grouped data show only marginal benefits as to lipid levels, blood pressure, or endothelial function. Small RCTs in low- to moderate-risk patients show little change in lipid levels<sup>111 112, 113</sup>. On the other hand, one meta-analysis shows a 5% reduction in LDL levels in patients randomized to high legume intake,<sup>114</sup> documenting that this reduction had no effect on hard CV disease endpoints. RCTs have shown a benefit on blood pressure in patients with moderate hypertension.<sup>115</sup> In keeping with this, a large sample of RCTs studies<sup>116</sup> and an earlier meta-analysis<sup>117</sup> show no benefit from soy supplementation on normotensive patients. Consistent with prior meta-analyses<sup>114</sup> a recent RCT shows no benefit of soy on NO bioavailability and BP in moderately hypertensive, postmenopausal women.<sup>118</sup> However, subsequent meta-analyses have challenged this statement. Due to a potential anti-inflammatory and vaso-protective benefit, studies has examined the effect of soy on endothelial function. A recent meta-analysis of RCTs shows no benefit of soy on endothelial function,<sup>119</sup> a moderate benefit of soy supplementation being only documented when age-related results

are adjusted for baseline endothelial function. Thus, presently there is little direct evidence that legume intake alone has direct CV disease benefits. It should thus be hypothesized that legume intake must be part of the MD, and cannot be supplemented in isolation for CV disease protection.

**Plants and polyphenols.** An international panel of experts reviewed the effects of a moderate consumption of beer on human health has been carried out by.<sup>120</sup> Low-moderate (up to 1 drink per day in women, up to 2 in men), non-bingeing beer consumption, reduces the risk of CV disease. This effect is comparable to that of wine, at similar alcohol amounts. Moderate consumption of either beer or wine may confer greater CV protection than spirits. Although specific data on beer are inconclusive, observational studies indicate that low-moderate alcohol consumption is associated with a reduced risk of developing neurodegenerative disease. There is no evidence that beer drinking differs from other alcoholic beverages as to the risk of some cancers. Besides the obvious exceptions (people engaged in actions that require concentration, skill or coordination; children; adolescents; pregnant women, individuals at risk for alcoholism, and those with cardiomyopathy, cardiac arrhythmias, depression, and/or liver/pancreatic diseases), evidence suggests a J-shaped relationship between alcohol consumption and all-cause mortality, lower risks for moderate alcohol consumers than for abstainers (or heavy drinkers) being found.<sup>120</sup> Studies in model organisms (e.g., *C. elegans*, *D. melanogaster*), and in laboratory rodents suggest that red wine constituents (e.g., resveratrol) may positively affect both health and lifespan.<sup>121, 122</sup> In a mouse model, resveratrol activates transcriptional factor Nrf2 and lowers oxidative stress, hence protecting the endothelium<sup>123</sup> and inhibiting inflammation in macrophages (by downregulating the proinflammatory NF $\kappa$ B expression).<sup>124</sup> Resveratrol induces Sirt1<sup>125-127</sup>, and it is conceivable that the endothelium protection and NF $\kappa$ B inhibition appears to be connected to Sirt1 expression. Olive oil phenols induce proteosomal activity and Sirt1 signalling.<sup>128, 129</sup> The role of polyphenols in gene regulation via sirtuins and

transcription factors Nrf2 and NFκB is now clear.<sup>130</sup> Quercetin (a polyphenol found in onions) also induces Sirt1.<sup>127</sup> Mice consuming diets rich in olive oil phenolics (e.g., hydroxytyrosol) exhibit decreased oxidative damage markers (e.g., lipid peroxides, protein carbonyls) and improved expression of Nrf2-dependent genes encoding antioxidant (γGCS, NQO1) and cardioprotective proteins (e.g. paraoxonase).

**n-3 Polyunsaturated fatty acids.** The theory that eating fish, a major component of the MD may protect against cardiac death was first derived from the results of a secondary prevention trial, the Diet And Reinfarction Trial (DART), which showed a significant ≈30% reduction both in total and CV mortality in patients who consumed at least two servings of fatty fish per week.<sup>131</sup> The authors suggested that the protective effect of fish might result from a preventive effect on ventricular fibrillation (VF), since no benefit was observed on the incidence of non-fatal AMI. The hypothesis was consistent with the evidence that the very-long-chain n-3 fatty acids, the dominant fatty acids in fish oil and fatty fish, have major effects on the occurrence of VF in the setting of myocardial ischemia/reperfusion in several animal models.<sup>132</sup> In dogs, using an in vivo model of sudden cardiac death (SCD), Billman et al showed a marked reduction of VF after intravenous administration of pure n-3 fatty acids, including the very-long-chain fatty acids present in fish oil and ALA.<sup>133</sup>

A second aspect of the involvement of n-3 fatty acids in SCD is related to their role in the metabolism of eicosanoids. In competition with n-6 fatty acids, precursors of prostaglandins and thromboxane with potent pro-aggregatory and vasoconstrictive effects, n-3 fatty acids are the precursors of a broad array of structurally diverse and potent bioactive lipids (including eicosanoids, prostaglandins and thromboxane), which play a major role in the prevention of VF during myocardial ischemia/reperfusion.<sup>134</sup> Suppression (≥70%) of ventricular premature complexes in middle-aged patients with frequent ventricular extra systoles randomly assigned to take either fish oil or placebo has been

documented.<sup>135</sup> Survivors of AMI<sup>136</sup> and healthy men<sup>137</sup> improved their measurements of heart rate variability while receiving fish oil. This is in keeping with the fact that parasympathetic cardiac tone provides protection against VF.<sup>138</sup> Epidemiological studies support the hypothesis of a clinically significant antiarrhythmic effect of n-3 fatty acids in secondary prevention of CAD.<sup>139</sup> In a large prospective study (more than 20 000 participants with a follow-up of 11 years), Albert et al found that the risk of SCD was 50% lower in men who consumed fish at least once a week than in those who had fish less than once a month.<sup>140</sup> In that study, the main protective effect of fish consumption (or of very-long-chain n-3 fatty acids) was related to a reduction of arrhythmia. In a double blind trial in patients with implantable cardiac defibrillator, Leaf reported a 40% reduction of recurrent ventricular arrhythmias following fish oil capsules<sup>141</sup>, but this hypothesis was challenged<sup>142</sup> Presently, there is no clear explanation for that discrepancy between these two trials. Dietary confounders (e.g. saturated fatty acid intake; background marine/plant n-3 vs n-6 fatty acid intake, trans fatty acid intake) which could interfere with the n-3 fatty acids given with the capsules, were not measured in these trials nor were they included for adjustments in the calculations of the risks. The GISSI-Prevenzione trial addressed the question of the health benefits of vitamin E and very-long-chain n-3 fatty acids (EPA+ DHA). Patients (n = 11,324) surviving a recent AMI (≈3 months) were randomly assigned to supplements of n-3 fatty acids (1 g daily), vitamin E (300mg daily), both or none (control) for 3.5 years. The primary efficacy endpoint was the combination of death and non-fatal AMI and stroke. Secondary analyses included overall mortality, CV mortality and SCD. Treatment with n-3 fatty acids significantly lowered the risk of the primary endpoint (15% decrease of the relative risk). Overall mortality was reduced by 20% and CV mortality by 30%. However, the effect on SCD (45% lower) accounted for most of the benefits seen in the primary combined endpoint and both overall and CV mortality. There was no difference across the treatment groups for non-fatal CV events, a result comparable to that of DART.<sup>131</sup> Two central questions remain to be addressed with respect to these

data. 1) In the GISSI- Prevenzione trial, all patients were advised (before randomization) to follow a MD type of diet after their AMI. In their report, the GISSI investigators confirmed that the patients of both groups actually did so, > 80% of them reporting daily olive oil consumption.<sup>143</sup> Whether such patients would have been protected while consuming a non-MD is unknown so far. However, similar to the Lyon Diet Heart Study,<sup>9, 12</sup> pooling together the randomized groups and adjusting for age, sex, smoking, concomitant drug therapy and randomized treatment, the GISSI investigators found that the higher the MD adherence (as evaluated by an MD score) the lower the risk of dying (from any cause), a 50% difference in such risk being found between the best and the worst MD adherence.<sup>144</sup> 2) Unpublished data (the European IMMIDIET Project) suggest that compared with British (South of London) and Belgian (Flemish) populations, the Italian population is relatively deficient in n-3 fatty acids. It is not sure whether the results with such a low dose of n-3 fatty acids would have been similar in populations with higher intakes in n-6 and trans fatty acids.

Al in all, large case-control studies and prospective intervention trials consistently showed that dietary and non-dietary intake of  $\omega$ -3 fatty acids directly or indirectly affects cardiac electrophysiology and that n-3 fatty acids supplementation lowers AMI and SCD in patients with CAD.<sup>145, 146-148</sup> However, experimental data also suggest newer directions to be pursued in the area, the anti-atherogenic and anti-inflammatory properties of n-3 FA having been largely investigated in *in vitro*, animal and human studies. Cellular models of early atherogenesis based on cultured endothelial cells challenged with various pro-atherogenic stimuli show that both DHA and EPA significantly affect major critical events leading to endothelial activation, including the expression of VCAM-1. Such regulatory effects occur in a range of DHA concentrations compatible with nutritional supplementation to a normal Western diet and are strictly related in magnitude to the extent of incorporation into total cell lipids.<sup>149-151</sup> In addition to the expression of transmembrane molecules involved in leukocyte recruitment, effects of DHA and EPA also involve the pro-inflammatory and chemoattractant soluble proteins

IL-6,<sup>152</sup> IL-8,<sup>151</sup> macrophage-colony stimulating factor (M-CSF),<sup>153</sup> and monocyte chemoattractant protein (MCP)-1.<sup>154</sup> Such effects are associated by reduced monocyte adhesion to cytokine-activated endothelium.<sup>150, 151</sup> *An antioxidant effect* can also be documented in cultured endothelial cells supplemented with DHA.<sup>153, 155, 156</sup> A reduced membrane assembly and activation of the ROS-producing enzyme complex NADPH-oxidase, has been reported as a likely consequence of plasma membrane changes occurring upon DHA incorporation.<sup>155</sup> On the other hand, when supplemented to macrophages in culture, EPA and DHA significantly reduce the stimulated release of MMPs,<sup>154, 157</sup> thus likely contributing to plaque-stabilizing effects of PUFA in humans.<sup>158</sup> In addition, fish oils prevent serotonin-induced smooth muscle cells proliferation,<sup>159</sup> an effect that is involved in preventing restenosis after endovascular interventions.

## **Clinical Vascular Diseases**

### **Athrombosis.**

Atherothrombosis -the substrate of the large majority of complications of atherosclerosis leading to clinical vascular disease and the leading cause of death worldwide,<sup>160</sup> is an unpredictable, sudden rupture or erosion/fissure of the atherosclerotic plaque,<sup>161</sup> leading to platelet activation and thrombus formation in the vessels.<sup>162</sup> Thrombus formation is a dynamic process in which platelets aggregate but also spontaneously disaggregate, leading to embolization of platelet aggregates from an evolving thrombus.<sup>163</sup> In the case of an occlusive thrombus, depending on the localization of the atherosclerotic plaque, there will be an acute ischemic event in the coronary, cerebral or peripheral vascular territory, potentially leading to permanent tissue damage. In the case of a non-occlusive thrombus, ischemic symptoms are temporary. Occlusive thrombosis in atherosclerotic coronary arteries may give rise to major clinical events such as AMI, cardiac death and acute coronary syndrome (ACS). Atherothrombosis of the cerebral arteries may result in transient ischemic attacks (TIAs) or ischemic stroke. In the peripheral arteries, thrombosis superimposed on atherosclerotic plaques contributes to the progression of peripheral arterial disease (PAD), producing intermittent claudication (leg pain on walking that is relieved by rest); ischemic necrosis and, potentially, loss of the limb. Hence, the same underlying vascular process cause ACS, TIA, stroke, and PAD.<sup>164</sup> Because of the generalized nature of atherosclerosis, symptoms in one vascular bed, for example, AMI, are highly predictive of risk of further ischemic atherothrombotic events elsewhere.<sup>165</sup>

### **Cardiovascular Disease (CVD)**

CVD, the major complication of atherothrombosis, is the number one cause of death worldwide, with yearly deaths expected to increase from 17.3 to 23.6 million by 2030.<sup>166</sup> Today CV deaths accounts for approximately 1/3 of all deaths globally. Medical expenses and medication costs associated with the treatment of

CVD are huge, totalling \$126 billion in 2010 in the US.<sup>167</sup> The attention devoted to the CVD is due to the rapid increment of CV deaths during the last decades (12.5% increment).<sup>168</sup> In reality, in the 2005/2015 decade there was a 15.6% reduction of age-specific deaths.<sup>169-171</sup> However, this was relevant in High-income countries (HICs) than in Middle-income countries (MICs) and Low-income countries (LICs).<sup>170, 172</sup> Accordingly, the vast majority of CVD deaths now occur in LICs and MICs. In 2013, the World Health Organization, launched the “25x25 Global Action Plan”, a project aimed at reducing the mortality by 25% by 2025. This project focuses on correction of 4 mains health-related behaviors: tobacco use, diet, physical activity, and alcohol.<sup>173</sup> The occurrence of CVD is multifactorial and major risk factors are T2DM, hypertension, smoking habit, overweight, and dyslipidemia. Early recognition and treatment of patients at high risk of atherosclerosis is a major goal to reduce the incidence of atherothrombotic events and CV disease.

### **Ischemic Heart Disease**

IHD is the leading component of the CVD burden. Both the prevalence and the mortality of IHD increase dramatically with age.<sup>169</sup> During the past 25 years, both the incidence and mortality (age standardized) have decreased globally, the greatest decline being found in HICs.<sup>174, 175</sup> Age-standardized mortality also remains high in South Asia, North Africa, and the Middle East.<sup>169</sup> On the other hand, the large increases documented during the 1990s in Eastern Europe and Central Asia are now reversing.<sup>169, 174</sup> Years of life lost because of IHD are highest in South Asia, mostly reflecting early onset of IHD.<sup>174, 175</sup>

### **Congestive Heart Failure**

Congestive Heart Failure (CHF) due to ischemic heart disease (IHD), hypertensive heart disease, or cardiomyopathy/ myocarditis contributes significantly to disease burden.<sup>169</sup> Both the prevalence of CHF and the associated mortality increase with age.<sup>169</sup> Despite advances in CHF management during the past 3 decades, data from HICs suggest that 5-year survival after the diagnosis of CHF is still only 50-



60%, mortality rates being substantially higher in LICs and MICs.<sup>176, 177</sup> Population based studies in North America and Europe estimate a prevalence of CHF of 1% to 2%, with 80% of new cases occurring in those >65 years of age.<sup>176, 178</sup> Limited data from Asia suggest that the prevalence of CHF may range there between 1% and 7%. However such estimates predominantly rely on either single-center or hospital based studies, which may not truly reflect community rates.<sup>179</sup>

### **Atrial Fibrillation**

Atrial fibrillation (AF) is the sixth leading cause of CVD-related mortality and the eighth leading cause of disability among CV conditions.<sup>168, 169</sup> The prevalence of AF increases dramatically in older age groups as does the associated mortality.<sup>169</sup> The age-adjusted prevalence and incidence of AF have increased during the past decades.<sup>180</sup> The highest prevalence of AF has been reported in North America and the lowest in the Asia-Pacific region.<sup>180</sup> However, these data also may not be reliable because few large community-based studies have examined AF epidemiology outside of Western countries, and methods used to detect AF vary.

### **Rheumatic Heart Disease**

Rheumatic heart disease (RHD) is the fifth leading cause of CVD-related mortality and ranks sixth in disability from CV conditions. The disease burden is concentrated in poor countries, where overcrowding and reduced access to care coexist with an inadequate management of valvular disease.<sup>169</sup> Current estimates suggest that the highest prevalence of RHD now occur in countries of Oceania, South Asia, South East Asia, Central Asia, Sub-Saharan Africa, parts of the Middle East, and in the Caribbean.<sup>181</sup> Since 1990, the prevalence of RHD appears to have increased in these endemic regions while incident acute rheumatic fever has decreased.<sup>182</sup> Although these differing trends may be related to longer survival of patients with RHD, this may also be the result of more RHD cases being identified earlier with wider use of echocardiography.<sup>181</sup>

## **Cerebrovascular disease**

Stroke is the second leading contributor to CVD disease burden. The prevalence of stroke increases with age, peaking in those between 74 and 79 years of age.<sup>169</sup> Stroke-related mortality also increases with age.<sup>169</sup> Approximately 63% of ischemic and 80% of hemorrhagic stroke now occur in LICs and MICs. Ischemic stroke is more common than hemorrhagic stroke although hemorrhagic stroke is associated with higher mortality and contributes more to disability.<sup>183, 184</sup> On average, populations in MICs and LICs suffer strokes 6 years younger than in HICs.<sup>185</sup> Countries with the highest age-standardized prevalence of stroke currently are in Oceania, Eastern Europe, Central Asia, and South- East Asia while mortality from stroke is highest in Oceania and Sub-Saharan Africa.<sup>169, 185</sup>

In a world of magnetic resonance imaging the historical definition of TIA as “a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia without acute infarction”<sup>187</sup> lasting less than 24 hours is no longer appropriate. Although most patients are asymptomatic at presentation and have normal physical examination,<sup>188</sup> the incidence of acute ischemic stroke within 48 hours of an emergency visit for TIA is 4.8% (182/3,814 patients; 95% CI 4.0% to 5.6%).<sup>189</sup> Secondary stroke prevention—the rapid implementation of multiple interventions—reduces the outcome of stroke by 80%.<sup>190-193</sup> Because accurate diagnosis, rapid testing, and implementation of treatments can prevent disabling and fatal strokes, TIA has enormous public health importance.<sup>188</sup>

## **Subarachnoid hemorrhage**

Subarachnoid hemorrhage accounts for 5 to 10% of all strokes in the United States,<sup>194</sup> and affected patients tend to be younger than those affected by other subtypes of stroke, which results in a greater loss of productive life.<sup>195</sup> Subarachnoid hemorrhage without a preceding trauma is due to an intracranial aneurysm rupture in 80% of cases. Among the patients with aneurysmal subarachnoid hemorrhage who survive, half suffer long-term neuropsychological

effects and decreased quality of life.<sup>196</sup> Early identification and treatment of the aneurysm can prevent aneurysm re-rupture and address sequelae from the initial rupture. Intervention may be appropriate in cases of subarachnoid hemorrhage that are not caused by aneurysms (e.g., cases involving arteriovenous malformation), but up to 10% of cases of non-aneurysmal subarachnoid hemorrhage involve no vascular abnormality, and surgical or endovascular treatment is not necessary.<sup>197</sup>

### **Peripheral vascular disease**

PAD affects more than 5% of population older than 60.<sup>198</sup> In the US, PAD affects about 8 – 10 million Americans, and every year it causes 500,000 hospitalizations and 100,000 angiograms.<sup>199</sup> Significant CAD (in at least one coronary artery) has been documented in 60% – 80% of patients with PAD, and hemodynamically significant carotid artery stenosis (by duplex ultrasound) has been found in 12% – 25% of cases.<sup>200</sup> The risk of AMI is increased by 20% – 60%, whereas the risk of coronary death is increased 2 – 6-fold in PAD patients.<sup>160</sup> For this reason, early diagnosis of PAD may help identify patients at risk for CV events.<sup>201</sup> PAD is associated with a 40% increase in the risk of stroke, and PAD severity is positively associated with the incidence of TIAs and stroke.<sup>199</sup> The clinical spectrum of PAD is widely variable: patients may either be asymptomatic or have pain as a result of a minimal walking.<sup>202</sup> Most asymptomatic patients with PAD will be identified through ankle-brachial index (ABI) screening.<sup>203</sup> ABI (i.e. the ratio of the highest systolic blood pressure in the lower limb to that of the arm) is an easy, reliable means for evaluating PAD severity.<sup>204</sup> PAD with intermittent claudication (IC) is often undiagnosed and, in turn, undertreated. The low percentage of diagnosis (~ 30%) among those with a PAD is of concern because of the high risk of adverse outcomes related to the worsening of PAD.<sup>205-207</sup> Among those with ABI 0.9, ~ 25% will experience worsening claudication necessitating surgical repair or amputation. In a 10-year follow-up<sup>208</sup>, about 55% of PAD (ABI 0.9) patients died of CV disease, 10% of cerebrovascular disease, and 25% of non-vascular reasons. Less

than 10% died of other vascular events (mostly, aortic aneurysms in the abdomen). In another follow-up<sup>209</sup>, 10-year mortality was 61.8% in males with symptomatic PAD (ABI 0.9); in comparison, in males without PAD (ABI 0.9) mortality was 16.9%. Mortality rates in females were 33.3% and 11.6%, respectively. Less than 25% of patients with PAD (ABI 0.9) survived for 10 y, vascular mortality being the dominant cause of death in that setting. After correction for established risk factors, PAD severity was an independent predictor of death.

Critical limb ischemia (CLI; ABI 0.4), is observed in 12% of the PAD population.<sup>210</sup> In most cases, CLI is an advanced thrombotic complication of PAD, due to inadequate resting blood flow to the lower limbs, and is marked by rest pain, ulceration, and eventually gangrene and loss of the limb.<sup>211</sup> CLI is seldom the result of an acute event (e.g. embolism, thrombosis, or trauma). Patients with CLI are candidates for prompt revascularization. CLI increases mortality: in the first year after the diagnosis 25% of patients (45% with amputation) will die, and 30% of them will have amputations, whereas only 45% will survive with both legs. After 5 years more than 60% of patients have died.<sup>212</sup>

## **Subclinical Vascular Diseases: Methods of Detection**

### **Carotid Intima media thickness (c-IMT)**

c-IMT assessment is a non-invasive imaging test for subclinical atherosclerosis.<sup>213, 214</sup> This test has been widely accepted as one of the strongest predictors of major CV events (stroke, AMI, CHF, CV death).<sup>215, 216</sup> The presence of carotid plaques is an even more reliable predictor of CV events than c-IMT.<sup>217</sup> Thus, this surrogate marker of subclinical atherosclerosis provides important prognostic information over and above traditional CV risk factors.

### **High resolution B-Mode Eco-tomography**


B-Mode ultrasonography is a non-invasive technique that allows to study subclinical atherosclerosis of the major surface vascular districts. Morphological information relating both to the lumen and the blood vessel are achieved by using this technique. High Resolution B-Mode Eco-tomography uses high frequency ultrasound (7-13 Mhz) and provides real-time bi-dimensional images of the major unshielded surfaces of blood vessels. This technique also provides detailed information on the size and characteristics of early small injuries of the wall.<sup>218-222</sup> B-Mode ultrasonography shows a great sensitivity, specificity, accuracy and reproducibility.<sup>223</sup> It is cheaper than invasive techniques and allows for carefully performing studies on the evolution of atherosclerosis and the effect of treatments. Limits of B-Mode Eco-tomography include: the inability to display anechogenous structures (e.g. lipid areas) or structures with blood-like acoustic impedance (hemorrhage inside a plaque or recent thrombotic occlusions).<sup>224</sup> Eco-color Doppler and angiography should be preferred when measuring calcific stenosis.

### **Ultrasound anatomy of carotid arteries**

In a typical ultrasonographic image, the common carotid, the carotid bifurcation and the internal and external carotid arteries are easily detectable (**Figure 2**). In ultrasonographic images, the beginning of the dilation of the bifurcation is the distal

limit of the common carotid and is recognized by the presence of a medium-intensive physiological thickening, the "bifurcation crest/peak". The bifurcation, separates the internal carotid, -which discharges the frontal parts of the brain and the vision organs-, and the external carotid that disrupts the neck, face, and cranial walls. The Carotid bifurcation has two key anatomical reference points that allow it to be identified. The lower margin of the carotid bifurcation is defined by the proximal part of the bifurcation dilation, the upper limit is given by the so-called "flow-divider", which separates the origin of the internal and external arteries. The internal carotid is delimited proximally by the flow-divider and differs from the outer carotid for the larger caliber and for the origin with a typically bulbous morphology. The branch of the thyroid artery from the outer carotid artery further differentiates the two arteries.<sup>225</sup>

**Figure 2.** Carotid Bifurcation



**Thickness of the intramammary complex (or extracranial carotids IMT)**

IMT of the extracranial carotids is the most important parameter that can be evaluated using B-Mode ultrasonography. The anatomical correspondence between the ultrasonic image and the intimal average complex has been

documented more than 30 years ago<sup>220</sup> in a study where a real estimate of the mean intimal thickness was obtained by measuring the distance between the "blood-intima" and "media-adventitia" interfaces of the abdominal aorta and of common carotid arteries. This method is now standardized and is used as a reference standard for studying carotid atherosclerosis and for evaluating CV risk. The major benefit of the c-IMT analysis is that it allows the evaluation of individual subjects to develop early atherosclerotic disease, before the occurrence of atherosclerotic lesions (plaques). In addition to being an index of local atherosclerosis,<sup>226, 227</sup> c-IMT also predicts similar lesions in other districts e.g. the coronary vasculature.<sup>215, 223, 228-232</sup> c-IMT is also directly related with major risk factors for atherosclerosis.<sup>74, 233-236</sup> Current epidemiological data indicate that  $\geq 1$  mm c-IMT increase in asymptomatic adults is a risk factor for AMI and/or cerebrovascular disease.<sup>237</sup> c-IMT thus provides a comprehensive view of over time injuries on the arterial wall due to risk factors,<sup>237</sup> and has been proposed to be included in algorithms for refining CV risk estimates<sup>215, 238</sup> The predictive value of c-IMT is further strengthened by the identification of high-risk patients for cardio- and cerebro-vascular events.<sup>215, 239</sup> Accordingly, this technique is currently employed in clinical and research centers to assist physicians to prescribe pharmacological treatment in primary prevention in patients at high CV risk.<sup>240</sup>

## **MD and subclinical disease**

### **MD and c-IMT**

Few epidemiological studies have addressed the relationships between MD and c-IMT.<sup>34, 35, 241, 242</sup> Two studies have investigated the relationship between MD and c-IMT progression in cohorts of children or elderly individuals,<sup>242-245</sup> and a single interventional study, carried out in a Mediterranean population (PREDIMED), has addressed the effect of MD on c-IMT progression. To date there are no large observational studies addressing the relationship between MD adherence and c-IMT progression in populations from different European countries with different nutritional patterns/habits.

In view of its capacity to predict incident coronary events, c-IMT has been proposed as a surrogate marker of coronary atherosclerosis.<sup>213, 246</sup> Analysis of baseline data of the IMPROVE study has identified latitude as the strongest independent determinant of c-IMT.<sup>247</sup> The association between latitude and carotid atherosclerosis profile remained statistically significant over and above traditional and new vascular risk factors (VRFs) and baseline Framingham risk score (FRS).<sup>248, 249</sup> In addition, a significant association between c-IMT and c-IMT progression and future vascular events has been shown in the IMPROVE study.<sup>247, 249</sup>

### **MD and Carotid Plaques**

The association between MD adherence and carotid plaque thickness and area was first evaluated in an observational study that included 1,374 participants of the population-based Northern Manhattan Study (60% female, 60% Hispanic, 18% White, 19% Black, mean age  $66 \pm 9$  years).<sup>250</sup> c-IMT and plaque were measured using B-mode ultrasound. A MD adherence score (range = 0–9, 9 representing maximal adherence) was employed as a continuous variable and as quintiles (3/4/5/6 –9 vs. 0–2). There was no association between MD and c-IMT or plaque presence. MD adherence was inversely associated with the 75th percentile of



plaque thickness and median of plaque area in quantile regression analyses. These associations persisted after controlling for demographics, smoking habit, physical activity, and total energy consumption (effect of a 1-point increase in MD score on the 75th percentile of plaque thickness =  $-0.049$  mm,  $p = 0.03$ ; median of plaque area =  $-0.371$  mm<sup>2</sup>,  $p = 0.03$ ), and when also controlling for vascular disease biomarkers, medication use, BMI, and previous cardiac disease. The protective associations were strongest for a MD score of 5 (4th quintile) vs. 0–2 (bottom quintile). Differential effects of a MD on plaque thickness and area across race/ethnic groups was suggested.<sup>250</sup> In the same cohort, no association with clinical stroke was found. However, larger studies have found an association of MD with clinical stroke<sup>251</sup> and associations of MD with imaging biomarkers of cerebrovascular damage.<sup>252, 253</sup> Studies have also shown that the top quartile of carotid plaque area (vs. the lowest quartile) is associated with a 3–4-fold increased risk of stroke, AMI or death.<sup>254, 255</sup> Accordingly, plaque area may be a better measure of atherosclerosis than plaque thickness,<sup>254-257</sup> plaques progressing along the carotid artery 2–3 times faster than for thickening.<sup>258</sup> Despite the relationship between carotid plaque burden and risk of clinical events, few studies have examined the role of vascular risk factors in relation to this novel marker of disease risk. Likewise, whether the association between MD and carotid plaque burden is consistent with a dose–response relationship or a threshold effect is unknown so far.

### **MD and Vascular Stiffness**

Whether adherence to the MD, obesity, and BP are related to indices of AS has been evaluated in childhood. Two hundred and seventy-seven children aged 12 years were measured with the R6.5 Pulsecor® monitor, which performs measurements using an upper arm BP cuff held at above systolic pressure for a short time.<sup>259</sup> Of such children, 43% were overweight or obese. The AI in the brachial artery, the peripheral pulse pressure to central pulse pressure (PPP/PPP) ratio, and the reflected wave transit time to height ratio were used as indices of

AS. The degree of adherence to the MD was assessed by the KIDMED index, which includes 16 questions on specific dietary habits. In multivariate regression models, the KIDMED index had a negative correlation with AI ( $\beta=-0.114$ ;  $p=0.026$ ) and this relation was independent of obesity. In contrast, indices of AS were related to mean peripheral BP ( $\beta=0.110$ ;  $p=0.063$ ), heart rate ( $\beta=-0.508$ ;  $p=0.000$ ), and height ( $\beta=-0.370$ ;  $p=0.000$ ), while BMI had an independent correlation to PPP/PPP ( $\beta=-0.182$ ;  $p=0.039$ ).<sup>259</sup>

Information in adults only pertains to acute postprandial conditions in subjects simultaneously receiving wine and olive oil.<sup>260</sup> Fifteen healthy subjects consumed four standard meals on different days, containing 50 g of olive oil and 250 ml of wine, in a randomized cross-over study design. Two types of wine [red (R) and white (W)] and two types of olive oil [green (G) and refined (O) (rich and poor in antioxidants, respectively)] were used in all possible combinations. Applanation tonometry and aortic pulse wave analysis were performed when fasting and 1, 2 and 3 hours post-prandially. A second group of 15 healthy individuals matched for age, gender and body mass index served as controls. All meals decreased AIx (RO and RG,  $P<0.001$ ; WO,  $P=0.007$ ; and WG,  $P=0.039$ ). The AIx reduction after RG, RO, WO and WG was significantly different from the AIx response of the control group. No difference was observed in the reduction of AIx between sessions, but a significantly earlier peak decrease in AIx, as well as a prolonged decreasing effect, was observed after RG and RO consumption compared to WO and WG. Central systolic and diastolic pressure were diminished after all four combinations of wine and olive oil ( $P<0.05$ ), an information consistent with the concept that a combined consumption of wine and olive oil provides beneficial postprandial effects on hemodynamics.<sup>260</sup>

### **MD and FMD.**

The relationship between diet and endothelial dysfunction has been examined in epidemiological and interventional studies. The prospective cohort Nurse's Health Study compared endothelial function as related to two dietary patterns<sup>261</sup>: a food

pattern characterized by a high intake of fruits, vegetables, whole grains, fish and poultry, and a Western food pattern characterized by higher intake of red meat, processed meat, refined cereals and fries. Regardless of risk factors such as smoking and age, and after controlling for body weight, women who consumed a "prudent" diet had significantly lower levels of E-selectin -a biological marker of endothelial dysfunction-, than women who they consumed a Western diet.

## MD and Conventional Vascular Risk Factors for CAD

### Blood pressure

The Dietary Approaches to Stop Hypertension (DASH) clinical trial<sup>18</sup> enrolled 459 adults with systolic BPs of <160 mm Hg and diastolic BPs 80–95 mm Hg. Initially, the subjects were fed a control diet that was low in fruits, vegetables, and dairy products, and a diet that has a fat content typical of the average US diet. Then they were randomly assigned to receive: 1) the control diet; 2) a diet rich in fruits and vegetables; or 3) a “combination” diet rich in fruits, vegetables, and low-fat dairy products with reduced saturated and total fat. The “combination” diet was associated with 5.5 mm Hg and 3.0 mm Hg lower systolic and diastolic BPs, respectively, than the control diet ( $p < 0.001$ ), while the fruits-and vegetables diet reduced systolic BP by 2.8 mm Hg more ( $p < 0.001$ ) than the control diet. Among the 133 subjects with hypertension, the combination diet reduced systolic and diastolic BP by 11.4 mm Hg and 5.5 mm Hg more, respectively, than the control diet ( $p < 0.001$  for each). Among the 326 subjects without hypertension, the corresponding reductions were 3.5 mm Hg ( $p < 0.001$ ) and 2.1 mm Hg ( $p = 0.003$ ).<sup>18</sup> These findings argue for not limiting to single nutrients the focus of dietary changes for BP control. Blood pressure variability (BPV) is a novel risk factor for CVD. It is unknown whether dietary pattern plays a role in modulating BPV.<sup>262</sup> As many as 274 consecutive patients with stable CAD were followed-up. The MD score (MDS) was derived for all individuals upon recruitment, blood pressure (BP) was measured during each subsequent clinic visit and the visit-to-visit BPV was calculated. The occurrence of major adverse CV events (MACEs) and all-cause mortality were monitored. After a mean follow-up of  $77 \pm 12$  months, 16.1% of the study population developed MACEs. About 11.3% died from all causes. Patients who developed MACEs or all-cause mortality had a greater systolic BPV compared to those who did not develop an adverse event. Patients who developed a MACE had a lower MDS and further analysis revealed those who developed a stroke had a lower MDS compared with those who did not, but there were no significant

differences in MDS between CAD patients with or without subsequent acute coronary syndrome, CV, or all-cause mortality. After adjusting for confounding variables, a high MDS was an independent predictor for low systolic BPV (B  $-0.74$ , 95% confidence interval  $-1.27$  to  $-0.21$ ,  $P < 0.01$ ) and was protective against a subsequent stroke (hazards ratio  $0.48$ , 95% confidence interval  $0.24$  to  $0.94$ ,  $P = 0.03$ ).<sup>262</sup>

### **Physical activity**

It is known that the age-dependent decline in endothelial and microvascular integrity may be reversed when combining an 8-week exercise with an MD intervention. Whether the risk-reduction improvement in microcirculatory and cardiorespiratory functions are sustained in this age-group after a 1-year follow-up has been also investigated.<sup>263</sup> Twenty sedentary healthy participants (age,  $55 \pm 4$  years) underwent cardiopulmonary exercise tolerance test and were assessed for their upper- and lower-limb vascular endothelial cutaneous vascular conductance (CVC) using laser Doppler fluximetry (LDF) with endothelium-dependent [ACh (acetylcholine chloride)] and endothelium-independent [sodium nitroprusside] vasodilation, 1 year after completing the intervention. With respect to ACh, compared to baseline, both MD and exercise groups improved their microvascular responses, a stronger improvement in the MD group in comparison to the exercise group, for ACh ( $p = 0.04$ ,  $d = 0.41$ ) being found. In the upper body, the time point and group interaction for ACh, indicated a non-statistically significant ( $p = 0.07$ ,  $d = 0.24$ ) improvement for MD. Cardiorespiratory improvement in ventilatory threshold was maintained 1 year after ( $12.2 \pm 3.0$  vs.  $13.2 \pm 3.2 \text{ ml} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$ ,  $p = 0.05$ ). Since the original improvements were still evident, particularly in the microcirculatory and cardiorespiratory assessments, 1 year after the initial study, the data were taken to suggest that a brief intervention combining MD with exercise in this high-risk group is a promising long-term health benefit strategy.<sup>263</sup>

## Glucose control

Some studies in T2DM patients reported a positive effect of the MD on glycemic control,<sup>264-269</sup> others did not.<sup>270-272</sup> A recent meta-analysis has addressed some of the unmet issues in this area.<sup>273</sup> The control diets comprised low-fat diet, usual dietary habits, non-restricted calorie low-carbohydrate diet, the 2003 American Diabetes Association (ADA) diet and high-carbohydrate diet. Although the MD diet varied across studies, all the included diets comprised the basic characteristics of an MD diet. However, two studies compared three separate diets, one study<sup>268</sup> compared a MD versus two types of control diets, and the other one compared two versions of MD versus a control diet. Finally, two trials<sup>270, 272</sup> used a high-monounsaturated fatty acid-enriched intervention diet, that was comparable to the traditional MD. These different 11 arms were evaluated separately.<sup>273</sup> Nine studies with 11 arms (n = 1,178 patients) contributed data for the change in HbA<sub>1c</sub> from baseline. Compared with control diets, the MD was associated with a significant reduction in HbA<sub>1c</sub> (mean difference, - 0.30; 95% CI, - 0.46 to - 0.14) by using a random effects model. Evidence of between-study heterogeneity was found in this analysis ( $I^2 = 67.2\%$ ;  $P = 0.001$ ). Changes in fasting plasma glucose (FPG) levels were pooled from six studies with seven arms (n = 580 patients). Subjects who consumed MD had decreased FPG levels (-0.72 mmol/l; CI, - 1.24 to - 0.21) compared with subjects who consumed control diets. Heterogeneity of the effect measures on FPG was detected ( $I^2 = 66.1\%$ ;  $P = 0.007$ ). Five studies with six arms (n = 531 patients) measured fasting insulin. Compared with control diets, there was a minimal but statistically significant decline in fasting insulin levels (-0.55  $\mu$ U/ml; CI, - 0.81 to - 0.29) in subjects who used MD. No heterogeneity was observed ( $I^2 = 0.0\%$ ;  $P = 0.46$ ). As to insulin resistance, although the beneficial effect of MD compared with control diet was not statistically significant (mean difference, - 0.55; CI, - 1.53 to 0.42), the MD had greater probability on improving insulin resistance. Moderate heterogeneity was present between the studies ( $I^2 = 45.8\%$ ;  $P = 0.137$ ).<sup>273</sup> Six studies with seven arms reported changes in BMI from baseline. A random effects meta-analysis comprising 520 patients randomly

assigned to the MD and 500 assigned to the control diets were employed for this study. The MD was more effective in decreasing BMI compared with the control diets (mean difference,  $-0.29$  kg/m<sup>2</sup>; 95% CI,  $-0.46$  to  $-0.12$ ;  $I^2 = 0.0\%$ ;  $P = 0.976$ ). As to body weight, six studies involving 835 patients showed that MD was associated with a significant weight loss as compared with control diets ( $0.29$  kg; CI,  $-0.55$  to  $-0.04$ ;  $I^2 = 0.0\%$ ;  $P = 0.924$ ). In addition, compared with control diets, MD also significantly decreased total cholesterol (mean difference,  $-0.14$  mmol/l; 95% CI,  $-0.19$  to  $-0.09$ ) and triglyceride ( $-0.29$  mmol/l; CI,  $-0.47$  to  $-0.10$ ) concentrations and increased HDL-cholesterol ( $0.06$  mmol/l; CI,  $0.02$  to  $0.10$ ), without affecting LDL cholesterol ( $-0.11$  mmol/l; CI,  $-0.24$  to  $0.01$ ). There was moderate heterogeneity for the analyses of triglyceride ( $I^2 = 58.0\%$ ;  $P = 0.03$ ) and HDL ( $I^2 = 53.6\%$ ;  $P = 0.04$ ) cholesterol. Finally, a trend towards reduction in systolic ( $-1.45$  mmHg; CI,  $-1.97$  to  $-0.94$ ;  $I^2 = 0.0\%$ ;  $P = 0.58$ ) and diastolic ( $-1.41$  mmHg; CI,  $-1.84$  to  $-0.97$ ;  $I^2 = 0.0\%$ ;  $P = 0.95$ ) blood pressure was found in the MD groups.<sup>273</sup>

### **Total cholesterol**

The relationship between serum total cholesterol and long-term mortality from (CAD) in different cultures was first analyzed in the Seven Countries Study.<sup>274</sup> Total cholesterol was measured at baseline and at 5- and 10-year follow-up in 12,467 men aged 40 through 59 years in 16 cohorts located in seven countries: five European countries, the United States, and Japan. To increase statistical power six cohorts were formed, based on similarities in culture and cholesterol changes during the first 10 years of follow-up. The age-standardized CAD mortality rates in the six cohorts ranged from 3% to 20%. The RRs for the highest compared with the lowest cholesterol quartile ranged from 1.5 to 2.3, except for Japan (RR of 1.1). For a cholesterol level of  $\approx 5.45$  mmol/L (210 mg/dL), CAD mortality rates varied from 4% to 5% in Japan and Mediterranean Southern Europe to  $\approx 15\%$  in Northern Europe. Except for Japan, the relative increase in CAD mortality due to a given cholesterol increase was similar in all cultures. Using a linear approximation,

a 0.50-mmol/L (20-mg/dL) increase in total cholesterol corresponded to an increase in CAD mortality risk of 12%.<sup>274</sup>

### **LDL-cholesterol**

Lowering LDL-cholesterol concentration is the primary target of therapy for the prevention of CV disease (CVD).<sup>275-277</sup> However, in addition to LDL-Cholesterol concentrations, it has been shown that a more detailed analysis of LDL physico-chemical properties (e.g., size and oxidation) provides further insight into individual CV risk,<sup>278, 279</sup> individuals with a predominance of small, dense LDL particles (sdLDL) being at increased risk of CAD compared to those with larger, buoyant LDL particles.<sup>280-282</sup> Compared with large LDL, sdLDL possess a lower affinity for the LDL receptor and a longer half-life in plasma<sup>283</sup>, bind more tightly to arterial proteoglycans<sup>284</sup>, penetrate the arterial sub-endothelium more easily<sup>285</sup> and are more susceptible to oxidation.<sup>286</sup> LDL oxidation contributes to atherosclerotic plaque formation by causing endothelial dysfunction, the release of inflammatory cytokines and macrophage transformation into foam cells.<sup>279</sup> Accordingly, oxidized LDL (oxLDL) concentrations have been identified as an important marker of atherosclerotic lesions.<sup>279, 287</sup> Sex disparities have been reported for LDL physico-chemical properties, men being characterized by a higher proportion of sdLDL and greater concentrations of oxLDL than premenopausal women.<sup>288-293</sup> A specific study was carried out to verify whether the impact of MD on LDL size distribution, as well as on oxLDL concentrations differs between men and women. It appeared that adhering to the MD, in addition to a clinically-relevant reduction in LDL-cholesterol concentrations, has additional positive effects on LDL particle size phenotype, leading to a favorable redistribution from smaller to larger LDL in men, but not in women.<sup>294</sup>

### **HDL-cholesterol**

Dietary supplementation of unsaturated FA protects against atherosclerosis and CV events.<sup>295</sup> The effects of dietary FA on the lipid metabolism have been widely



investigated: mono- and poly-unsaturated FA (MUFA/PUFA) supplemented to the diet are effective in lowering total cholesterol (TC) and LDL cholesterol, while saturated FA (SFA) increase TC and LDL-cholesterol.<sup>61, 296</sup> HDL cholesterol shows a slight decrease with PUFA dietary supplementation.<sup>61</sup> However this concept has been challenged.<sup>296</sup> Plasma levels of PUFA, but not SFA, are associated with lower apolipoprotein AI (apo-AI) and HDL-C levels in the Framingham study, but with different features in men and women.<sup>297</sup> How plasma non-esterified fatty acids (NEFA) composition correlates with plasma HDL-C levels in a free living population of Southern Italy that follows a “modern” version of the MD with a lower content of fibers and an excess of introduced calories in comparison with the “traditional” diet has been addressed in one study.<sup>298</sup> Olive oil constitutes the majority of dietary fat, in this study. The study population was characterized by a high prevalence of obesity<sup>298, 299</sup> and MetS.<sup>299</sup> On average, HDL-C levels of this population were slightly lower than the Italian levels.<sup>298, 299</sup> HDL-C levels of this population correlated positively with the proportion of plasma PUFA and negatively with SFA. Among individual NEFA, HDL-C levels strongly and negatively correlated with C14:0, C18:1n9 and C20:1n9, and positively with C16:1. An “in vitro” model of cultured hepatoma cells was then conditioned with NEFA and those FA that best correlated with plasma HDL-C levels in the population, or that resulted very abundant in the plasma, as C18:0. This “in vitro” study documented that myristic acid modified the HDL binding to liver cultured cells. C14:0 increased the nonspecific binding of HDL to cell surface and it did not affect the saturable receptor-mediated binding. C14:0. Thus, myristic acid is negatively correlated with plasma levels of HDL-C in a MD characterized by an excess of obesity and MetS, and part of this correlation might be explained by an increase of HDL binding to hepatic HSPG and subsequent cholesteryl esters stripping by proteoglycans-bound lipases.<sup>300</sup>

## **Triglycerides**

Observational studies have found an association between elevated triglyceride (TG) levels and increased risk for CV disease morbidity and mortality. In the 1990s, the lipid research clinics follow-up study<sup>301</sup>, the physicians' health study<sup>302</sup>, and a meta-analysis of 17 population-based prospective studies<sup>303</sup> consistently found that increased concentrations of TGs are associated with an increased risk of AMI, CAD, and mortality, independent of HDL concentrations.<sup>304-306</sup> In recent years, a genetic predisposition to elevated TG levels has also been documented.<sup>307</sup> TGs have also independently contribute in the causal pathway of atherosclerosis. The effect of the MD on TGs has been thoroughly investigated. In a 3-mo intervention, a MD supplemented with walnuts reduced TGs by 0.15 mmol/L compared with a low-fat control diet.<sup>308</sup> One 3-mo intervention trial compared a low-fat diet and a MD for effects on TG-rich lipoprotein (TRL), TGs, and TRL-TGs.<sup>309</sup> In both groups, TGs were 0.2 mmol/L lower after adjustment for BMI; TRL-TGs were also lower by 0.16 mmol/L in the MD group.

## **Smoking habit**

Vardavas et al.<sup>310</sup> performed a literature search to investigate whether adherence to MD might have a role to modify the deleterious effects on human health of active and passive smoking. They found that both epidemiological and laboratory studies show that MD has a protective effect against biochemical and molecular processes that lead to cancer, CV disease and respiratory illness. Based on the high daily intake of vitamins and antioxidants, MD provides a variety of compounds that positively affect certain outcomes related to smoking. Moreover, some diseases attributable to smoking, such as lung cancer, asthma and CV disease, are inversely associated with the use of certain antioxidants and lipids.

## Obesity

Traditional nutritional advice for the treatment of obesity and associated disorders has emphasized avoiding animal fat and, preferably, all types of dietary fat, and replacing them with carbohydrate (CHO).<sup>311</sup> The central arguments against animal fats consumption and of fatty foods in general, have been a high content in cholesterol-rising saturated fatty acids (SFA) and excess energy, thought to promote obesity. Scientific evidence has accumulated concerning the beneficial role of diets with a relatively high MUFA content on CV risk factor outcomes, including diabetes.<sup>312</sup> The debate on what is the best nutrient to replace energy sources from SFA in the diet, CHO or MUFA, has indirectly been solved by the Women's Health Initiative study<sup>313</sup> in which the lack of protective effect of a high-CHO diet against CV disease has been documented. Recent results from a 20-year follow-up of the prospective Nurses' Health Study<sup>314</sup> suggest that a low-CHO diet (high-fat and/or high-protein) does not promote CAD and might actually reduce its incidence when the diet is high in unsaturated fat and vegetable proteins. The results of observational studies in Mediterranean countries, where people complying with the MD consume significant amounts of olive oil, have shown that increasing adherence to such high-fat, high-MUFA dietary pattern is associated with decreasing obesity rates.<sup>315-317</sup> Accordingly, a prospective study from a Mediterranean country has shown that increasing olive oil use is not associated with weight gain.<sup>318</sup> Moreover, a recent cohort study (n=613 individuals) has demonstrated, after 6 years of follow up, a lower incidence of obesity in those who consumed olive oil than in those who consumed sunflower oil.<sup>319</sup> Another randomized trial with ad libitum MD enriched with olive oil or mixed nuts, the PREDIMED study, showed no 3-month weight gain with these high-fat diets.<sup>308</sup> Restricted energy diets that were relatively high in fat because they incorporated olive oil were effective alternatives to the traditional low-fat diet for initial weight loss and maintenance in feeding studies in obese persons.<sup>320, 321</sup> A satiating effect of olive oil intake with ensuing food compensation might explain its lack of a fattening effect. In this regard, experimental evidence has been provided that

mobilization of intestinally-derived oleoylethanolamide, a lipid messenger of satiety, is enabled by uptake of dietary oleic acid.<sup>322</sup> These positive effects accounted for by the MD have also been observed in other European region. In a recent study including a sample size of almost 500,000 individuals from 10 Mediterranean, Central, and Northern European countries, the adherence to a MD, modified to apply across Europe, was associated with lower waist circumference in men and women after controlling for BMI, total energy intake, and other potential confounders. Interestingly, the inverse association between MD Score and waist circumference was stronger in men and women from Northern European regions who were overweight or obese.<sup>323</sup> In another prospective cohort study (EPIC-PANACEA) in 373,803 individuals from 10 European Countries,<sup>324</sup> individuals with a high adherence to the MD showed a 5-y weight change of -0.16 kg (95% CI: -0.24, -0.07 kg) and were 10% (95% CI: 4%, 18%) less likely to develop obesity than individuals with a low adherence to the MD pattern.

## **Sex**

Sex differences in the impact of the MD on glucose/insulin homeostasis have been documented (see above). Whether these sex-related effects were associated with changes in NEFA has been verified in 38 men and 32 premenopausal women (24–53 y).<sup>325</sup> Variables were measured during a 180 min Oral Glucose Tolerance Test (OGTT) before and after the MD. A sex-by-time interaction for plasma insulin iAUC was found (men: -17.8%,  $P = 0.02$ ; women: +9.4%,  $P = 0.63$ ;  $P$  for sex-by-time interaction = 0.005). A sex-by-time interaction was also observed for insulin sensitivity (Cederholm index,  $P = 0.03$ ), for which only men experienced improvements (men: +8.1%,  $P = 0.047$ ; women: -5.9%,  $P = 0.94$ ). In contrast, no sex difference was observed for glucose and C-peptide responses. Trends toward a decrease in NEFA AUC ( $P = 0.06$ ) and an increase in NEFA suppression rate ( $P = 0.06$ ) did not show any sex difference. Changes in NEFA were not associated with change in insulin sensitivity. Compared to women, more favorable changes in

glucose/insulin homeostasis were observed in men. These differences in response to the MD are not explained by sex differences in NEFA response.

Long-term adherence to the MD following a nutritional intervention promoting the Mediterranean food pattern in Canadian men and women presenting CV risk factors has also been evaluated.<sup>326</sup> The 12-week nutritional program used a motivational interviewing approach and included individual and group sessions. A food frequency questionnaire was administered to evaluate dietary intakes from which a Mediterranean score (Medscore) was derived and the Three-Factor Eating Questionnaire allowed for assessing eating behaviors. Measurements were performed at baseline and after the 12-week nutritional intervention, and then at 3 and 6-month post intervention. No gender difference was observed in changes in the Medscore during the nutritional intervention and follow-up. However, the Medscore returned towards baseline values during follow-up in men and women ( $P < 0.0001$ ). Men reported larger decreases in red and processed meat and larger increases in whole fruit intakes than women ( $P = 0.03$  and  $P = 0.04$ , respectively). Men showed a greater decrease in habitual susceptibility to disinhibition than women ( $P = 0.03$ ). A gender by time interaction was found for waist circumference, i.e. men having lower waist circumference at the end of the intervention as well as at follow-up than at baseline. Women's waist circumference decreased in response to the intervention only ( $P = 0.05$ ). Changes observed in total-cholesterol (C) to HDL-C ratio, triglyceride levels and triglycerides to HDL-C ratio were more pronounced in men than in women after the intervention as well as at follow-up ( $P \leq 0.03$ ).

### **Aging**

Dietary manipulation might be a major tool for partially modifying the structure and consequently the features of biological membranes.<sup>327</sup> The possibility of supporting cell membranes with specific membrane components that are characterized by an elevated turnover allows to ameliorate and/or counteract modifications induced by the activity of free radicals. If the new fatty acids to be

used in this process are provided in the form of virgin olive oil, a variety of benefits are likely to occur. With its very high content of MUFA (mainly oleic acid), olive oil greatly enriches all biological membranes so that it partially and gradually replaces the other fatty acids, mainly PUFA. This process produces membranes that are less susceptible to oxidative injury because of the increased concentration of oleic acid. It is important to emphasize that the propagation of lipid peroxidation phenomena requires the fatty acids to possess two or more double bonds.<sup>327</sup> On the other hand, virgin olive oil also contains large amounts of free-radical scavengers (e.g.  $\alpha$ -tocopherol, several different phenolic compounds and even coenzyme Q) that neutralize the toxic species and sometimes even prevent the early steps of their formation.<sup>328-330</sup> The efficacy of dietary interventions based on virgin olive oil to modify the fatty acid pattern of biological membranes making them less prone to oxidative modifications, has been widely demonstrated.<sup>61, 331-333</sup> In addition, MUFA lead to favorable changes in the lipid profile of lipoproteins, generating LDL particles more resistant to oxidative modifications.<sup>334</sup> Therefore, it has been suggested that MD might be a new, promising direction in the treatment (and in the prevention) of age-related diseases, as a useful adjuvant to the corresponding pharmacological therapy.<sup>327</sup>

## **MD and Emerging Vascular Risk Factors**

### **Fatty acids profile**

The beneficial effect of MD is thought to be related to its ability to affect several key risk factors.<sup>335</sup> Through the intake of antioxidants, fiber, and polyunsaturated fats, MD lowers blood pressure and plasma homocysteine concentrations, improves endothelial function, and insulin resistance, and decreases the risk of thrombosis and of ventricular arrhythmias.<sup>32, 259, 336-340</sup> On the other hand, vis-à-vis the seminal concept in the Seven Countries Study that 10-yr coronary mortality rate was significantly related to sample average saturated fatty acid intake in the habitual diet, several authors have emphasized reductions in CV risk -in primary

and secondary prevention studies-, when replacing saturated fatty acid intake with MUFA and/or PUFA <sup>341-343</sup>. FA influence plasma levels of atherogenic lipoproteins<sup>344</sup> and affect several aspects of inflammation,<sup>345</sup> a key mechanism in atherothrombosis.<sup>346</sup>

Presently, among a variety of debated dietary recommendations to decrease the risk of CV disease, reducing the intake of saturated fatty acid (SFA) (or replacing it with monounsaturated or polyunsaturated fatty acids) is a priority in CV prevention guidelines.<sup>347, 348</sup> However, the results of two meta-analyses have questioned the link between saturated fat intake and risk.<sup>349, 350</sup> Even though the FA profile of individuals is influenced by dietary intake - as is the case of LA and ALA- it is also endogenously modulated by the activity of specific enzymes.<sup>351</sup> Studies <sup>36, 352-354</sup> indicate that, compared with healthy subjects, patients with CAD exhibit higher blood levels of trans fatty acids and SFA and lower levels of PUFA, with controversial data about n-6 PUFA, especially AA.<sup>355</sup> Blood levels of palmitic acid are strongly associated with CAD.<sup>356</sup> Whether, however, blood FA: 1) is an index of the quality of food intake; 2) it might be used as a tool to estimate diet quality and compliance with a nutritional advice, and 3) the adverse plasma fatty acid profile in patients with CAD can be favorably modified by consuming a MD, has not been established in previous reports.

## **Inflammation**

So far, the beneficial effect of MD against CAD has been accounted for by the ability of this dietary pattern to modify traditional risk factors of atherosclerosis. Recently, some authors have suggested that the anti-inflammatory effect—at the level of the vessel wall- may be key to explain the link between MD adherence and low CV mortality.<sup>357</sup> There is compelling evidence that inflammation is crucial at all stages of the atherosclerotic process.<sup>358</sup> Early phases of atherosclerosis (fatty streak formation) involve the recruitment of inflammatory cells from the circulation, their adhesion to endothelium and migration to sub-endothelial space, a complex process which involves adhesion molecules (e.g. interleukin [(IL])

production and up-regulation on endothelial cells and leucocytes.<sup>359</sup> Adhesion molecule expression on circulating peripheral blood mononuclear cells is a crucial step for the firm adhesion of such cells to the endothelium during the inflammatory reaction linked to atherosclerosis development.<sup>358, 359</sup> Thereafter, resident macrophages and lymphocytes become activated and secrete cytokines that in turn activate other cell types leading to a self-perpetuating inflammatory process in the vascular wall that is instrumental in plaque formation, vulnerability and rupture leading to thrombosis.<sup>358, 359</sup> Thus, ongoing inflammation is also crucial in the development of instability and rupture of atheromatous plaques and the development of ischaemic events in most advanced stages of the disease.<sup>358, 359</sup>

Adipose tissue is both a dynamic endocrine organ, and a highly active metabolic tissue. Fat produces and secretes adipokines, which play an important role in the induction of insulin resistance and in the atherosclerotic process. Visceral adiposity is more strongly associated with insulin resistance than subcutaneous fat. However, the precise chain of events linking over-nutrition, obesity, activation of the innate immune system and reduced insulin sensitivity in peripheral tissues remains incompletely understood.<sup>360</sup> In a randomized controlled study in 120 obese women, a multidisciplinary program aimed at reducing weight through lifestyle changes (diet and exercise) was associated with reduced levels of CRP and IL-6, and increased levels of adiponectin, associated with improved insulin sensitivity.<sup>361</sup> Mechanisms underlying a dietary intervention in patients at increased cardiac risk were also explored<sup>357</sup> in 180 patients (99 men and 81 women) with the MetS randomized to receive a MD-style diet (instructions about increasing daily consumption of whole grains, vegetables, fruits, nuts and olive oil) vs. a cardiac-prudent diet (less than 30% fat intake). After 2 years, while endothelial function improved, body weight decreased more in the intervention group than in the control group, but even after controlling for weight loss, inflammatory markers, such as IL-6, IL-7, IL-18 and CRP, and insulin resistance declined more in the MD intervention group than in the control group. Only 40



patients in the intervention group still had MetS after 2 years when compared with 78 patients on the control diet.

### **Oxidative stress.**

It is long been known that ROS produced by activated leukocytes and macrophages are crucial to control invading microorganisms. Now it is clear that these intermediary metabolites produced under physiological conditions during oxygen metabolism, also play a critical role as signal molecules in health and disease. Mitochondria are the most important source of intracellular ROS. However, ROS can be generated by a variety of enzymes including oxidases, cyclooxygenases and lipoxygenases. The primary ROS produced in the body is superoxide anion ( $O^{2-}$ ), which is generated from a 1-electron reduction of molecular oxygen. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is the main source of  $O^{2-}$  in mammalian cells.<sup>362</sup> NADPH oxidase is a multicomponent enzyme that has a membrane portion known as cytochrome  $b_{558}$  (that comprises a large gp91phox, and a smaller p22phox subunit), which is inactive until it is associated with the cytosolic component (p47phox, p67phox and p40phox). Under physiological conditions, reactive and incompletely reduced forms of oxygen are detoxified into water by anti-oxidant defence and repair enzymes to maintain a low steady state of toxic oxidants.<sup>363</sup> Steady-state levels of  $O^{2-}$  depend on both their rate of production and the activity of a wide array of dietary antioxidants and endogenous antioxidant enzymes such as glutathione (GSH, reduced form), catalase, and superoxide dismutase (SOD).<sup>364</sup> In plasma, glutathione (GSH, reduced form) and glutathione disulphide (GSSG, oxidized form) are transported from tissues by concentration-dependent transport systems.<sup>365</sup> Results from animal experiments have shown that the of GSH to GSSG ratio (GSH/GSSG) in plasma decreases in response to tissue oxidative stress.<sup>366</sup> Therefore, GSH/GSSG may be preferable to either GSH or GSSG alone as an overall indicator of the redox status and to be used as a marker of oxidative stress.<sup>367</sup> In mammals, there are 3 isoforms of SOD: a cytosolic or copper/zinc (Cu/Zn- SOD), a

manganese (MnSOD) localized in mitochondria, and an extracellular form of Cu/ZnSOD. Although produced by distinct genes, these 3 SODs catalyze the same reaction: dismutation of  $O^{2-}$  into hydrogen peroxide plus molecular oxygen.<sup>368</sup> While an imbalance in the mitochondrial respiratory chain is the main source for the generation of abnormally high levels of ROS, an impaired antioxidant capacity leads to an excess in the production of ROS as well, and in turn to oxidative stress, i.e. to the disruption of the redox signalling and control<sup>369</sup> with subsequent oxidation of macromolecules, and tissue damage and dysfunction.<sup>370</sup> In particular, oxidative stress is involved in major events related to CV disease such as DNA damage, tissue remodelling, and alterations in gene expression.<sup>371</sup> Biochemically, GSH/GSSG redox decreases lipid hydroperoxides by reducing these peroxides into alcohols and suppressing their generation.<sup>372, 373</sup> Decreased lipid hydroperoxides, in turn, lower oxidized LDL and slow the atherosclerotic process.<sup>372, 373</sup> Additionally, a lower GSH/GSSG may result in protein glutathionylation and oxidatively altered GSH-GSSG redox signalling<sup>367</sup> and associated gene expression and apoptosis, which may contribute to atherosclerosis. Clinically, an unfavourable GSH/GSSG has been found in patients with AMI<sup>374</sup> and has been related to the progression of atherosclerotic lesions after percutaneous coronary interventions.<sup>375</sup> Among multiple key factors in the physiology of the endothelium, oxidative stress has been identified as a major regulatory mechanism. Current evidence is that MD leads to improved redox balance, increased nitric oxide bioavailability and decreased availability of pro-inflammatory and pro-oxidant molecules.<sup>339, 357, 376, 377</sup> Old studies from this Institution have reported that phenols -natural antioxidants present in virgin olive oil-, affect endothelial function in a dose-dependent manner.<sup>378</sup> The possibility that key components of MD act synergistically on endothelial function through their antioxidant properties has been also addressed. The combination of high-phenol virgin olive oil and red wine (rich in antioxidants) induce favorable effects on postprandial flow-mediated dilatation in healthy young men.<sup>379</sup> Although the exact molecular routes underlying these effects are

still matter of investigation, hydroxytyrosol (a key phenol antioxidant of virgin olive oil) and resveratrol –a major antioxidant of red wine-, both exert their vaso-protective effects in response to oxidative injury by the activation of the Nrf2 pathway, which, in turn, promotes the expression of antioxidants, e.g. NAD(P)H:quinone oxidoreductase 1.<sup>123, 380</sup> Moreover, polyphenols cause nitric oxide, and endothelium-derived hyperpolarizing factor mediated relaxation.<sup>381</sup> Compelling evidence suggests an association between oxidative stress and obesity/insulin resistance. In nearly 3,000 patients from the Framingham Heart Study, an association between increasing body mass index and increasing systemic oxidant stress has been reported.<sup>382</sup> Data from 2,002 nondiabetic subjects of the community-based Framingham Offspring Study indicate that, even after correcting for BMI, systemic oxidative stress is associated with insulin resistance in individuals at average or high risk of diabetes. (metabolic syndrome or IFG)<sup>383</sup> Short-term (up to six months) caloric restriction in overweight men and women produced significant body weight reduction associated with decreased DNA damage, another surrogate marker of oxidative stress.<sup>384</sup> Finally, individuals at high CV risk who improved their diet toward a MD pattern show significant reductions in cellular lipid levels and LDL oxidation.<sup>385</sup> Adiponectin -a protective factor against atherosclerosis and insulin resistance-, plays an important role in modulating both insulin sensitivity and concentrations of circulating plasma glucose and NEFA, a lower concentration of circulating plasma of NEFA being a good predictor of reduced insulin sensitivity and increased risk of T2DM.<sup>386</sup> Accordingly, a MD-type of diet reduces the need for glucose-lowering drugs and improves short-term glucose control more than a low-fat diet in overweight patients with newly diagnosed T2DM.<sup>103</sup> Regardless of caloric restriction, a prolonged adherence to MD in overweight men results in a rise in circulating level of adiponectin, and lowers several markers of oxidative stress.<sup>387</sup> In 987 diabetic women from the Nurses' Health Study with no history of CV, the closer the adherence to a MD the higher the adiponectin concentration.<sup>388</sup> Of the components of the MD pattern, alcohol, nuts, and whole grains show the

strongest association with adiponectin concentrations. In insulin-resistant offspring of obese T2DM patients, a MD rich in MUFA (23%) improves insulin sensitivity, and this is associated with increased postprandial adiponectin mRNA gene expression in peripheral adipose tissue.<sup>389</sup> All in all, in addition to lowering blood pressure, and total cholesterol and triglycerides; increasing HDL-cholesterol, and improving insulin sensitivity, a prolonged adherence to MD, with or without caloric restriction in overweight or obese men, is associated with reduced oxidative stress. The latter changes are amplified when MD is associated with calorie restriction and increased physical activity.<sup>390</sup> This information is particularly important for individuals who carry additional risk factors, such as T2DM, obesity, and the metabolic syndrome, and fail, as most do, to have a consistent and long-term weight loss.

## Rationale

Since the first data from the Seven Countries Study,<sup>391</sup> several studies carried out in different populations have established a beneficial role for the main components of MD as to the occurrence of all-cause cardiovascular (CV) disease, including CVD and chronic degenerative diseases, malignancy, lipid metabolism, blood pressure, and pathophysiological settings such as endothelial dysfunction and overweight.<sup>392</sup>

A systematic review of prospective cohort studies that have analysed the relation between the adherence to several MD scores and the risk of CV mortality in primary prevention settings (404,491 subjects), confirmed these findings showing that a two point increase in the adherence to MD scores was significantly associated with 9% reduction of the risk of cardiovascular mortality, largely independent of vascular risk factors (VRFs).<sup>393</sup> To this end, a literature-based MD score based on nine items that may predict the CV risk at individual level has been proposed.<sup>394</sup>

Concerning the relationships between MD score and subclinical atherosclerosis (as indexed by carotid intima media thickness; c-IMT) and/or its change over time (cIMT progression), the results reported in the literature are sparse and often inconsistent.<sup>34, 242-245, 250</sup> Epidemiological studies investigating the association between MLDP and c-IMT progression in large cohorts are completely lacking. As to oxidative stress status evaluation, it is increasingly clear that in different stages during the atherothrombotic process, abnormally high levels of reactive oxygen species (ROS) are generated that can overwhelm antioxidant systems and adversely affect cell function by causing oxidative post-translational injury.<sup>395</sup> A similar altered equilibrium can be found when evaluating both inflammation markers and blood fatty acids profile in patients with CVD.<sup>396, 397</sup> Indeed, blood fatty acids (FA) composition has been implicated in cardiovascular risk, presumably through changes in oxidative stress and inflammation, two mechanisms involved in the pathogenesis of atherothrombosis.<sup>36</sup> Previous data

from our group suggest that patients with CAD adhere less to features of MD and exhibit a different fatty acid profile compared to healthy subjects.<sup>396</sup>

### **Aims of the present study**

Primary objectives of the present study were to evaluate:

- 1) The relationship between MD adherence and c-IMT progression;
- 2) Whether such relationship is similar in populations from different European countries with different nutritional patterns/habits (e.g. in people living far from the Mediterranean area);
- 3) Whether the relationship between MD (or of its components) and baseline c-IMT burden is consistent with a dose–response relationship or a threshold effect;
- 4) Whether the relationship between MD, baseline c-IMT, and clinical events involves changes in major and emerging (e.g. inflammation, oxidative stress, and FA composition) vascular risk factors.
- 5) Whether and to what extent MD adherence relates to inflammatory markers, markers of an oxidative stress status, and to FAs profile in males and females with a recent history of coronary revascularization.

## Methods

For the objectives of the present report, data from two major studies carried out in this Institution have been analyzed: the IMPROVE Study and the RISMED Study. Additional information concerning these two studies are reported below.

### The IMPROVE Study

Study objectives The primary objective of the IMPROVE study was to evaluate the association between Mediterranean-like dietary pattern (MLDP) and c-IMT progression over 15 months and to assess whether c-IMT progression was an independent predictor of risk of future vascular events (VEs) (AMI, cardiovascular death, stroke, or any intervention in the carotid, coronary, or peripheral arterial districts) occurring from the 15th to the 36th month in the follow-up. To achieve this goal the 3-year follow-up was split into two time periods: from 0 to 15 months to measure the c-IMT changes over time and from 15 to 36 months to collect VEs.<sup>249</sup>

### Study design.

The design and the major results of the IMPROVE studies have been published elsewhere.<sup>249, 398</sup> Briefly, the IMPROVE study is a multicenter, longitudinal, observational study, funded by European Union (EU) within the V<sup>th</sup> framework program, which involves seven recruiting Centers in five European countries: Finland (two Centers), France, Italy (two Centers), the Netherlands, and Sweden. The study was designed according to the rules of Good Clinical Practice (GCP), and the ethical principles established in the Declaration of Helsinki. Each participant provided two different informed consents; one for general participation in the study and one for genotyping.<sup>247</sup> The protocol was designed for a study duration of 36 months. Recruitment of a total of 3,598 patients (514 per center) was targeted. About 21,000 subjects were screened: 3,400 in Milan, 1,450 in the first Kuopio center and 2,354 in the second, 4,239 in Stockholm, 4,050 in the



Netherlands, 3,804 in Perugia, and 1,800 in Paris. Men and women, aged from 55 to 79 years, with at least three VRFs, asymptomatic for cardiovascular diseases and free from any conditions that might limit longevity or c-IMT visualization were considered as eligible for the study. Individuals who met the eligibility criteria and who signed both informed consents were enrolled in the study. Due to its observational nature, participation did not require any change in medication(s).<sup>247</sup> A total of 3,711 individuals were enrolled, aged 54-79 years were enrolled. All participants never had a cardio- or cerebro-vascular event before enrolment and all have at least three VRFs. Subjects were considered to be exposed to a VRF when one of the following criteria was satisfied: male sex or at least 5 years after menopause for women; hypercholesterolemia (mean calculated LDL-C blood levels > 160 mg/DL or treatment with lipid lowering drugs); hypertriglyceridemia (triglycerides levels > 200 mg/DL after diet or treatment with triglycerides lowering drugs); hypoalphalipoproteinemia (HDL-C < 40 mg/DL); hypertension (diastolic blood pressure > 90 mmHg and/or systolic blood pressure >140 mmHg or treatment with anti-hypertensive drugs); diabetes or impaired fasting plasma glucose (blood glucose level > 110 mg/DL or treatment with insulin or oral hypoglycemic drugs);<sup>399</sup> smoking habits (at least 10 cigarettes/day for at least thirty months); family history of cardiovascular diseases. Exclusion criteria were: age under 54 or over 79 years; abnormal anatomical configuration of neck and muscles, marked tortuosity and/or depth of the carotid vessels and/or uncommon location of arterial branches; personal history of AMI, angina pectoris, stroke, TIA, aortic aneurysm, intermittent claudication, surgical intervention of revascularization in carotid, coronary or peripheral arterial territories, CHF (III-IV NYHA Class); and history of serious medical conditions that might limit longevity (e.g. cancer).<sup>249</sup>

#### **Ultra sonographic protocol.**

Carotid ultrasound was performed using seven identical ultrasonic machines (Technos system, ESAOTE), equipped with 5-10 MHz linear array probes. All

machines were identically calibrated. Calibration was checked with a phantom before the start of the study and after 1 year. Sonographers and readers were trained and certified by the coordinating Center (Department of Pharmacological and Biomolecular Sciences) in Milan. The far walls of the left and right common carotid (CC), the bifurcation (BIF) and the internal carotid artery (ICA) were visualized in anterior, lateral and posterior angles and recorded on sVHS videotapes. Images were acquired with the subject's head rotated approximately 45° opposite to the side being imaged and the three angles were acquired with the transducer held approximately at 45°, 20° and 60° from the vertical. Each selected image of the CCs (in their entire length), the BIFs, and the first proximal centimeter of the ICAs were measured in at least three different frames randomly distributed within the cardiac cycle. In order to explore the influence of the cardiac cycle on IMT measurements, in a subsample of 100 subjects, CC- $IMT_{mean}$  was re-measured using a dedicated software,<sup>400</sup> which allows continuous measurements of IMT within 3 to 5 beats, thus allowing recording of the kinetics of IMT changes associated to cardiac cycle. Peak systolic and end-diastolic IMT measurements, as well as their average, were then compared with IMT measurements obtained according to the IMPROVE protocol without electrocardiographic synchronization. Preliminary data showed that IMT measurements obtained with the IMPROVE protocol ( $0.667\pm 0.172$  mm) well fitted with the mean value ( $0.665\pm 0.172$ ) of IMT measurements obtained in peak systolic ( $0.631\pm 0.164$  mm) and end-diastolic ( $0.699\pm 0.172$  mm) phases, with a very good correlation ( $r = 0.9993$ ) and a minimal bias. In each carotid segment (1 cm length), both mean and maximal IMT were evaluated. Plaques were incorporated into these measurements. Eleven C-IMT variables were considered:  $1^{st}CC-IMT_{mean}$ ,  $1^{st}CC-IMT_{max}$ ,  $CC-IMT_{mean}$ ,  $CC-IMT_{max}$ ,  $BIF-IMT_{mean}$ ,  $BIF-IMT_{max}$ ,  $ICA-IMT_{mean}$ ,  $ICA-IMT_{max}$ ,  $IMT_{mean}$ ,  $IMT_{max}$  and  $IMT_{mean-max}$ .  $1^{st}CC-IMT_{mean}$  is the average of six mean IMT values obtained by measuring both left and right CC (1 cm length proximal to the bifurcation) in the 3 angles (anterior, lateral and posterior). The greatest among all the maximal IMT values measured in each one of these six  $1^{st}CC$

segments (two carotids x three angles) was defined  $1^{st}CC-IMT_{max}$ .  $CC-IMT_{mean}$  is the average of all mean IMT values obtained from left and right CC visualized in their entire length (excluding the 1<sup>st</sup> cm) with sequential probe movements of 1 cm length, according to the 3 scan angles (anterior, lateral and posterior). The total number of segments visualized ranged from 6 to 24 according to the subject's length of the neck. In each segment, the software automatically provided also the maximal IMT value. The greatest among all the maximal IMT values detected in each one of the 6 to 24 CC segments was defined as  $CC-IMT_{max}$ .  $BIF-IMT_{mean}$  is the average of six mean IMT values obtained by measuring both left and right BIF (1 cm length) in the 3 angles (anterior, lateral and posterior). The greatest among all the maximal IMT values measured in each one of these 6 BIF segments (left and right Bif x three angles) was defined  $BIF-IMT_{max}$ .  $ICA-IMT_{mean}$  is the average of six mean IMT values obtained by measuring both left and right ICAs (the 1<sup>st</sup> cm proximal to bifurcations) in the 3 angles (anterior, lateral and posterior). The greatest among all the maximal IMT values measured in each one of these 6 ICA segments (left and right ICA x three angles) was defined  $ICA-IMT_{max}$ . Composite variables ( $IMT_{mean}$ ,  $IMT_{max}$  and  $IMT_{mean-max}$ ) refer to the whole carotid tree:  $IMT_{mean}$  is the average of  $1^{st}CC-IMT_{mean}$ ,  $CC-IMT_{mean}$ ,  $BIF-IMT_{mean}$  and  $ICA-IMT_{mean}$ .  $IMT_{max}$  is the greatest value among  $1^{st}CC-IMT_{max}$ ,  $CC-IMT_{max}$ ,  $BIF-IMT_{max}$  and  $ICA-IMT_{max}$ .  $IMT_{mean-max}$  is the average of  $1^{st}CC-IMT_{max}$ ,  $CC-IMT_{max}$ ,  $BIF-IMT_{max}$  and  $ICA-IMT_{max}$ .

About 62% of participants were followed throughout the study by the same sonographer, and all scans for each subject were assigned to a single reader after coding and were read blindly in the centralized laboratory of Milan using a dedicated software (M'Ath, Metris SRL France).<sup>401</sup> These measurements were not reported to patients. The total number of carotid plaques ( $IMT_{max} > 1.5$  mm) in each carotid segment and in the whole carotid tree (also normalized according to the number of segments actually visualized) and the number of non-visualized carotid segments were also recorded. To evaluate changes of C-IMT over time, ultrasonographic measurements were repeated at 15 months using the same

ultrasonographic protocol (positions and angles of ultrasound transducer with respect to the neck) used at baseline. C-IMT change for each ultrasonographic variable, expressed in mm/year, was calculated as the difference between the 15-month measurement and the corresponding baseline value divided by the length of the time of intervention.

The variables selected for the statistical analyses were the changes per year of mean and maximum IMT values of the first centimeter of CC proximal to the bifurcation ( $1^{\text{st}}\text{CC-IMT}_{\text{mean-progr}}$  and  $1^{\text{st}}\text{CC-IMT}_{\text{max-progr}}$ ), of the remaining part of CC ( $\text{CC-IMT}_{\text{mean-progr}}$  and  $\text{CC-IMT}_{\text{max-progr}}$ ), of BIF ( $\text{Bif-IMT}_{\text{mean-progr}}$  and  $\text{Bif-IMT}_{\text{max-progr}}$ ) and of ICA ( $\text{ICA-IMT}_{\text{mean-progr}}$  and  $\text{ICA-IMT}_{\text{max-progr}}$ ) as well as the changes of the mean, maximum and mean-maximum IMT values of the whole carotid tree ( $\text{IMT}_{\text{mean-progr}}$ ,  $\text{IMT}_{\text{max-progr}}$ , and  $\text{IMT}_{\text{mean-max-progr}}$ ). To explore hypothesis that vascular risk may be better associated with a focal rather than diffuse progression and that the maximal change may occur in any site regardless of its location and its initial size, the “Fastest- $\text{IMT}_{\text{max-progr}}$ ”, i.e. the greatest value chosen among the progressions of  $\text{IMT}_{\text{max}}$  detected in the eight carotid segments measured was also considered. Examples of the Fastest- $\text{IMT}_{\text{max-progr}}$  in three subjects are shown in (Supplemental Figure IV). The precision of the ultrasonographic measurements at baseline has been reported.<sup>247, 398</sup>

### **Laboratory analyses.**

Laboratory analyses were performed at baseline and at month 30. Several biological samples were kept in a biobank. Specifically, the biobank contains 14 aliquots of 0.5 mL EDTA plasma and 8 aliquots of 0.5 mL serum for each subject. In addition, for each subject, 2 x 5 mL whole blood was stored for DNA extraction. DNA was purified (in the Atherosclerosis Research Unit, Karolinska Institute Stockholm, Sweden) from all patients who signed informed consent for genetic studies. Blood sampling for laboratory tests was performed after an overnight fast. Plasma glucose concentration, blood cell count, hematocrit and differential counts were measured locally. Blood for centralized biochemical analyses was kept at

room temperature for a minimum of 30 min to allow clotting to occur. Serum, prepared by centrifugation at 2,000g for 20 min, was dispensed in polypropylene tube and frozen at  $-80^{\circ}\text{C}$  prior to shipment for centralized biochemical analyses and biobanking in Stockholm (Karolinska Institute Stockholm, Sweden). Serum concentrations of total, HDL and LDL cholesterol (by Friedewald's formula), triglycerides, uric acid, high-sensitive C-reactive protein (hs-CRP) and creatinine were analyzed in a centralized laboratory in Stockholm (Department of Clinical Chemistry, Karolinska University Hospital Solna, Stockholm, Sweden) with the use of LX Beckman instruments. Cholesterol, triglycerides and uric acid were measured with enzymatic methods, creatinine with colorimetry-alkaline picric and hs-CRP with turbidimetry (NIPIA methods). Additional information concerning methods for laboratory analyses have been reported.<sup>247</sup>

#### **Nutrition variables, physical activity, smoking habits, and psychosocial variables.**

Milk, wine, beer, spirits consumption and total amount of alcohol were recorded in terms of "DL/day". Fruit consumption was recorded in terms of "pieces a day". The consumption of meat, fish and eggs was recorded in terms of "times a week". The consumption of tea and coffee was recorded in terms of "times a day". Although collected in a semi-quantitative way, these variables were used in the analyses in terms of consumers ( $>0$ ) or not consumers ( $=0$ ). The main type of fat consumed (lard, butter, olive oil, seed oil, margarine) and the type of milk consumed (not skimmed, semi-skimmed, skimmed) were also recorded.<sup>247</sup>

#### **Quality control.**

*Standard operating procedures (SOPs)* Before the start of the study, investigators were provided with detailed Standard Operating Procedures (SOPs) and were required to abide by them, in conformity with GCP. *Case Report forms (CRFs)* Data were collected using electronic CRFs allowing automatic control of all entered data by logic controls and range checks, and easy identification of missing data. Once compiled, each file was sent to the data management Center (DMC) and included

into the central database without any further typing. *Confidentiality of data* Information about participant identity (name, address, phone number and identity in the study) was retained at each recruitment center. To protect confidentiality, all information transferred to the central DMC (University of Milan) was anonymized. *Monitoring* of data quality was performed by regular site visits, mail and telephone interviews. *Record retention.* Each principal investigator retains copies of all relevant information for a period of 15 years after the completion of the study.<sup>247</sup>

### **The Mediterranean-Like Dietary Pattern (MLDP) score.**

At baseline, dietary intake maintained during the year preceding enrolment was assessed by a semi-quantitative 11 items food-frequency questionnaire, administered by trained personnel. A MLDP score adherence score analogous to the Greek Mediterranean Index<sup>24</sup> and based on only seven nutritional items (fruits, fish, wine, olive oil, meat, milk and eggs) was then constructed. Since the amount and type of vegetables, legumes, nuts and cereals consumed largely differs among populations<sup>402</sup>, the items included in the questionnaire were limited to foods well diffused in all the countries involved. For fruit or fish, high consumption (top tertile of their distributions, i.e. fruit  $\geq 3$  servings/day and fish  $> 2$  times/week) was scored one, other intakes received 0 points; for meat, eggs or milk a low intake (bottom tertile of their respective distributions, i.e. meat  $< 2$  times/week, eggs  $\leq 1$  times/week, milk  $\leq 3$  DL/day) received 1 point. A predominant consumption of olive oil, rather than of other types of fat, and a moderate consumption of wine (1-2 glasses/day) also received one point. Based on the scale obtained, score 0 indicates minimal adherence and score 7, maximal adherence to MLDP. Such MLDP was adopted being its indices inversely associated with the incidence of stroke in a recent Italian study.<sup>403</sup> The predictive performance of the MLDP score was first validated versus the incidence of vascular events and then tested versus primary endpoints (i.e. 15-mo c-IMT progression). Because a

standardized questionnaire and a common clinical and subclinical assessment were used, the results for the entire cohort could be readily compared among IMPROVE centers and among EU. Besides diet, IMPROVE also included a baseline assessment of socio-demographic, anthropometric, lifestyle, clinical and biochemical measures.

## **The RISMED Study**

### **Study objectives**

The RISMED Study was a randomized, parallel groups, open-label, intervention trial in which a 3-mo intensively advised MD was tested vs. an usual low-fat dietary advice to assess: 1) the possibility to favorably modify the adverse plasma fatty acid (FA) profile in patients with CAD by consuming a MD; 2) the effect of a MD on the oxidative balance and on indices of systemic inflammatory activity, and the relationship between these potential changes and the modification of the blood FA pattern, and 3) whether blood FA is an index of the quality of food intake and whether it might be used as a tool to estimate diet quality and compliance with a nutritional advice.

### **Study design**

Participants (n= 75 per arm) were males and females, age 30-75, with a recent history of coronary revascularization, randomized after clinical stabilization (at least 60 days after any coronary procedure or event). Blood parameters (blood FA, total cholesterol, LDL-C, HDL-C, triglycerides, glucose), anthropometric variables (weight, height, waist circumference and BMI), blood pressure and heart rate were measured at randomization and at the end of the treatment. Exclusion criteria were: patients with diabetes mellitus, food intolerance, BMI < 19 or > 33, or those who assume drugs or food supplements with omega-3 FAs or natural or synthetic antioxidants.

### **Nutritional advice.**

MD was personalized in term of total calories, and included: fatty fish at least 3 times a week; legumes 2-3 times a week; raw or cooked vegetables (preferably antioxidant-rich), twice a day; fresh fruits twice a day; 30 to 45 g olive oil a day; men: 1-2 glasses of red wine a day, women: 1 glass of red wine a day; not more than 150 g red meat a week. Cold cuts, sweets, cakes, butter, fatty cheese were



discouraged. The control group received dietary counselling for mild weight loss (when needed) and low intake of saturated fats (<10% of total energy) and sugar rich foods. Dietary assessment was administered at enrolment by a validated dietary recall tool, the EPIC FFQ (food frequency questionnaire). Compliance to the assigned diet was assessed at the middle of the study using a 7-day food diary. The score proposed by Trichopoulou et al<sup>24</sup> was computed in both groups as a measure of adherence to the MD. A 7- day dietary recall was administered during the second month of the study to assess participants' compliance. Food and macronutrient intake throughout the year before inclusion was also estimated at enrolment using a validated FFQ of the EPIC, administered by a registered nutritionist. To assess whether blood FA is a reliable index of the quality of food intake, data obtained with the FFQ were correlated with the level of classes and specific types of FA in blood. Moreover, the change between baseline and final levels of FA classes and types were correlated with the compliance to the MD as assessed through a 7-day dietary recall performed at the middle of the study, a higher compliance with diet being associated with greater changes in levels of FA.

### **Laboratory analyses.**

Blood and urinary samples were used for routine biochemical determinations. For *blood FA analysis*, whole blood, obtained from a fingertip of fasting subjects, was collected on a special adsorbent embedded with the antioxidant butylhydroxytoluene (Blood Collection kit, Sigma-Aldrich, St. Louis, MO). FA methyl esters, directly prepared by transesterification, were analyzed by gas liquid chromatography at oven temperature from 120 °C to 235 °C.<sup>404</sup> The following indices of oxidative stress and systemic inflammatory activity were determined at randomization and at the end of the study: hs-CRP; whole blood reduced glutathione (GSH) and its oxidized form (GSSG). hs-CRP was measured by immunoturbidimetry. Newly developed methods were used to measure GSH and GSSG. Each will be described in detail below together with the method employed for determining blood FA profile.

### **FAs profile determination.**

Advantage of this method mainly consists in the fact that the profile of FAs reflects both plasma and red blood cell composition. Blood sampling is performed at the beginning and at the end of the study by fingertip puncture with an automatic punctured pen for diabetics with a disposable lancet. Blood drops are collected on an adsorbent paper strip (Sigma-Aldrich) suitable for chromatographic analysis of FA. Such paper contains two areas of 1.4 cm<sup>2</sup> each allowing for the collection of about 50 µl of blood that can be easily removed for extraction of FAs analysis. To avoid the degradation of the FA throughout the storage period, the adsorbent paper is soaked with the antioxidant butylhydroxytoluene (BHT) in ethanol (5 µg/µl) prior to sampling. To prevent degradation of the blood sample, once the blood is dried, the chromatographic strips are packed in individual envelopes (Ziplock), with the addition of a silica scrubber, and the samples are stored at -19° C for ≈two weeks. Preliminary studies documented that: 1) no chromatographic peak attributable to the adsorbent paper is detected in the chromatographic analysis of FAs, and 2) the samples treated according to this method are stable up to a few years. For the determination of the FA, a portion of chromatographic paper (1cm<sup>2</sup>) with the blood sample is transferred into vials with a sealed cap and a teflon protective seal. Each vial is added with 0.6 ml of 3N methanol solution in hydrochloric acid (Supelco) and the vial is placed in a dry thermostat bath at 90° C for 1 hour (Liebish Laboratechnick). After FA methylation and cooling in a cold room at 4° C, 1 ml of water; 1 ml of KCl saturated solution, and 400 µl of n-hexane are added to each vial to continue FAs methyl esters (FAME) extraction. After agitation, samples are centrifuged for 8 minutes at 3,250 rpm at a temperature of 6° C to facilitate phase separation and extract the supernatant containing the FA methyl esters. Finally, FAMEs are analyzed by injecting approximately 0.5 µl of each sample into the GC 2010 Shimadzu gas chromatograph equipped with PTV injector and FID detector and connected to a dedicated DDS 1000 software for data collection and processing. The auxiliary gas employed is helium, and the column used is a DB-FFAP (Agilent) with a length of 15 m, an inside diameter of 10

mm and a film of 0.10  $\mu\text{m}$  thick. The temperature of the column chamber is programmed as follows: an increase of 25°C/minute from 150° C to 205° C, isotherm at 205° C for 5 minutes, a further increase of 25° C / minute to 220° C, isotherm at 220° C for 2 minutes and finally an increase of 8°C/min to 248° C which is maintained for the next 9 minutes. Since a rapid gas chromatograph is used, with a run time of 19 minutes and 80 seconds each, the pressure is a higher than expected based on information from usual gas chromatographs ( $\approx 7.5$  bar). This increment allows for the detection of FAs with a carbon number ranging from 14 to 24. When processed with the appropriate software, the chromatograms obtained allow the data to be expressed as percentage values of the total FAs. Product to precursor ratios of specific FAs are calculated as surrogates of the activity of specific enzymes involved in FA metabolism; C16:1n-7/C16:0 ratio estimated  $\Delta 9$  stearoyl-CoA desaturase-1 (SCD1) and C18:3n-6/ C18:2n-6 ratio estimated  $\Delta 6$  desaturase (D6D).<sup>404</sup> The reproducibility of this analytical method has been tested by analyzing samples of old methylated FAs from a single subject to which, on the same day, two blood samples were analyzed over three different time periods (the same day, after one week and three weeks after storage) and three blood samples analyzed in the same day but picked up respectively at fasting, before the lunch and two hours after the meal.

#### **Measurement of GSH and GSSG.**

Chemicals and reagents: -l-Glutamyl-l-Cysteinyl-Glycine (GSH), -l-glutamyl-lcysteinyl-glycine disulfide (GSSG), trichloroacetic acid (TCA), ethylenediaminetetraacetic acid (EDTA) and all HPLC grade and LC–MS grade solvents were purchased from Sigma–Aldrich (St. Louis, MO, USA). Chromatographic columns were purchased from Phenomenex (Torrance, CA, USA). Millex®-GV Syringe filter units (13 mm, 0.22 m) were obtained from Millipore (Bedford, MA, USA).<sup>405</sup>

### Method development and validation

GSH and GSSG were measured on whole blood added with 10% trichloroacetic acid (TCA) in 1 mM EDTA solution to precipitate proteins and stored at -80°C until analysis. Levels of GSH and GSSG were assessed by LC-MS/MS method using a TSQ Quantum Access (Thermo Fisher Scientific, San Jose, CA, USA) triple quadrupole mass spectrometer coupled with ESI operated in MRM in positive mode.

Separation of analytes was carried out on a Luna PFP analytical column (100x2.0 mm, 3 µm, Phenomenex, Torrance, CA, USA). The LC mobile phases were: (A) ammonium formate 0.75 mM adjusted to pH 3.5 with formic acid and (B) methanol. Separation was performed under isocratic conditions with 99% mobile phase A at flow rate of 200 µL/min and a column temperature of 35°C. The MRM for GSH (m/z 308.1→m/z 76.2 + 84.2 + 161.9) and GSSG (m/z 613.2→m/z 230.5 + 234.6 + 354.8) were performed with collision energy optimized for each compound. Levels of GSH and GSSG were expressed as µmol/g Hb.

### Calibration standards and quality controls

Stock solutions of GSH and GSSG were prepared at 1 mM in 10% TCA solution and stored at -80°C. Calibrators containing both GSH and GSSG were prepared daily by diluting the stock solutions with 0,1% formic acid. In-house quality control (QC) samples of 3 different concentrations levels (GSH: 8, 2, 0.5 µM and GSSG: 1, 0.25, 0.625 µM), were prepared daily. A pooled whole blood supernatant (PWBS) was aliquoted and stored at -80°C and used in the validation procedures.

### Linearity, calibration, and matrix effects evaluation.

Linearity of the assays was assessed by repeated (n=3) analysis of calibrators with concentrations ranging from 0 to 100 µM. Calibration curves were prepared in the concentration ranges between 0.5-8 µM and 0.0625-1 µM for GSH and GSSG respectively. The curves were constructed by plotting the peak area vs the analyte concentration. Linear regression analysis was used to determine the slope, intercept, and correlation coefficient (r). Calibration curves were prepared both in

0.1% formic acid and in 400-fold diluted PWBS to evaluate potential matrix effects by comparing the slope of the standard calibration curve with the slope of matrix-matched standard curve.

#### Precision, accuracy and recovery.

Intra-day precision was evaluated by replicate preparations and analysis of quality controls (QCs) (n=6) and of PWBS (n=6) performed on the same day. To assess the inter-day precision, the same analyses were repeated on 3 different days. Intra-day and inter-day precision was expressed as coefficient of variation (CV).

Accuracy was evaluated in “standard addition” experiments. The same GSH and GSSG amounts used for QCs were spiked into both PWBS (n=6) and 0.1% formic acid, and then quantified. Accuracy was evaluated by comparing the estimated (measured) with the added (true) concentrations. Accuracy (bias, %) was expressed as:  $((\text{Measured value} - \text{True value}) / \text{True value}) \times 100$ . Recovery (%) was evaluated by adding the same GSH and GSSG amounts, used for QCs, into fresh collected whole blood samples (n=6) kept on ice, before the TCA precipitation.

#### Lower limit of detection (LOD) and quantification (LLOQ)

The LOD of an individual analytical procedure is the lowest amount of analyte in a sample that can be detected, but not necessarily quantified, as an exact value. It was assessed as the smallest detectable signal in diluted whole blood supernatant, above baseline noise (signal to noise ratio, S/N =3). The LLOQ (i.e. the lowest amount of analyte in a sample that can be quantitatively determined with suitable precision and accuracy) was defined as the concentration of GSH and GSSG when their signal was 10 times that of the blank (S/N=10).

## **Statistical analyses**

### **The IMPROVE study**

Quantitative variables were summarized as mean  $\pm$  standard deviation (SD), or median (interquartile range) when appropriate. Variables with skewed distributions were log-transformed before analysis. Baseline characteristics of subjects, stratified by MLDP score categories, were compared by linear regression and chi-square for trend, as appropriate. Multivariable linear regression with stepwise selection was employed to identify independent predictors of MLDP. In the validation analysis, the association between MLDP score and VEs was assessed by three Cox models: Model-1: unadjusted. Model-2: adjusted for age, gender and stratified by latitude. Model-3: as model 2 plus lifelong exposure to cigarette smoking (pack-years), body mass index (BMI), education (as indexed by years of school), physical activity, occupation (categorized as: 1, white collars; 2, service workers and 3, manual workers), plasma concentrations of LDL and HDL cholesterol, triglycerides, glucose, hs-CRP, creatinine, pulse pressure, antiplatelet and statin treatments. Kaplan-Meier curves stratified by classes of MLDP score were also computed. The relationship between MLDP score and c-IMT or c-IMT progression was evaluated by linear regression models adjusted for the same set of covariates as Cox models. In the case of c-IMT progression, the analyses were also adjusted for the corresponding c-IMT baseline value. A further Cox model was run including model 3 covariates plus baseline c-IMT and Fastest-IMTmax-progr. All tests were two-sided and carried out by the SAS statistical package v. 9.4 (SAS Institute Inc., Cary, NC, USA).

### **The RISMED study**

Continuous variables are presented as mean $\pm$ SD, and differences between two groups (LFD and MD) were compared using the t-test for independent samples. Categorical variables were reported as frequency and percentages, and they were compared using the chi-square test. The association between MD and Oxidative

stress status and between oxidative stress and single items of the Mediterranean diet were testing by Pearson correlation. A p value <0.05 was considered statistically significant. All data were collected in an Excel database and analyses were performed using SAS version 9.4 (SAS Institute, Cary, North Carolina).

## Results

### The IMPROVE Study

Baseline characteristics of participants with and without VEs are shown in **table 1**. Mean age was 64.2 years, and 47.9% of subjects were males. A total of 514 (13.9%) participants were free from relevant pharmacological treatments. Starting from the 15-month visit, at which time changes in C-IMT were assessed, the median follow-up was 21.5 months (interquartile range, 20.8–22.7). Among the 3,482 subjects included in the analysis, 129 (3.7%) developed a VE in the follow-up period: 15 had an AMI (0 fatal), 26 were hospitalized for angina pectoris, 24 underwent angioplasty, and 10 coronary bypass grafting. There were 2 sudden cardiac deaths; 21 ischemic strokes (0 fatal); 22 TIAs, 2 peripheral revascularization, and 7 new diagnoses of intermittent claudication. Twenty-one participants had >1 VE during the follow-up. The baseline characteristics of subjects with and without incident VEs are shown in **Table 1**. Fewer than 10% of all subjects changed their medications during follow-up.



**Table 1.** Baseline characteristics of participants without and with VEs

	Without events (n = 3353)	With events (n = 129)	P value
<i>Kuopio, n (%)</i>	936 (27.9)	42 (32.6)	
<i>Stockholm, n (%)</i>	497 (14.8)	18 (13.9)	
<i>Groningen, n (%)</i>	443 (13.2)	31 (24.0)	
<i>Paris, n (%)</i>	460 (13.7)	10 (7.8)	
<i>Milan, n (%)</i>	520 (15.5)	14 (10.9)	
<i>Perugia, n (%)</i>	497 (14.8)	14 (10.9)	<0.001
<b>Anthropometric Variables</b>			
<i>Men, n (%)</i>	1591 (47.5)	72 (55.8)	0.06
<i>Age (years)</i>	64±5	65±6	0.02
<i>BMI (Kg/m<sup>2</sup>)</i>	27.2±4.2	27.7±4.7	0.20
<i>Waist/Hip ratio</i>	0.9±0.1	0.9±0.1	0.22
<i>DBP (mmHg)</i>	82±10	82±10	0.91
<i>SBP(mmHg)</i>	142±18	145±21	0.05
<b>Smoking habits</b>			
<i>Current smokers, n (%)</i>	479 (14.3)	29 (22.5)	
<i>Former smokers, n (%)</i>	1229 (36.7)	53 (41.1)	
<i>Never smokers, n (%)</i>	1642 (49.0)	47 (36.4)	<0.01
<i>Pack-years</i>	10.7±16.9	14.4±16.2	0.01
<b>Biochemical risk factors</b>			
<i>Total Cholesterol (mmol/L)</i>	5.49±1.13	5.43±1.03	0.53
<i>HDL Cholesterol (mmol/L)</i>	1.27±0.36	1.17±0.29	<0.001
<i>Triglycerides (mmol/L)</i>	1.29 (0.92,1.87)	1.44 (1.08,2.11)	0.06
<i>LDL Cholesterol (mmol/L)</i>	3.55±1.01	3.52±0.94	0.72
<i>Uric Acid (μmol/L)</i>	313.8±71.6	324.4±71.4	0.10
<i>hs-CRP (mg/L)</i>	1.80 (0.75, 3.50)	2.16 (0.73, 4.42)	0.10
<i>Blood Glucose (mmol/L)</i>	5.5 (4.95, 6.3)	5.6 (5.1, 6.5)	0.11
<i>Creatinine (μmol/L)</i>	78.9 (68.1, 90.4)	81.4 (72.5, 94.4)	0.47
<i>Framingham risk score</i>	22.2 (14.6, 33.8)	29 (17, 44.6)	<0.001
<i>Framingham risk score classes:</i>			
<i>≤5%, n (%)</i>	40 (1.24)	1 (0.83)	
<i>&gt;5, ≤10%, n (%)</i>	339 (10.5)	7 (5.8)	
<i>&gt;10, ≤15%, n (%)</i>	520 (16.1)	18 (14.9)	
<i>&gt;15, ≤20%, n (%)</i>	520 (16.1)	10 (8.3)	
<i>&gt;20%, n (%)</i>	1806 (56.0)	85 (70.3)	0.01
<b>Pharmacological treatments</b>			
<i>Lipid lowering drugs, n (%)</i>	1384 (41)	45 (35)	0.15
<i>Statins, n (%)</i>	1349 (40)	43 (33)	0.12
<i>Fibrates, n (%)</i>	261 (8)	7 (5)	0.32
<i>Fish oil, n (%)</i>	115 (3)	4 (3)	0.84
<i>Antihypertensives, n (%)</i>	1889 (56)	74 (57)	0.82
<i>Beta blockers, n (%)</i>	774 (23)	39 (30)	0.06
<i>Calcium antagonists, n (%)</i>	535 (16)	22 (17)	0.74
<i>ACE inhibitors, n (%)</i>	655 (20)	18 (14)	0.12
<i>Sartans, n (%)</i>	505 (15)	20 (16)	0.89
<i>Diuretics, n (%)</i>	769 (23)	30 (23)	0.93
<i>Insulin, n (%)</i>	123 (4)	8 (6)	0.14
<i>Estrogens supplementation, n (%)</i>	213 (6)	2 (2)	0.03

Data are mean±SD and median (interquartile ranges) for continuous variables or number (percent) of subjects in group for categorical variables. Duration of smoking, Cigarettes/day, Pack-years have been calculated excluding never smokers; P values were calculated by Wilcoxon Rank-Sum Test or by Chi-square when appropriate.

### **Adherence to MLDP**


Patient's characteristics according to classes of MLDP score are detailed in **Table 2**. MLDP score was negatively and significantly associated with almost all traditional VRFs. As expected the proportion of participants with a MLDP score  $>3$  was the highest in Italy, intermediate in France and the lowest in northern Europe (**Figure 3**)

**Table 2.** Patient's characteristics according to classes of MLDP score

Characteristics	MLDP SCORE 0-1 (N=1098)	MLDP SCORE 2-3 (N=1868)	MLDP SCORE 4-7 (N=737)	P-trend
<b>Latitude</b>				
<i>Kuopio</i>	472 (43)	520 (27.8)	56 (7.6)	
<i>Stockholm</i>	177 (16.1)	291 (15.6)	64 (8.7)	
<i>Groningen</i>	319 (29.1)	191 (10.2)	17 (2.3)	
<i>Paris</i>	68 (6.2)	275 (14.7)	158 (21.4)	<0.0001
<i>Milan</i>	37 (3.4)	282 (15.1)	234 (31.8)	
<i>Perugia</i>	25 (2.3)	309 (16.5)	208 (28.2)	
<b>Vascular Risk Factors</b>				
<i>Framingham Risk Score</i>	27.4 (18.7, 40.7)	22.1 (14.3, 33.0)	17.5 (11.2, 27.6)	<0.0001
<i>European Score</i>	5.4 (3.2, 9.0)	3.8 (2.3, 6.7)	2.9 (1.8, 5.1)	<0.0001
<i>Male</i>	580 (52.8)	919 (49.2)	275(37.3)	<0.0001
<i>Age</i>	64.8 ± 5.4	63.9 ± 5.31	63.9 ± 5.7	0.0001
<i>BMI (kg/m<sup>2</sup>)</i>	28.4 ± 4.43	27.18 ± 4.22	25.83 ± 3.64	<0.0001
<i>Waist/hip ratio</i>	0.93 ± 0.09	0.92 ± 0.09	0.9 ± 0.09	<0.0001
<i>DBP (mm Hg)</i>	84 ± 10	82 ± 10	79 ± 9	<0.0001
<i>SBP(mm Hg)</i>	147 ± 18	142 ± 18	135 ± 18	<0.0001
<i>Hypertension</i>	844 (76.9)	1288 (69.0)	420 (57.0)	<0.0001
<i>Diabetes mellitus</i>	375 (34.2)	425 (22.8)	113 (15.3)	<0.0001
<b>Smoking habits</b>				
<i>Never smokers</i>	498 (45.4)	878 (47)	407 (55.2)	
<i>Former smokers</i>	398 (36.2)	727 (38.9)	246 (33.4)	<0.0001
<i>Current smokers</i>	202 (18.4)	263 (14.1)	84 (11.4)	
<i>Pack-years</i>	20 (9, 33.2)	17 (7.8, 28.1)	16.3 (7.5, 30.0)	0.03
<b>Family history of:</b>				
<i>Coronary artery Disease</i>	738 (70.7)	1170 (64.7)	407 (57.8)	<0.0001
<i>Cerebrovascular Disease</i>	374 (34.1)	689 (36.9)	259 (35.1)	0.49
<i>Peripheral vascular disease</i>	118 (10.7)	236 (12.6)	89 (12.1)	0.3
<b>Social Class</b>				
<i>Office work</i>	322 (32.0)	743 (42.9)	314 (47.7)	
<i>Service work</i>	374 (37.2)	562 (32.4)	202 (30.7)	<0.0001
<i>Manual work</i>	309 (30.7)	428 (24.7)	142 (21.6)	
<i>Study years</i>	10.0 ± 3.4	10.6 ± 4.1	10.5 ± 4.2	0.002
<b>Biochemical variables</b>				
<i>Total Cholesterol, mmol/L</i>	5.32 ± 1.11	5.47 ± 1.12	5.8 ± 1.12	<0.0001
<i>HDL Cholesterol, mmol/L</i>	1.23 ± 0.36	1.26 ± 0.36	1.32 ± 0.37	<0.0001
<i>Triglycerides, mmol/L</i>	1.31 (0.94, 1.91)	1.31 (0.94, 1.91)	1.28 (0.9, 1.8)	0.09
<i>LDL Cholesterol, mmol/L</i>	3.39 ± 0.96	3.52 ± 1.02	3.83 ± 0.97	<0.0001
<i>Uric Acid, µmol/L</i>	320 (273, 369)	310 (263, 357)	298 (253, 352)	<0.0001
<i>hs-CRP, mg/L</i>	2.14 (0.89, 3.90)	1.77 (0.76, 3.53)	1.55 (0.62, 3.12)	<0.0001
<i>Blood glucose, mmol/L</i>	6.26 ± 1.82	5.9 ± 1.64	5.43 ± 1.15	<0.0001


Values are mean ± SD, or median (interquartile range) or n (%). P values were calculated by linear regression or by chi square for trend.

**Figure 3.** MLDP score adherence and latitude



**Figure 4** shows that the risk of event in subject consuming items present in a MLDP was lower than the risk of those in whom the consumption threshold was not reached. This is especially clear for those consuming fish >2 times/week whose risk of event was 39% lower than that of the ones that consumed fish < 2 times/week; a similar risk reduction was found in those consuming meat <2 times/week (that have a 34% risk reduction) compared to than those that consume meat > 2 times/week.

**Figure 4** Single items of an MLDP t and the risk of events



At multivariable analysis (**Table 3**), latitude was the strongest ( $r^2=0.1768$ ) independent determinant of MLDP score. Social and behavior variables such as BMI; smoke; pulse pressure; Hs-CRP; creatinine; education (expressed as study years); occupation; physical activity; HDL-cholesterol; use of antiplatelet agents; insulin treatment and statin treatment were also significantly associated. By contrast, sex, age, blood glucose, triglycerides, uric acid, white blood cell (WBC) count, family history of PAD, CVD and CAD and pharmacological treatments ( $\beta$ -blockers, calcium antagonists, ACE inhibitors, ARB, diuretics, insulin, oestrogens, statin, fibrates and fish-oil) were not significantly associated to MLDP score.

**Table 3.** Variables independently associated with Mediterranean-like dietary pattern (MLDP) score by multivariable linear regression with stepwise selection.

<b>Variables</b>	<b>Beta*</b>	<b>SE</b>	<b>P value</b>	<b>Partial r<sup>2</sup></b>
<i>Latitude (degrees)</i>	-0.09	0.003	<0.0001	0.1768
<i>Education (study years)</i>	0.03	0.01	<0.0001	0.0074
<i>Use of antiplatelet agents</i>	0.19	0.06	0.0007	0.0050
<i>Physical activity (1 step)</i>	0.11	0.03	0.0003	0.0038
<i>Log Hs-CRP (mg/L)</i>	-0.14	0.04	0.0009	0.0036
<i>Pack-years of cigarettes</i>	-0.003	0.001	0.009	0.0034
<i>HDL-cholesterol (mmol/L)</i>	0.20	0.06	0.002	0.0033
<i>Creatinine (μmol/L)</i>	-0.003	0.001	0.02	0.0024
<i>Body mass index (Kg/m<sup>2</sup>)</i>	-0.02	0.01	0.002	0.0022
<i>Insulin treatment</i>	-0.25	0.11	0.03	0.0020
<i>Pulse pressure (mmHg)</i>	-0.004	0.002	0.02	0.0020
<i>Statin treatment</i>	0.12	0.04	0.006	0.0019
<i>Occupation (office work)</i>	0.10	0.05	0.03	0.0015

\*β values indicate changes in MLDP score associated with a unit increment in the predictor. Variables not significantly associated were: sex, age, blood glucose, triglycerides, uric acid, WBC count, family history of PAD, CAD and CAD and other pharmacological treatments (β-blockers, calcium antagonists, ACE inhibitors, ARB, diuretics, insulin, estrogens, fibrates and fish-oil).

When the variables independently associated with MLDP were evaluated as related to each center, a significant positive correlation between MLDP and education, as indexed by study years, was observed in Paris  $p=0.04$ ; Groningen  $p=0.03$ ; Stockholm  $p<0.0001$ ; Kuopio  $p<0.0001$  Centers,) but not in Italian Centers.

#### Validation analysis (MLDP score vs VEs)

Before testing the MLDP adherence score versus the primary endpoint (i.e. the association with c-IMT-progression), whether MLDP score was associated with VEs was analyzed. Among the 3,703 subjects enrolled in the IMPROVE Study, 215 (7.96%) developed a first VE within the 36-month follow-up. Of the VEs, 32 were hard ischemic strokes and 37 were hard coronary events. Number of events according to MLDP score classes are in **Table 4**.

**Table 4.** Vascular events stratified according to the Mediterranean-like dietary pattern (MLDP) score.


Type of events	MLDP Score		
	0-1 n (%)	2-3 n (%)	4-7 n (%)
Total Events (cardio+ cerebro + peripheral vascular events)	101 (9.2)	94 (5)	20 (2.7)
Hard cerebrovascular events (ischemic stroke)	19 (1.7)	12 (0.6)	1 (0.1)
Hard coronary events (AMI + sudden cardiac death)	15 (1.4)	17 (0.9)	5 (0.7)

**Table 3** shows that latitude was the strongest independent determinant of MLDP score, accounting for approximately 83% of the variation explained by the regression model ( $p<0.0001$ ).

**Figure 5 panel A** shows the Kaplan-Meier incidence curves of the combined endpoint stratified by MLDP score classes. The rate of events was highest in subjects with score 0-1; lower in those with score 2-3 and lowest in those with score 4-7.



**Figure 5.** Association of the IMPROVE MLDP score with CV events (composite end-point). Kaplan Meier event-free survival curves.



When hard coronary and hard cerebrovascular events were analyzed separately, the protective effect of MLDP was stronger with respect to cerebrovascular than to coronary endpoints (**Figure 5, Panel B and C**). Being the association with VEs highly significant, MLDP adherence score was considered as being validated and, as such, suitable for the assessment of its association with c-IMT change over time.

### **MLDP score and c-IMT**

In an unadjusted model, MLDP was significantly associated with baseline c-IMT variables. The associations, however, disappeared when smoking, physical activity, education, occupation, and CV risk factors (BMI, heart rate, lipids, glucose, creatinine, uric acid, CRP) were included into the model (**Table 5**).

**Table 6** shows the mean ( $\pm$ SD) values of c-IMT progression variables stratified by MLDP score categories and association between MLDP score and c-IMT progressions by unadjusted (Model 1) or adjusted (Models 2-3) linear regression models. A significant negative trend was found between MLDP score and most of c-IMT-progression variables, regardless of adjustment for all potential confounders (**Table 6, Models 1-3**).

**Table 5** Association between MLDP score and baseline carotid C- IMT by multivariable unadjusted or adjusted linear regression models§\*.

MLDP score	Model 1		Model 2		Model 3	
	Beta (95% CI)	P value	Beta (95% CI)	P value	Beta (95% CI)	P value
<b>IMT<sub>mean</sub></b>						
2-3 vs 0-1	-0.05 (-0.06, -0.03)	<0001	-0.02 (-0.03, 0.00)	<b>0.03</b>	0.00 (-0.02, 0.01)	0.69
4-7 vs 0-1	-0.08 (-0.10, -0.07)	<0001	-0.02 (-0.03, 0.00)	0.11	0.01 (-0.01, 0.03)	0.46
Trend	-0.02 (-0.03, -0.02)	<0001	-0.01 (-0.01, 0.00)	<b>0.03</b>	0.00 (0.00, 0.01)	0.64
<b>IMT<sub>max</sub></b>						
2-3 vs 0-1	-0.17 (-0.23, -0.11)	<0001	-0.06 (-0.12, 0.00)	0.06	-0.01 (-0.08, 0.05)	0.66
4-7 vs 0-1	-0.27 (-0.35, -0.20)	<0001	-0.03 (-0.11, 0.05)	0.48	0.04 (-0.05, 0.12)	0.40
Trend	-0.08 (-0.10, -0.06)	<0001	-0.02 (-0.04, 0.00)	0.14	0.01 (-0.02, 0.03)	0.65
<b>IMT<sub>mean-max</sub></b>						
2-3 vs 0-1	-0.10 (-0.13, -0.07)	<0001	-0.03 (-0.06, 0.00)	<b>0.04</b>	-0.01 (-0.04, 0.03)	0.74
4-7 vs 0-1	-0.16 (-0.20, -0.12)	<0001	-0.02 (-0.06, 0.02)	0.30	0.02 (-0.02, 0.06)	0.32
Trend	-0.04 (-0.05, -0.04)	<0001	-0.01 (-0.02, 0.00)	0.15	0.00 (-0.01, 0.02)	0.36
<b>1° CC mean</b>						
2-3 vs 0-1	-0.02 (-0.04, -0.01)	<0001	-0.01 (-0.02, 0.01)	0.35	0.00 (-0.01, 0.02)	0.63
4-7 vs 0-1	-0.05 (-0.06, -0.03)	<0001	-0.01 (-0.03, 0.01)	0.24	0.01 (-0.01, 0.02)	0.47
Trend	-0.01 (-0.02, -0.01)	<0001	0.00 (-0.01, 0.00)	0.16	0.00 (0.00, 0.01)	0.49

§. Definitions of such variables and their abbreviations are reported in the Additional material of this study.

**Model 1:** unadjusted; **Model 2:** adjusted for age, sex, latitude; **Model 3:** as model 2 plus smoking, body mass index, education, physical activity, occupation, lipids (LDL and HDL cholesterol and triglycerides), Hs-CRP, creatinine, plasma glucose, pulse pressure.


**Table 6.** Progression of ultrasonographic variables according to classes of Mediterranean-like dietary pattern (MLDP) score (column 3) and association between MLDP Score and carotid artery intima media thickness (c-IMT) progression by multivariable unadjusted or adjusted linear regression models (Models 1-3).

Progression variables	Classes of MLDP score	Mean ±SD	Contrasts	Model 1		Model 2		Model 3	
				Beta (95% C.I.)	P value	Beta (95% C.I.)	P value	Beta (95% C.I.)	P value
PF CC-IMT <sub>mean-progr</sub>	0-1	5.9±37	—	—	—	—	—	—	—
	2-3	1.6±35.5	2-3 vs 0-1	-4.3 (-7, -1.5)	<b>0.002</b>	-2.2 (-5, 0.6)	0.1	-1.9 (-4.9, 1.2)	0.2
	4-7	-0.04±31.6	4-7 vs 0-1	-5.9 (-9.3, -2.5)	<b>0.0007</b>	-1.5 (-5.3, 2.2)	0.4	-1 (-5.1, 3.2)	0.6
			trend	-1.4 (-2.3, -0.6)	<b>0.001</b>	-0.2 (-1.2, 0.7)	0.6	-0.1 (-1.2, 1)	0.9
IMT <sub>mean-progr</sub>	0-1	16.9±66.8	—	—	—	—	—	—	—
	2-3	11.5±51.9	2-3 vs 0-1	-5.4 (-9.7, -1.2)	<b>0.01</b>	-3.9 (-8.3, 0.5)	0.08	-4.1 (-8.8, 0.5)	0.08
	4-7	5.9±45.3	4-7 vs 0-1	-11 (-16.3, -5.7)	<b>&lt;0.0001</b>	-7.6 (-13.4, -1.7)	<b>0.01</b>	-8.2 (-14.4, -1.9)	<b>0.01</b>
			trend	-2.8 (-4.2, -1.5)	<b>&lt;0.0001</b>	-2 (-3.5, -0.5)	<b>0.01</b>	-2.1 (-3.8, -0.5)	<b>0.01</b>
IMT <sub>max-progr</sub>	0-1	43.8±322.3	—	—	—	—	—	—	—
	2-3	45.2±289.9	2-3 vs 0-1	1.3 (-21, 23.6)	0.91	-2.0 (-25, 21.1)	0.9	-4.4 (-29.2, 20.5)	0.73
	4-7	20.5±245.9	4-7 vs 0-1	-23.3 (-51.1, 4.4)	0.10	-30.6 (-61.4, 0.2)	0.05	-35.3 (-69, -1.7)	<b>0.04</b>
			trend	-6.8 (-13.7, 0.2)	0.06	-9.2 (-17, -1.3)	<b>0.02</b>	-11.4 (-20, -2.7)	<b>0.01</b>
IMT <sub>mean-max-progr</sub>	0-1	33.9±148.8	—	—	—	—	—	—	—
	2-3	32.6±123.8	2-3 vs 0-1	-1.3 (-11.2, 8.6)	0.80	-1.6 (-11.8, 8.7)	0.8	-2.6 (-13.7, 8.5)	0.65
	4-7	19.4±111.6	4-7 vs 0-1	-14.5 (-26.8, -2.2)	<b>0.02</b>	-15.2 (-28.9, -1.6)	<b>0.03</b>	-16.1 (-31.1, -1.1)	<b>0.04</b>
			trend	-4.1 (-7.1, -1)	<b>0.01</b>	-4.5 (-7.9, -1)	<b>0.01</b>	-5 (-8.9, -1.2)	<b>0.01</b>
Fastest IMT <sub>max-progr</sub>	0-1	292±294.8	—	—	—	—	—	—	—
	2-3	257±271.1	2-3 vs 0-1	-35 (-55.6, -14.4)	<b>0.0009</b>	-23 (-44.2, -1.8)	<b>0.03</b>	-22.6 (-45.6, 0.5)	0.06
	4-7	215.2±225.1	4-7 vs 0-1	-76.8 (-102.5, -51.2)	<b>&lt;0.0001</b>	-50.8 (-79.2, -22.5)	<b>0.0004</b>	-44.1 (-75.4, -12.9)	<b>0.01</b>
			trend	-20.8 (-27.2, -14.4)	<b>&lt;0.0001</b>	-14.4 (-21.6, -7.3)	<b>&lt;0.0001</b>	-13.4 (-21.4, -5.4)	<b>0.001</b>


**Model 1:** unadjusted; **Model 2:** adjusted for age, sex, latitude; **Model 3:** as model 2 plus pack-years, body mass index, education, physical activity, occupation, lipids (LDL and HDL cholesterol and triglycerides), plasma glucose, high sensitive C-Reactive Protein, creatinine, pulse pressure, antiplatelet,

A significant association was also found between MLDP score and c-IMT progression variables (**Figure 5; Figure 6, and Table 7**) Accordingly, when plotted vs the MLDP score, progression of  $IMT_{mean-max}$  was nearly 2-fold lower in those with MLDP scores 4-5 than in those with MD scores 0-1 (0.019 vs. 0.035 mm/yr,  $P_{trend}=0.01$ ). No association was found between MLDP score and baseline c-IMT (**Figure 6**). The significant association between MLDP score and Fastest- $IMT_{max-prog}$  is shown in **Figure 7**.

**Figure 5.** Carotid IMT and IMT progression according to MLDP score.



**Figure 6. MLDP and IMT in the IMPROVE Study**




**Table 7.** Association between MLDP and C-IMT progressions by multivariable unadjusted or adjusted linear regression models.

	Beta (95% C.I.)	P value	Beta (95% C.I.)	P value	Beta (95% C.I.)	P value
<b>IMT<sub>mean-max-progr</sub></b>						
MD score 2-3 vs 0-1	-1.3 (-11.2, 8.6)	0.80	-1.6 (-11.8, 8.7)	0.76	-1.5 (-12.6, 9.5)	0.79
MD score 4-7 vs 0-1	-14.5 (-26.9, -2.2)	0.02	-15.2 (-28.9, -1.6)	0.03	-14.8 (-29.8, 0.19)	0.05
Trend	-4.1 (-7.2, -1.0)	0.01	-4.5 (-7.9, -1.0)	0.01	-4.6 (-8.5, -0.80)	0.02
<b>IMT<sub>mean-progr</sub></b>						
MD score 2-3 vs 0-1	-5.4 (-9.7, -1.2)	0.01	-3.9 (-8.3, 0.5)	0.08	-4.0 (-8.6, 0.6)	0.09
MD score 4-7 vs 0-1	-11.0 (-16.3, -5.7)	<0.0001	-7.6 (-13.5, -1.7)	0.01	-8.0 (-14.2, -1.7)	0.01
Trend	-2.9 (-4.2, -1.5)	<0.0001	-2.0 (-3.5, -0.5)	0.01	-2.1 (-3.7, -0.5)	0.01
<b>IMT<sub>max-progr</sub></b>						
MD score 2-3 vs 0-1	1.3 (-21.0, 23.6)	0.91	-2.0 (-25.0, 21.1)	0.87	-3.0 (-27.7, 21.8)	0.81
MD score 4-7 vs 0-1	-23.3 (-51.1, 4.4)	0.10	-30.6 (-61.4, 0.23)	0.05	-33.4 (-67.0, 0.14)	0.05
Trend	-6.8 (-13.7, 0.17)	0.06	-9.2 (-17.0, -1.4)	0.02	-10.8 (-19.4, -2.2)	0.01
<b>Fastest IMT<sub>max-progr</sub></b>						
MS score 2-3 vs 0-1	-0.03 (-0.06-0.01)	<b>0.0009</b>	-0.02 (-0.04-0.00)	<b>0.03</b>	-0.02 (-0.04-0.00)	0.12
MS score 4-7 vs 0-1	-0.08 (-0.10-0.05)	<b>&lt;0001</b>	-0.05 (-0.08-0.02)	<b>0.0004</b>	-0.04 (-0.07-0.01)	<b>0.01</b>
Trend	-0.021(-0.03-0.01)	<b>&lt;0001</b>	-0.014 (-0.02-0.01)	<b>&lt;0001</b>	-0.012 (-0.02-0.04)	<b>0.003</b>

**Model 1:** unadjusted; **Model 2:** adjusted for age, sex, latitude; **Model 3:** as model 2 plus smoking, body mass index, education, physical activity, occupation, lipids (LDL and HDL cholesterol and triglycerides), Hs-CRP, creatinine, plasma glucose, pulse pressure.

**Model 4:** model 4+baseline fastest+ fastest.

Figure 7. Association between MLDP and Fastest-IMT<sub>max-progr</sub>






### MLDP score and indices of inflammation.


There was a significant negative correlation between hs-CRP and MLDP adherence when correcting these results for confounders (age, gender, latitude) the results were further confirmed ( $r = -0.034$ ;  $p < 0.0001$ ). (**Figure 8**).

**Figure 8.** Effect of MLDP on hs-CRP



A significant negative correlation was observed when analyzing WBC and MLDP adherence and correcting these results for confounders (age, gender, latitude) (Figure 9).

Figure 9. Effect of MLDP on WBC



## The RISMED Study

Characteristics according to diet of 52 patients (ongoing analysis) (28 LFD and 24 MD) so far analyzed are detailed in **Table 8**. Mean age was 61.3 years for MD group and 62.8 for LFD. Moreover, 83.3% of subjects in the MD group were males whereas males 89.5% in the LFD.

No difference was found by comparing the two groups as stratified according to the parameters listed above.

**Table 8.** Baseline characteristics of participants


Variable	MD group (n=24)	LFD group (n=28)	<i>p</i> value (MD vs LFD)
<b>Demographic characteristics</b>			
Age - years	61.3±7.4	62.8±7.2	0,47
Male gender - no. (%)	20 (83.3)	25 (89.5)	0,53
<b>Clinical characteristics</b>			
BMI - Kg/m <sup>2</sup>	27.3±3.4	27.9±4.2	0,54
Total cholesterol (mg/dL)	173.6±26.4	162.3±36.1	0,21
LDL cholesterol (mg/dL)	100.7±24.2	88.2±28.5	0,73
HDL cholesterol (mg/dL)	50±14.4	51.5±16.6	0,93
Triglycerides (mg/dL)	114.6±66.4	113.1±58.8	0,10
Fasting glycemia (mg/dL)	101.1±10.2	103.8±10.4	0,35
<b>Pharmacological treatments</b>			
Fibrates - no. (%)	0 (0.0)	1 (3.6)	0,35
Statins - no. (%)	19 (79.2)	26 (92.9)	0,15
β-blockers - no. (%)	13 (54.2)	18 (64.3)	0,46
ACE inhibitors - no. (%)	8 (33.3)	7 (25.0)	1,00
ARB - no. (%)	11 (45.8)	10 (35.7)	0,46
Sartans - no. (%)	1 (4.2)	0 (0.0)	0,27
Diuretics - no. (%)	8 (33.3)	8 (28.6)	0,71
Antiplatelet- no. (%)	24 (100.0)	28 (100.0)	1,00
Anticoagulants - no. (%)	0 (0)	1 (3.6)	0,35
Antinflammatory- no. (%)	5 (20.8)	3 (10.7)	0,31
Antiarrhythmics Drugs - no. (%)	3 (10.7)	3 (10.7)	0,84
Antidiabetic drugs - no. (%)	2 (8.3)	0 (0.0)	0,12
Gastroprotective drugs - no. (%)	20 (83.3)	19 (67.9)	0,20
Vitamins - no. (%)	1 (4.2)	1 (3.6)	0,91

*Quantitative variables were expressed as mean±SD and categorical variables as n(%). Body mass index (BMI), myocardial infarction(MI), low density lipoprotein (LDL), high density lipoprotein (HDL), dose area product (DAP), fluoroscopy time (FT), effective dose (ED).*

### Correlation between inflammatory markers and MD adherence

A significant negative correlation between MD delta score adherence and hs-CRP was found ( $r = -0.40778$ ;  $p = 0.0027$ ) following 3-mo of diet (**Figure 10**). An inverse no significant correlation of WBC with MD delta score adherence ( $r = -0.03$ ;  $p = 0.84$ ) was also documented.

**Figure 10.** Correlation between hs-PCR and MD score adherence




### MD and FAs profile

Several components of the blood fatty acid profile differed between cases and controls (**Figure 11**) following a 3-mo of dietary intervention. MD patients had significantly lower C16:0 (Palmitic acid) content as compared to LFD patients. Total monounsaturated fatty acid (MUFA) and C18:1 (oleic acid) were similar in both groups, whereas C16:1 (palmitoleic acid) and C20:1 were higher in MD group than in LFD group. MD also had higher total PUFA-n-6, C20:3n-6 (dihomo- $\gamma$ -linolenic acid DHLA), C20:4n-6 (arachidonic acid), C22:4n-6, C22:5n-6 (docosapentaenoic acid) than controls. In addition, there were also higher total PUFA-n-3, C22:5n-3 (DPA) and C22:6n-3 (DHA) in patients that followed an MD as compared to LFD

controls. **Figure 11** also shows differences between groups in FA ratios, MD diet showing higher n-3 fatty acids compared to LFD. Moreover, there was a lower n-6/n-3 ratio in patients that received an MD than in controls. Likewise, positive significant correlations between MD adherence score and C20:1 ( $r=0.36$ ;  $p=0.03$ ); C20:3n-6 (dihomo- $\gamma$ -linolenic acid DHGLA) ( $r=0.33$ ;  $p=0.05$ ); C20:4n-6 (arachidonic acid) ( $r=0.46$ ;  $p=0.005$ ); C22:6n-3 (DHA) ( $r=0.47$ ;  $p=0.004$ ), and n-3 fatty acids ( $r=0.36$ ;  $p=0.03$ ), were observed. Finally, a significant negative correlation was documented between MD adherence score and C16:0 (Palmitic acid) and n-6/n-3 ratio ( $r=-0.36$ ;  $p=0.03$ ).

**Figure 11.** Fatty acid profile in cases and controls after 3-mo diet




\*p value ≤ 0.05

## MD and Oxidative stress status

When analyzed together, the MD group and the LFD group had a significant reduction of GSSG/GSH ratio ( $p=0.005$ ) 3 months after a healthier diet pattern. In parallel, the MD group and the LFD group had a similar weight loss (MD  $-3.20$ ; C.I. 95%  $-4.49, -1.92$   $p<0.001$ ; LFD  $-3.34$ ; C.I. 95%  $-4.53, -2.16$   $p<0.001$ ) and a similar waist circumference reduction (MD  $-3.96$ ; C.I. 95%  $-5.17, -2.74$   $p<0.001$ ; LFD  $-3.61$ ; C.I. 95%  $-4.87, -2.34$   $p<0.001$ ) at completion of the 3-mo healthier dietary patterns. However, when splitting the results based on the different diet followed by the patients, only those that followed a MD dietary pattern had a reduction in the oxidative stress status ( $p=0.016$ ) (**Figure 12**).

also


**Figure 12.** GSSG/GSH ratio in cases and controls after 3-mo diet



### Correlation between oxidative stress and single items of the MD

A significant negative correlation between GSSG/GSH ratio (**Figure 13**) and the quantity of legumes consumed in the MD diet ( $r=-0.33$ ;  $p=0.03$ ) was found.

**Figure 13.** Correlation between GSSG/GSH ratio and legumes consumption







### Correlation between oxidative stress and FAs profile

A significant negative correlation between GSSG/GSH ratio (**Figure 14**) and the alfa-linolenic acid ALA (C18:3n-3) ( $r=-0.43$ ;  $p=0.01$ ) content was found. Consistent with the antioxidant activity of PUFA, a significant positive correlation between GSSG/GSH ratio (**Figure 15**) and n-6/n-3 ratio ( $r=0.38$ ;  $p=0.02$ ) was found.

**Figure 14.** Correlation between GSSG/GSH ratio and alfa-linolenic acid



**Figure 15.** Correlation between GSSG/GSH ratio and n-6/n-3



## Discussion

In this new analysis of the IMPROVE Study we have shown that, by using a non-invasive ultra-sonographic diagnostic technique, that allows the assessment of c-IMT changes over time, it is possible to detect the effect of a specific diet in a relatively short time (15 months). The dietary pattern considered was the Mediterranean diet, which was measured by using a relatively simple food frequency questionnaire (Mediterranean-like dietary pattern adherence score - MLDP-) validated a priori vs VEs. In addition, in this new analysis of the IMPROVE Study we have also shown the involvement of the inflammatory pattern, documenting that MLDP is associated to hs-CRP and, in North Europe only, with white blood cells. Such relationship is in keeping with data stemming from the second part of this thesis (the RISMED Study) which show: 1) that by consuming a MD it is possible to modify favorably the plasma fatty acid (FA) profile known to be altered in patients with CAD; 2) that blood FA profile is an index of the quality of food intake which might be used as a tool to estimate diet quality and compliance with nutritional advices; 3) that MD is able to affect some indices of inflammation and oxidative balance; and 4) that there is a relationship between these inflammatory/oxidative changes and the modification of the blood FA pattern.

### **MLDP adherence and c-IMT or c-IMT change over time.**

The IMPROVE is the unique observational study that, besides the associations between MLDP and cross-sectional c-IMT, evaluated also the association with c-IMT progression. This association was best detected by using the Fastest  $IMT_{max-progr}$ , the unique carotid IMT progression variable that previous data of the IMPROVE study have shown to be strongly associated to VEs.<sup>249</sup> In addition, we have shown that these associations were stronger in carotid segments with the highest atherosclerotic involvement, i.e. carotid bifurcations, suggesting a stronger impact of MLDP on focal atherosclerosis rather than generalized thickening of the vessel wall.<sup>250</sup> Taken together, these data support the usefulness of carotid

atherosclerosis change over time as a surrogate endpoint to assess the effects of dietary interventions in epidemiological studies instead of baseline c-IMT measurements only. In fact, with c-IMT measured at baseline, we did not find any association with MLDP. The latter issue was previously investigated in three observational studies.<sup>241, 250, 406</sup>

In the first, a cross-sectional study from South of Italy carried out on 929 adults without known diabetes or atherosclerotic cardiovascular disease, no significant association was found between a dietary pattern similar to the one reported here and carotid atherosclerosis, defined as the presence of plaques and/or increased intima-media thickness.<sup>406</sup>

The second, included 1,374 participants of the Northern Manhattan Study. Although no cross-sectional association between MLDP and c-IMT (or presence/absence of plaque) was found, a significant association with plaque size obtained comparing the top vs 1-3 quartiles of plaque thickness and comparing the plaque area above or below the median was found in regression analyses after controlling for confounders.<sup>250</sup>

In the third one, a cross-sectional study carried out in 110 HIV-infected patients and 131 non-HIV-infected participants, a poor adherence to a MLDP score was associated in multivariable analysis with higher risk of subclinical atherosclerosis, indexed by both  $c\text{-IMT} \geq 0.9$  mm and/or presence of at least one carotid plaque.<sup>241</sup> So, our results are in line with the results from Buscemi et al.,<sup>406</sup> at least partially, with those from Gardener et al,<sup>250</sup> but not with those of Viskovic et al.<sup>241</sup>

The lack of associations between MLDP and cross-sectional c-IMT after adjustment for confounders can be explained, considering that the one-time measured c-IMT reflects the complete burden of genetic and environmental factors acting throughout the entire life of the subjects, whereas carotid IMT change over time is mainly the response to VRFs and behaviors acting in relatively recent times.

Indeed, the food questionnaire we administered to our middle age population, likely reflected the diet followed in the last years, whereas no information was available about the life-long food behavior.

Another issue that deserves to be highlighted concerns the relationship between MLDP and VEs in different European Countries. With one exception,<sup>402</sup> only single-nation studies have so far addressed the relation between MD scores and VEs (Greece,<sup>24</sup> USA,<sup>407</sup> north Sweden<sup>408</sup>). However, rather than the association itself, the important information stemming from these new analyses from the IMPROVE Study lies on the fact that such association is independent of baseline c-IMT and c-IMT progression. Such issue, never reported before, suggests that the protective effects of MD on VEs acts through mechanisms that are not directly related to the size and growth of atherosclerotic plaques, but to other mechanisms e.g. low-grade inflammation. In line with these considerations, several authors outlined the association between immune and inflammatory processes and the composition of gut microbiota<sup>409</sup> which, in turn, has been related to dietary habits, especially to MD.<sup>410, 411</sup> Notably, Hs-CRP, a widely accepted marker of low grade inflammation, is an important (although not the only) mediator of the effect of MD on VEs<sup>412</sup>.

#### **MLDP score adherence, vascular events and latitude.**

The simplified IMPROVE-Study MLDP score, included: fruits, fish, wine, olive oil, meat, milk and eggs. Despite such simplification, we have shown that the rate of events was highest in subjects with score 0-1; intermediate in those with score 2-3 and low in those with score 4-7. This suggests that it is possible to gather information of the effect of a Mediterranean-type of diet on CV disease even considering few dietary items. The present results are in keeping with other reports in the area.

In the study performed by Estruch et al., the Authors observed that in subjects at high risk of cardiovascular disease, MD plus olive oil and MD plus nuts are able to reduce the incidence of major cardiovascular events.<sup>413</sup>

With the exception of the EPIC-Netherlands cohort,<sup>414</sup> the concept of high consumption of eggs, meat, and fried foods and high risk of acute VEs is true in 52 countries in the INTERHEART study;<sup>415</sup> in the US population,<sup>416-419</sup> and in China.<sup>420</sup> On the other hand, at variance with the results of some,<sup>415, 417-423</sup> but not all studies,<sup>424, 425</sup> a low risk of developing CAD is seen with the use of plant-based nutritional patterns (as in the REGARDS Study).<sup>426-428</sup>

Despite European countries have increasingly similar patterns of food availability, likely due to the invading fast-food culture that has spread dramatically in the Mediterranean area,<sup>429</sup> the new information raised from the IMPROVE study results documents that the rate of VEs across the 5 European countries involved in the study vary along a north to south geographical gradient and correlate significantly with the intake of major components of the MD food, with a greater adherence to the MLDP score being associated with a lower likelihood of having VEs.

We have also shown that the association between VEs and the MLDP score is stronger in North than in South European Countries, independently of anthropometric, lifestyle and other clinical characteristics.

Of note, also the association between MLDP score and the level of education is stronger in northern than in southern countries, thus confirming the results of Regmi et al.,<sup>430</sup> which showed that the income and the economic environment may have a crucial role in the context of the dietary pattern. One of the possible explanations is that while the items of MD diet are easily available to everybody and relatively cheap in the south of Europe, they are more expensive in northern countries and, as such, they are available only to the highest socio-economic classes.<sup>247, 431-433</sup> An alternative explanation might be the differences between

Mediterranean and non-Mediterranean countries in terms of socio-demographic, anthropometric and lifestyle factors. For example, a low socioeconomic environment has been associated with high stroke mortality in cohort studies<sup>434, 435</sup> and in studies investigating the geographic distribution of stroke.<sup>436, 437</sup>

The issue of different nutritional patterns in Europe has been previously analyzed. A large variability in nutrient intake across European populations with a geographical gradient within and between European countries has been described.<sup>438</sup> Three main region-specific patterns have been identified. In Mediterranean regions, including Greece, Italy, and the Southern of Spain, the nutrient patterns are mainly governed by a relatively high intakes of vitamin E and MUFA, whereas retinol and vitamin D intakes are relatively low. The general population in Germany, in the Netherlands and in the UK share relatively high intakes of PUFA and saturated fatty acids, and relatively low intakes of MUFA, in combination with a relatively high intake of sugar. These differences are justified by a diet rich in plant foods and olive oil in Greece, Italy and, to some extent, also in Spain.<sup>439, 440</sup> By contrast, the diet in the general population of northern countries (Germany, the Netherlands, and UK) is characterized by a higher consumption of animal, processed, and sweetened foods -including nonalcoholic beverages and soft drinks-, and, more specifically, added fats and dairy products, which are often fortified with retinol and vitamin D.<sup>439-442</sup> Margarine and processed meat are the main food sources of PUFA in Germany and the Netherlands.<sup>443</sup> Recently, a general north-south gradient for the contribution of highly industrially processed foods to overall food consumption in Europe has been shown.<sup>444</sup>

### **MD and inflammation**

As far as the relationship between MD and inflammation is concerned, the absence of correlation between MLDP score adherence and WBC and the

significant negative correlation with hs-CRP (Figure 8 and Figure 9) were documented in the IMPROVE study and confirmed in the RISMED Study.

These results, which suggest an involvement of the anti-inflammatory effect of MD, corroborate several previously reported data. For example, in the study of Jiang et al it was shown that a frequent intake of nuts is associated with decreased levels of IL-6, C-reactive protein, and fibrinogen in a population free of CAD.<sup>445</sup> Similarly, the study of Dell'Agli et al., showed that olive oil down-regulates vascular cell adhesion molecule-1, intercellular adhesion molecule-1 and E-selectin expression in the endothelium,<sup>446</sup> and decreases plasma levels of soluble intercellular adhesion molecule-1; soluble E-selectin; IL-6, and hs-CRP, in high-risk patients;<sup>447-449</sup> all widely accepted markers of inflammation.

MD supplemented with walnuts also decreases the level of soluble vascular cell adhesion molecule-1 in healthy subjects and in patients with hypercholesterolemia.<sup>450</sup> Moreover, two cross-sectional studies<sup>451, 452</sup> and a feeding trial in Mediterranean populations<sup>357</sup> further support the concept that MD exerts anti-inflammatory effects.<sup>453</sup>

The involvement of inflammation in such contest is also by an interventional study (the pilot study of the PREDIMED trial) in which the effects of the three dietary interventions (MD plus olive oil, MD plus nuts and low-fat diet) modify the expression of soluble adhesion molecules and cytokines related to atherosclerosis.<sup>308</sup> Such concept was previously suggested by studies showing that MD -or its components- are associated with a lower inflammatory status and/or an improved endothelial function.<sup>24, 358, 402, 450, 454</sup> Similar findings have been obtained by considering other healthy dietary patterns.<sup>358</sup>

In a sub-analysis carried out in a high-CAD-risk group of the PREDIMED population, it has been addressed also the role of immune cell activation and of soluble inflammatory biomarkers.<sup>455</sup> The authors observed, after 3 months of the



aforementioned three-dietary interventions, that the expression of CD49d (an adhesion molecule crucial for leucocyte homing), and of CD40 (a pro-inflammatory ligand) decreased in the MD plus olive oil group, in the MD plus nuts group but not in the low-fat diet group. In the two MD groups, a reduction in serum IL-6 and in the soluble intercellular adhesion molecule-1 was also observed while both these soluble markers resulted to be increased in the low-fat diet group. On the other hand, CRP decreased only in the MD plus olive oil group. This inhibition of both cell-mediated and humoral inflammatory pathways can be viewed as a possible molecular mechanism for the anti-atherosclerotic effect of the MD.

In both the IMPROVE and the RISMED Study, the beneficial effects of MD on inflammatory markers were comparable both considering the subjects treated with risk-reducing agents known to have anti-inflammatory properties (e.g. statins and angiotensin-converting enzyme inhibitors), and those not treated with such drugs. This suggests that the anti-inflammatory effect of MD is complementary to that provided by potentially anti-inflammatory pharmacological treatments.

The benefit of dietary change in the IMPROVE and in the RISMED Study occurred regardless of patients' age. This suggests that the anti-atherosclerotic effects of healthy foods are not limited to a specific phase of the disease (earlier or overt) and supports the recommendation that the MD is a tool potentially useful against CAD in all its stages.<sup>456</sup> Similar findings have been described by Estruch in a commentary of the PREDIMED study.<sup>456</sup> In such commentary, the author concluded that the adherence to MD might be considered as a health tool even in elderly patients at high risk of cardiovascular diseases.

### **MD and Oxidative stress**

As to the inverse association between adherence to MD and oxidative stress here reported, we believe that this result is relevant in view of the lack of randomized controlled trials assessing the effects of MD on glutathione redox pathways in the

general population. Our result is in keeping with data from animal experiments showing that polyphenols naturally present in Mediterranean foods decrease the GSSG/GSH ratio and GSSG concentrations without changing GSH concentrations.<sup>457, 458</sup>

One possible explanation of the GSSG/GSH ratio reduction can be found in the diverse nutrients present in a typical MD that can provide NADPH<sup>459</sup> (oxidized by glutathione reductase to revert GSSG to GSH).<sup>460</sup>

A “sparing effect” on the GSH/GSSG redox cycle may indeed contribute to an increased GSH/GSSG. By providing additional antioxidants (e.g. vitamin C, vitamin E, carotenoids, polyphenols, zinc, selenium) and ensuring adequate activity and efficiency of antioxidant enzymes,<sup>373</sup> MD may decrease the need for the GSH/GSSG antioxidant pathway, which may “spare” the GSH/GSSG recycle.<sup>461</sup>

As in the RISMED Study, several reports have addressed the possibility of an (inverse) association between MD adherence and oxidative stress. However, the results were not entirely consistent.

A few small trials<sup>462-465</sup> and one large trial<sup>385</sup>, examined short- or intermediate-term effects of MD on other circulating markers of oxidative stress, including urinary F2-isoprostanes<sup>463</sup>, plasma malondialdehyde<sup>464</sup>, and oxidized LDL.<sup>385, 458, 462, 465</sup> In the largest of these trials, subjects assigned to MD had lower oxidized LDL than did those following the control diet.<sup>385</sup> Other trials, however, yielded different results.

This inconsistency might be due to the different biomarkers measured. Individual markers may signal different metabolic pathways,<sup>369</sup> and it is conceivable that only some pathways are influenced by diet. The possibility of unmeasured confounding related to different genetic backgrounds and familial factors should also be considered.

### **MD and FAs profile**

Concerning variations of blood fatty acids, our results are in line with those from a study on 1,050 French elderly community dweller from Bordeaux (mean age 75-9 years), in whom MD adherence (scored as 0–9) was computed from a FFQ and 24 hours recall.<sup>395</sup> As in our study, after adjusting for several personal and environmental variables, plasma DHA, the EPA+DHA index and total n-3 PUFA were positively associated with MD adherence. At variance from our study, however, plasma palmitoleic acid was significantly inversely associated with MD adherence, and the n-6:n-3 PUFA, AA:EPA, AA:DHA and AA:(EPA+DHA) ratios were inversely associated with MD adherence. Similarities and differences between these two studies are now under intensive investigation in our laboratory. The possibility that higher than expected palmitoleic acid levels might be due to an enhanced conversion of palmitic acid in subjects receiving a MD has been recently proposed by our group.<sup>396</sup>

Moreover, the lower palmitic acid content observed in our study, is in line with that observed in the study by Shearer et al.,<sup>356</sup> that observed that blood levels of palmitic acid are strongly associated with CAD.

As to the negative correlation between GSSG/GSH and  $\alpha$ -linolenic acid (C18:3n-3) levels, and the simultaneous positive correlation between GSSG/GSH ratio and n-6/n-3 ratio, our data are in keeping with animal studies. A reduced hepatic lipid content, and a concomitant reduction in antioxidant response with higher GSSG/GSH ratio and reduction of indices of inflammation (i.e. serum tumor necrosis factor- $\alpha$ , IL-1 $\beta$ , and IL-6 levels) occurs following dietary supplementation of PUFA in obese male C57BL/6J mice fed a high fat diet.<sup>466</sup>

All in all, the relationship between oxidative changes and blood FA pattern modifications that emerges from the ongoing results of the RISMED argues for a direction to be pursued to identify mechanisms of the protective effect of MD.

## Limitations

The two studies analyzed here (and the combined discussion of their results) have some potential limitations: 1) being both observational studies, no causal relation can be demonstrated between MD and clinical or subclinical disease; 2) although a variety of potential confounders have been taken into account, a residual confounding effect of unmeasured factors cannot be ruled out; 3) the IMPROVE study has been carried out in different Countries whereas the RISMED Study has only taken into account Italian individuals; 4) at variance with the RISMED Study, in the IMPROVE Study diet was assessed only at the beginning of the study and dietary changes occurring later may have led to non-differential misclassification and underestimation of the true associations; 4) in both cases the dietary assessment was based on a food frequency questionnaire much simpler than that employed in other studies (e.g. the EPIC questionnaire<sup>24</sup>), and 5) pre-vs post analyses of the only RISMED Study have been carried out after only a 3-mo intensively advised MD in Mediterranean males and females with a recent history of coronary revascularization. However, the strength and the consistency of the data presented here suggest that the beneficial effect of an MD nutritional pattern can be easily extrapolated using a limited number of food items, and that its association with VEs is so strong to be detectable even in the presence of a certain degree of misclassification, including time of exposure to MD. In addition, the Italian population examined in the RISMED Study is superimposable to the Italian population evaluated in the IMPROVE Study. Furthermore, as in previous reports in the area,<sup>450</sup> in both studies, the beneficial effect of MD on inflammatory markers was comparable in subjects under stable treatment with agents that have demonstrable anti-inflammatory properties, -e.g. angiotensin- converting enzyme inhibitors and statins-, and in those not treated with these drugs, suggesting that the anti-inflammatory effect of the MD is in both cases complementary to that of the pharmacological treatment.

## Conclusions

Using a non-invasive ultrasonographic diagnostic technique to assess c-IMT changes over time, it is possible to detect the effect of a specific diet in a relatively short time (15 months), in this new analysis of the IMPROVE Study. In addition, by using a relatively simple food frequency questionnaire (MLPD score), validated *a priori* vs VEs in different European Countries, we have found that: 1) the significant association between MLDP adherence and VEs is independent of baseline c-IMT and c-IMT progression; 2) regardless of adjustment for potential confounders, a significant negative trend exists between MLDP score and most of c-IMT-progression variables (but not baseline c-IMT variables); 3) MLDP adherence is associated to both hs-CRP and white blood cells, the latter having a north to south gradient with stronger association in northern countries; 4) the latter relationship is in keeping with data stemming from the RISMED Study (showing that MD adherence may affect some indices of inflammation and the oxidative stress balance); 5) blood FA profile in the RISMED Study is an index of the quality of food intake which might be used as a tool to estimate diet quality and compliance with nutritional advices; 6) by consuming a MD it is possible to modify favorably the plasma FA profile known to be altered in patients with CAD, and 7) there is a relationship between inflammatory/oxidative changes and the modification of the blood FA pattern that occur adhering to a MD.

To test the diet heart concept, Ancel Keys organized a pilot study in 1957 in Nicotera, Calabria, where CAD was almost non-existent. Keys and his wife Margaret were highly impressed by the eating patterns of that and other Mediterranean cohorts, and decided to write, in the late '50s of the last Century, the book that became a best seller, "Eat Well and Stay Well" where great merit is given to MD for longevity.<sup>467, 468</sup> Common approaches that target multiple risk factors, are expected to improve the probability of a better health at older ages.<sup>469</sup> Reduced oxidative damage has been documented in calories-restricted, longer-surviving rodents.<sup>470</sup> Reduced oxidative stress and inflammation, and control of

body weight are important effects of MD. Thus, MD has the potential to be considered to prolong a healthy life in man.<sup>24, 339, 402, 471</sup>

## References

1. Trichopoulou A, Lagiou P. Healthy traditional mediterranean diet: An expression of culture, history, and lifestyle. *Nutrition reviews*. 1997;55:383-389
2. US Department of Health and Human Services UDoA. *Dietary guidelines for americans 2005*. Washington, DC: US Government Printing Office; 2005.
3. Trichopoulou A, Georgiou E, Bassiakos Y, Lipworth L, Lagiou P, Proukakis C, Trichopoulos D. Energy intake and monounsaturated fat in relation to bone mineral density among women and men in greece. *Preventive medicine*. 1997;26:395-400
4. Wilkins J. Good food and bad: Nutritional and pleasurable eating in ancient greece. *Journal of ethnopharmacology*. 2015;167:7-10
5. Mancini M, Stamler J. Diet for preventing cardiovascular diseases: Light from ancel keys, distinguished centenarian scientist. *Nutrition, metabolism, and cardiovascular diseases : NMCD*. 2004;14:52-57
6. Keys A. Coronary heart disease in seven countries. *Circulation*. 1970;41 1-211
7. Keys A, Aravanis C, Blackburn H, Buzina R, Djordjević B, Dontas A, Fidanza F, Karvonen M, Kimura N, Menotti A, Mohacek I, Nedeljković S, Puddu V, Punsar S, Taylor H, Van Buchem F. *Seven countries. A multivariate analysis of death and coronary heart disease*. . Cambridge Mass and London: Harvard University Press; 1980
8. Report of inter-society commission for heart disease resources. Prevention of cardiovascular disease. Primary prevention of the atherosclerotic diseases. *Circulation*. 1970;42:A55-95
9. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: Final report of the lyon diet heart study. *Circulation*. 1999;99:779-785
10. de Lorgeril M, Salen P, Caillat-Vallet E, Hanauer MT, Barthelemy JC, Mamelle N. Control of bias in dietary trial to prevent coronary recurrences: The lyon diet heart study. *European journal of clinical nutrition*. 1997;51:116-122
11. De Lorgeril M, Salen P, Martin JL, Mamelle N, Monjaud I, Touboul P, Delaye J. Effect of a mediterranean type of diet on the rate of cardiovascular complications in patients with coronary artery disease. Insights into the cardioprotective effect of certain nutriments. *Journal of the American College of Cardiology*. 1996;28:1103-1108
12. de Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, Guidollet J, Touboul P, Delaye J. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. *Lancet*. 1994;343:1454-1459
13. de Lorgeril M, Salen P. The mediterranean diet in secondary prevention of coronary heart disease. *Clinical and investigative medicine. Medecine clinique et experimentale*. 2006;29:154-158
14. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin e consumption and the risk of coronary disease in women. *The New England journal of medicine*. 1993;328:1444-1449
15. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, c-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies. *Jama*. 1998;279:1477-1482

16. Di Minno G, Grandone E, Margaglione M. Clinical relevance of polymorphic markers of arterial thrombosis. *Thrombosis and haemostasis*. 1997;78:462-466
17. Ernst E, Hammerschmidt DE, Bagge U, Matrai A, Dormandy JA. Leukocytes and the risk of ischemic diseases. *Jama*. 1987;257:2318-2324
18. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N. A clinical trial of the effects of dietary patterns on blood pressure. Dash collaborative research group. *The New England journal of medicine*. 1997;336:1117-1124
19. Rimm EB, Ascherio A, Giovannucci E, Spiegelman D, Stampfer MJ, Willett WC. Vegetable, fruit, and cereal fiber intake and risk of coronary heart disease among men. *Jama*. 1996;275:447-451
20. Trevisan M, Krogh V, Freudenheim J, Blake A, Muti P, Panico S, Farinaro E, Mancini M, Menotti A, Ricci G. Consumption of olive oil, butter, and vegetable oils and coronary heart disease risk factors. The research group ats-rf2 of the italian national research council. *Jama*. 1990;263:688-692
21. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, Charrondiere UR, Hemon B, Casagrande C, Vignat J, Overvad K, Tjonneland A, Clavel-Chapelon F, Thiebaut A, Wahrendorf J, Boeing H, Trichopoulos D, Trichopoulou A, Vineis P, Palli D, Bueno-De-Mesquita HB, Peeters PH, Lund E, Engeset D, Gonzalez CA, Barricarte A, Berglund G, Hallmans G, Day NE, Key TJ, Kaaks R, Saracci R. European prospective investigation into cancer and nutrition (epic): Study populations and data collection. *Public health nutrition*. 2002;5:1113-1124
22. Katsouyanni K, Rimm EB, Gnardellis C, Trichopoulos D, Polychronopoulos E, Trichopoulou A. Reproducibility and relative validity of an extensive semi-quantitative food frequency questionnaire using dietary records and biochemical markers among greek schoolteachers. *International journal of epidemiology*. 1997;26 Suppl 1:S118-127
23. Gnardellis C, Trichopoulou A, Katsouyanni K, Polychronopoulos E, Rimm EB, Trichopoulos D. Reproducibility and validity of an extensive semiquantitative food frequency questionnaire among greek school teachers. *Epidemiology*. 1995;6:74-77
24. Trichopoulou A, Costacou T, Bamia C, Trichopoulos D. Adherence to a mediterranean diet and survival in a greek population. *The New England journal of medicine*. 2003;348:2599-2608
25. Satija A, Yu E, Willett WC, Hu FB. Understanding nutritional epidemiology and its role in policy. *Adv Nutr*. 2015;6:5-18
26. Zazpe I, Sanchez-Tainta A, Estruch R, Lamuela-Raventos RM, Schroder H, Salas-Salvado J, Corella D, Fiol M, Gomez-Gracia E, Aros F, Ros E, Ruiz-Gutierrez V, Iglesias P, Conde-Herrera M, Martinez-Gonzalez MA. A large randomized individual and group intervention conducted by registered dietitians increased adherence to mediterranean-type diets: The predimed study. *Journal of the American Dietetic Association*. 2008;108:1134-1144; discussion 1145
27. Schroder H, Salas-Salvado J, Martinez-Gonzalez MA, Fito M, Corella D, Estruch R, Ros E. Baseline adherence to the mediterranean diet and major cardiovascular events: Prevencion con dieta mediterranea trial. *JAMA internal medicine*. 2014;174:1690-1692
28. Salas-Salvado J, Bullo M, Estruch R, Ros E, Covas MI, Ibarrola-Jurado N, Corella D, Aros F, Gomez-Gracia E, Ruiz-Gutierrez V, Romaguera D, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pinto X, Basora J, Munoz MA, Sorli JV, Martinez-



- Gonzalez MA. Prevention of diabetes with mediterranean diets: A subgroup analysis of a randomized trial. *Annals of internal medicine*. 2014;160:1-10
29. Salas-Salvado J, Bullo M, Babio N, Martinez-Gonzalez MA, Ibarrola-Jurado N, Basora J, Estruch R, Covas MI, Corella D, Aros F, Ruiz-Gutierrez V, Ros E. Reduction in the incidence of type 2 diabetes with the mediterranean diet: Results of the predimed-reus nutrition intervention randomized trial. *Diabetes care*. 2011;34:14-19
  30. Martinez-Gonzalez MA, Toledo E, Aros F, Fiol M, Corella D, Salas-Salvado J, Ros E, Covas MI, Fernandez-Crehuet J, Lapetra J, Munoz MA, Fito M, Serra-Majem L, Pinto X, Lamuela-Raventos RM, Sorli JV, Babio N, Buil-Cosiales P, Ruiz-Gutierrez V, Estruch R, Alonso A. Extravirgin olive oil consumption reduces risk of atrial fibrillation: The predimed (prevencion con dieta mediterranea) trial. *Circulation*. 2014;130:18-26
  31. Ruiz-Canela M, Estruch R, Corella D, Salas-Salvado J, Martinez-Gonzalez MA. Association of mediterranean diet with peripheral artery disease: The predimed randomized trial. *Jama*. 2014;311:415-417
  32. Domenech M, Roman P, Lapetra J, Garcia de la Corte FJ, Sala-Vila A, de la Torre R, Corella D, Salas-Salvado J, Ruiz-Gutierrez V, Lamuela-Raventos RM, Toledo E, Estruch R, Coca A, Ros E. Mediterranean diet reduces 24-hour ambulatory blood pressure, blood glucose, and lipids: One-year randomized, clinical trial. *Hypertension*. 2014;64:69-76
  33. Toledo E, Hu FB, Estruch R, Buil-Cosiales P, Corella D, Salas-Salvado J, Covas MI, Aros F, Gomez-Gracia E, Fiol M, Lapetra J, Serra-Majem L, Pinto X, Lamuela-Raventos RM, Saez G, Bullo M, Ruiz-Gutierrez V, Ros E, Sorli JV, Martinez-Gonzalez MA. Effect of the mediterranean diet on blood pressure in the predimed trial: Results from a randomized controlled trial. *BMC medicine*. 2013;11:207
  34. Sala-Vila A, Romero-Mamani ES, Gilabert R, Nunez I, de la Torre R, Corella D, Ruiz-Gutierrez V, Lopez-Sabater MC, Pinto X, Rekondo J, Martinez-Gonzalez MA, Estruch R, Ros E. Changes in ultrasound-assessed carotid intima-media thickness and plaque with a mediterranean diet: A substudy of the predimed trial. *Arteriosclerosis, thrombosis, and vascular biology*. 2014;34:439-445
  35. Murie-Fernandez M, Irimia P, Toledo E, Martinez-Vila E, Buil-Cosiales P, Serrano-Martinez M, Ruiz-Gutierrez V, Ros E, Estruch R, Martinez-Gonzalez MA. Carotid intima-media thickness changes with mediterranean diet: A randomized trial (predimed-navarra). *Atherosclerosis*. 2011;219:158-162
  36. Khaw KT, Friesen MD, Riboli E, Luben R, Wareham N. Plasma phospholipid fatty acid concentration and incident coronary heart disease in men and women: The epic-norfolk prospective study. *PLoS medicine*. 2012;9:e1001255
  37. Block G, Woods M, Potosky A, Clifford C. Validation of a self-administered diet history questionnaire using multiple diet records. *Journal of clinical epidemiology*. 1990;43:1327-1335
  38. Estruch R, Ros E, Martinez-Gonzalez MA. Mediterranean diet for primary prevention of cardiovascular disease. *The New England journal of medicine*. 2013;369:676-677
  39. Martinez-Gonzalez MA, Bes-Rastrollo M, Serra-Majem L, Lairon D, Estruch R, Trichopoulos A. Mediterranean food pattern and the primary prevention of chronic disease: Recent developments. *Nutrition reviews*. 2009;67 Suppl 1:S111-116
  40. Schroder H, Fito M, Estruch R, Martinez-Gonzalez MA, Corella D, Salas-Salvado J, Lamuela-Raventos R, Ros E, Salaverria I, Fiol M, Lapetra J, Vinyoles E, Gomez-

- Gracia E, Lahoz C, Serra-Majem L, Pinto X, Ruiz-Gutierrez V, Covas MI. A short screener is valid for assessing mediterranean diet adherence among older spanish men and women. *The Journal of nutrition*. 2011;141:1140-1145
41. Martinez-Gonzalez MA, Salas-Salvado J, Estruch R, Corella D, Fito M, Ros E. Benefits of the mediterranean diet: Insights from the predimed study. *Progress in cardiovascular diseases*. 2015;58:50-60
  42. Willett WC. Diet and health: What should we eat? *Science*. 1994;264:532-537
  43. Willett W, Sacks FM. Chewing the fat--how much and what kind? *The New England journal of medicine*. 1991;324:121-123
  44. Tzonou A, Lipworth L, Garidou A, Signorello LB, Laggiou P, Hsieh C, Trichopoulos D. Diet and risk of esophageal cancer by histologic type in a low-risk population. *International journal of cancer. Journal international du cancer*. 1996;68:300-304
  45. Trichopoulou A, Katsouyanni K, Stuver S, Tzala L, Gnardellis C, Rimm E, Trichopoulos D. Consumption of olive oil and specific food groups in relation to breast cancer risk in greece. *Journal of the National Cancer Institute*. 1995;87:110-116
  46. Tzonou A, Hsieh CC, Polychronopoulou A, Kaprinis G, Toupadaki N, Trichopoulou A, Karakatsani A, Trichopoulos D. Diet and ovarian cancer: A case-control study in greece. *International journal of cancer. Journal international du cancer*. 1993;55:411-414
  47. Kalapothaki V, Tzonou A, Hsieh CC, Karakatsani A, Trichopoulou A, Toupadaki N, Trichopoulos D. Nutrient intake and cancer of the pancreas: A case-control study in athens, greece. *Cancer causes & control : CCC*. 1993;4:383-389
  48. Kalandidi A, Katsouyanni K, Voropoulou N, Bastas G, Saracci R, Trichopoulos D. Passive smoking and diet in the etiology of lung cancer among non-smokers. *Cancer causes & control : CCC*. 1990;1:15-21
  49. Katsouyanni K, Trichopoulos D, Boyle P, Xirouchaki E, Trichopoulou A, Lisseos B, Vasilaros S, MacMahon B. Diet and breast cancer: A case-control study in greece. *International journal of cancer. Journal international du cancer*. 1986;38:815-820
  50. Trichopoulos D, Ouranos G, Day NE, Tzonou A, Manousos O, Papadimitriou C, Trichopoulos A. Diet and cancer of the stomach: A case-control study in greece. *International journal of cancer. Journal international du cancer*. 1985;36:291-297
  51. Manousos O, Day NE, Trichopoulos D, Gerovassilis F, Tzonou A, Polychronopoulou A. Diet and colorectal cancer: A case-control study in greece. *International journal of cancer. Journal international du cancer*. 1983;32:1-5
  52. Lipworth L, Martinez ME, Angell J, Hsieh CC, Trichopoulos D. Olive oil and human cancer: An assessment of the evidence. *Preventive medicine*. 1997;26:181-190
  53. Trichopoulou A. Olive oil and breast cancer. *Cancer causes & control : CCC*. 1995;6:475-476
  54. Tzonou A, Lipworth L, Kalandidi A, Trichopoulou A, Gamatsi I, Hsieh CC, Notara V, Trichopoulos D. Dietary factors and the risk of endometrial cancer: A case--control study in greece. *British journal of cancer*. 1996;73:1284-1290
  55. Bautista D, Obrador A, Moreno V, Cabeza E, Canet R, Benito E, Bosch X, Costa J. K-ras mutation modifies the protective effect of dietary monounsaturated fat and calcium on sporadic colorectal cancer. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. 1997;6:57-61
  56. Kohyama N, Nagata T, Fujimoto S, Sekiya K. Inhibition of arachidonate lipoxygenase activities by 2-(3,4-dihydroxyphenyl)ethanol, a phenolic compound from olives. *Bioscience, biotechnology, and biochemistry*. 1997;61:347-350

57. Cruz JA, Moreiras-Varela O, van Staveren WA, Trichopoulou A, Roszkowski W. Intake of vitamins and minerals. Euronut seneca investigators. *European journal of clinical nutrition*. 1991;45 Suppl 3:121-138
58. Trichopoulou A, Kouris-Blazos A, Vassilakou T, Gnardellis C, Polychronopoulos E, Venizelos M, Lagiou P, Wahlqvist ML, Trichopoulos D. Diet and survival of elderly greeks: A link to the past. *The American journal of clinical nutrition*. 1995;61:1346S-1350S
59. Willett WC, Trichopoulos D. Nutrition and cancer: A summary of the evidence. *Cancer causes & control : CCC*. 1996;7:178-180
60. Potter JD. Nutrition and colorectal cancer. *Cancer causes & control : CCC*. 1996;7:127-146
61. Mattson FH, Grundy SM. Comparison of effects of dietary saturated, monounsaturated, and polyunsaturated fatty acids on plasma lipids and lipoproteins in man. *Journal of lipid research*. 1985;26:194-202
62. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. *The New England journal of medicine*. 1997;337:230-236
63. Mensink RP, Katan MB. Effect of monounsaturated fatty acids versus complex carbohydrates on high-density lipoproteins in healthy men and women. *Lancet*. 1987;1:122-125
64. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knäuper M, Perk J, Priori SG, Pyörälä K, Reiner Z, Ruilope L, Sans-Menendez S, Scholte op Reimer W, Weissberg P, Wood D, Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A. European guidelines on cardiovascular disease prevention in clinical practice: Executive summary: Fourth joint task force of the european society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). *European heart journal*. 2007;28:2375-2414
65. American Heart Association Nutrition C, Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, Franklin B, Kris-Etherton P, Harris WS, Howard B, Karanja N, Lefevre M, Rudel L, Sacks F, Van Horn L, Winston M, Wylie-Rosett J. Diet and lifestyle recommendations revision 2006: A scientific statement from the american heart association nutrition committee. *Circulation*. 2006;114:82-96
66. Mensink RP, Katan MB. Effect of dietary fatty acids on serum lipids and lipoproteins. A meta-analysis of 27 trials. *Arteriosclerosis and thrombosis : a journal of vascular biology*. 1992;12:911-919
67. Shah M, Adams-Huet B, Garg A. Effect of high-carbohydrate or high-cis-monounsaturated fat diets on blood pressure: A meta-analysis of intervention trials. *The American journal of clinical nutrition*. 2007;85:1251-1256
68. Fuhrman B, Aviram M. Flavonoids protect ldl from oxidation and attenuate atherosclerosis. *Current opinion in lipidology*. 2001;12:41-48
69. Covas MI, Nyyssonen K, Poulsen HE, Kaikkonen J, Zunft HJ, Kiesewetter H, Gaddi A, de la Torre R, Mursu J, Baumler H, Nascetti S, Salonen JT, Fito M, Virtanen J, Marrugat J. The effect of polyphenols in olive oil on heart disease risk factors: A randomized trial. *Annals of internal medicine*. 2006;145:333-341
70. Visioli F, Caruso D, Grande S, Bosisio R, Villa M, Galli G, Sirtori C, Galli C. Virgin olive oil study (volos): Vasoprotective potential of extra virgin olive oil in mildly dyslipidemic patients. *European journal of nutrition*. 2005;44:121-127

71. Bellido C, Lopez-Miranda J, Blanco-Colio LM, Perez-Martinez P, Muriana FJ, Martin-Ventura JL, Marin C, Gomez P, Fuentes F, Egido J, Perez-Jimenez F. Butter and walnuts, but not olive oil, elicit postprandial activation of nuclear transcription factor kappaB in peripheral blood mononuclear cells from healthy men. *The American journal of clinical nutrition*. 2004;80:1487-1491
72. Widmer RJ, Freund MA, Flammer AJ, Sexton J, Lennon R, Romani A, Mulinacci N, Vinceri FF, Lerman LO, Lerman A. Beneficial effects of polyphenol-rich olive oil in patients with early atherosclerosis. *European journal of nutrition*. 2013;52:1223-1231
73. Marin C, Ramirez R, Delgado-Lista J, Yubero-Serrano EM, Perez-Martinez P, Carracedo J, Garcia-Rios A, Rodriguez F, Gutierrez-Mariscal FM, Gomez P, Perez-Jimenez F, Lopez-Miranda J. Mediterranean diet reduces endothelial damage and improves the regenerative capacity of endothelium. *The American journal of clinical nutrition*. 2011;93:267-274
74. Howard BV, Kritchevsky D. Phytochemicals and cardiovascular disease. A statement for healthcare professionals from the american heart association. *Circulation*. 1997;95:2591-2593
75. Dauchet L, Amouyel P, Hercberg S, Dallongeville J. Fruit and vegetable consumption and risk of coronary heart disease: A meta-analysis of cohort studies. *The Journal of nutrition*. 2006;136:2588-2593
76. He FJ, Nowson CA, Lucas M, MacGregor GA. Increased consumption of fruit and vegetables is related to a reduced risk of coronary heart disease: Meta-analysis of cohort studies. *Journal of human hypertension*. 2007;21:717-728
77. Beitz R, Mensink GB, Fischer B. Blood pressure and vitamin c and fruit and vegetable intake. *Annals of nutrition & metabolism*. 2003;47:214-220
78. Alonso A, de la Fuente C, Martin-Arnau AM, de Irala J, Martinez JA, Martinez-Gonzalez MA. Fruit and vegetable consumption is inversely associated with blood pressure in a mediterranean population with a high vegetable-fat intake: The seguimiento universidad de navarra (sun) study. *The British journal of nutrition*. 2004;92:311-319
79. Lin B, Morrison R. Higher fruit consumption linked with lower body mass index. *Food Rev*. 2002;25:28-32
80. Miura K, Greenland P, Stamler J, Liu K, Davignus ML, Nakagawa H. Relation of vegetable, fruit, and meat intake to 7-year blood pressure change in middle-aged men: The chicago western electric study. *American journal of epidemiology*. 2004;159:572-580
81. Crowe FL, Roddam AW, Key TJ, Appleby PN, Overvad K, Jakobsen MU, Tjonneland A, Hansen L, Boeing H, Weikert C, Linseisen J, Kaaks R, Trichopoulou A, Misirli G, Lagiou P, Sacerdote C, Pala V, Palli D, Tumino R, Panico S, Bueno-de-Mesquita HB, Boer J, van Gils CH, Beulens JW, Barricarte A, Rodriguez L, Larranaga N, Sanchez MJ, Tormo MJ, Buckland G, Lund E, Hedblad B, Melander O, Jansson JH, Wennberg P, Wareham NJ, Slimani N, Romieu I, Jenab M, Danesh J, Gallo V, Norat T, Riboli E. Fruit and vegetable intake and mortality from ischaemic heart disease: Results from the european prospective investigation into cancer and nutrition (epic)-heart study. *European heart journal*. 2011;32:1235-1243
82. Broekmans WM, Klopping-Ketelaars WA, Klufft C, van den Berg H, Kok FJ, van Poppel G. Fruit and vegetables and cardiovascular risk profile: A diet controlled intervention study. *European journal of clinical nutrition*. 2001;55:636-642

83. John JH, Ziebland S, Yudkin P, Roe LS, Neil HA. Effects of fruit and vegetable consumption on plasma antioxidant concentrations and blood pressure: A randomised controlled trial. *Lancet*. 2002;359:1969-1974
84. Knekt P, Ritz J, Pereira MA, O'Reilly EJ, Augustsson K, Fraser GE, Goldbourt U, Heitmann BL, Hallmans G, Liu S, Pietinen P, Spiegelman D, Stevens J, Virtamo J, Willett WC, Rimm EB, Ascherio A. Antioxidant vitamins and coronary heart disease risk: A pooled analysis of 9 cohorts. *The American journal of clinical nutrition*. 2004;80:1508-1520
85. Huxley RR, Neil HA. The relation between dietary flavonol intake and coronary heart disease mortality: A meta-analysis of prospective cohort studies. *European journal of clinical nutrition*. 2003;57:904-908
86. Hollman PC, Cassidy A, Comte B, Heinonen M, Richelle M, Richling E, Serafini M, Scalbert A, Sies H, Vidry S. The biological relevance of direct antioxidant effects of polyphenols for cardiovascular health in humans is not established. *The Journal of nutrition*. 2011;141:989S-1009S
87. Van Horn L. Fiber, lipids, and coronary heart disease. A statement for healthcare professionals from the nutrition committee, american heart association. *Circulation*. 1997;95:2701-2704
88. Katcher HI, Legro RS, Kunselman AR, Gillies PJ, Demers LM, Bagshaw DM, Kris-Etherton PM. The effects of a whole grain-enriched hypocaloric diet on cardiovascular disease risk factors in men and women with metabolic syndrome. *The American journal of clinical nutrition*. 2008;87:79-90
89. Tighe P, Duthie G, Vaughan N, Brittenden J, Simpson WG, Duthie S, Mutch W, Wahle K, Horgan G, Thies F. Effect of increased consumption of whole-grain foods on blood pressure and other cardiovascular risk markers in healthy middle-aged persons: A randomized controlled trial. *The American journal of clinical nutrition*. 2010;92:733-740
90. Brownlee IA, Moore C, Chatfield M, Richardson DP, Ashby P, Kuznesof SA, Jebb SA, Seal CJ. Markers of cardiovascular risk are not changed by increased whole-grain intake: The wholeheart study, a randomised, controlled dietary intervention. *The British journal of nutrition*. 2010;104:125-134
91. Mellen PB, Walsh TF, Herrington DM. Whole grain intake and cardiovascular disease: A meta-analysis. *Nutrition, metabolism, and cardiovascular diseases : NMCD*. 2008;18:283-290
92. Liu S, Stampfer MJ, Hu FB, Giovannucci E, Rimm E, Manson JE, Hennekens CH, Willett WC. Whole-grain consumption and risk of coronary heart disease: Results from the nurses' health study. *The American journal of clinical nutrition*. 1999;70:412-419
93. Jacobs DR, Jr., Meyer KA, Kushi LH, Folsom AR. Whole-grain intake may reduce the risk of ischemic heart disease death in postmenopausal women: The iowa women's health study. *The American journal of clinical nutrition*. 1998;68:248-257
94. He M, van Dam RM, Rimm E, Hu FB, Qi L. Whole-grain, cereal fiber, bran, and germ intake and the risks of all-cause and cardiovascular disease-specific mortality among women with type 2 diabetes mellitus. *Circulation*. 2010;121:2162-2168
95. Anderson JW, Baird P, Davis RH, Jr., Ferreri S, Knudtson M, Koraym A, Waters V, Williams CL. Health benefits of dietary fiber. *Nutrition reviews*. 2009;67:188-205
96. Adom KK, Liu RH. Antioxidant activity of grains. *Journal of agricultural and food chemistry*. 2002;50:6182-6187

97. Anderson JW, Hanna TJ, Peng X, Kryscio RJ. Whole grain foods and heart disease risk. *Journal of the American College of Nutrition*. 2000;19:291S-299S
98. Tarini J, Wolever TM. The fermentable fibre inulin increases postprandial serum short-chain fatty acids and reduces free-fatty acids and ghrelin in healthy subjects. *Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme*. 2010;35:9-16
99. Jenkins DJ, Wesson V, Wolever TM, Jenkins AL, Kalmusky J, Guidici S, Csima A, Josse RG, Wong GS. Wholemeal versus wholegrain breads: Proportion of whole or cracked grain and the glycaemic response. *BMJ*. 1988;297:958-960
100. Good CK, Holschuh N, Albertson AM, Eldridge AL. Whole grain consumption and body mass index in adult women: An analysis of nhanes 1999-2000 and the usda pyramid servings database. *Journal of the American College of Nutrition*. 2008;27:80-87
101. Hu FB, Manson JE, Willett WC. Types of dietary fat and risk of coronary heart disease: A critical review. *Journal of the American College of Nutrition*. 2001;20:5-19
102. Hu FB, Stampfer MJ. Nut consumption and risk of coronary heart disease: A review of epidemiologic evidence. *Current atherosclerosis reports*. 1999;1:204-209
103. Mente A, de Koning L, Shannon HS, Anand SS. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. *Archives of internal medicine*. 2009;169:659-669
104. Banel DK, Hu FB. Effects of walnut consumption on blood lipids and other cardiovascular risk factors: A meta-analysis and systematic review. *The American journal of clinical nutrition*. 2009;90:56-63
105. Mozaffarian D, Hao T, Rimm EB, Willett WC, Hu FB. Changes in diet and lifestyle and long-term weight gain in women and men. *The New England journal of medicine*. 2011;364:2392-2404
106. Kelly RB. Diet and exercise in the management of hyperlipidemia. *American family physician*. 2010;81:1097-1102
107. Salas-Salvado J, Fernandez-Ballart J, Ros E, Martinez-Gonzalez MA, Fito M, Estruch R, Corella D, Fiol M, Gomez-Gracia E, Aros F, Flores G, Lapetra J, Lamuela-Raventos R, Ruiz-Gutierrez V, Bullo M, Basora J, Covas MI. Effect of a mediterranean diet supplemented with nuts on metabolic syndrome status: One-year results of the predimed randomized trial. *Archives of internal medicine*. 2008;168:2449-2458
108. Bazzano LA, He J, Ogden LG, Loria C, Vupputuri S, Myers L, Whelton PK. Legume consumption and risk of coronary heart disease in us men and women: Nhanes i epidemiologic follow-up study. *Archives of internal medicine*. 2001;161:2573-2578
109. Sasazuki S. Case-control study of nonfatal myocardial infarction in relation to selected foods in japanese men and women. *Japanese circulation journal*. 2001;65:200-206
110. Zhang X, Shu XO, Gao YT, Yang G, Li Q, Li H, Jin F, Zheng W. Soy food consumption is associated with lower risk of coronary heart disease in chinese women. *The Journal of nutrition*. 2003;133:2874-2878
111. Wangen KE, Duncan AM, Xu X, Kurzer MS. Soy isoflavones improve plasma lipids in normocholesterolemic and mildly hypercholesterolemic postmenopausal women. *The American journal of clinical nutrition*. 2001;73:225-231
112. Sanders TA, Dean TS, Grainger D, Miller GJ, Wiseman H. Moderate intakes of intact soy protein rich in isoflavones compared with ethanol-extracted soy protein

- increase hdl but do not influence transforming growth factor beta(1) concentrations and hemostatic risk factors for coronary heart disease in healthy subjects. *The American journal of clinical nutrition*. 2002;76:373-377
113. Jenkins DJ, Kendall CW, Jackson CJ, Connelly PW, Parker T, Faulkner D, Vidgen E, Cunnane SC, Leiter LA, Josse RG. Effects of high- and low-isoflavone soyfoods on blood lipids, oxidized ldl, homocysteine, and blood pressure in hyperlipidemic men and women. *The American journal of clinical nutrition*. 2002;76:365-372
  114. Zhan S, Ho SC. Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. *The American journal of clinical nutrition*. 2005;81:397-408
  115. He J, Gu D, Wu X, Chen J, Duan X, Whelton PK. Effect of soybean protein on blood pressure: A randomized, controlled trial. *Annals of internal medicine*. 2005;143:1-9
  116. Liu XX, Li SH, Chen JZ, Sun K, Wang XJ, Wang XG, Hui RT. Effect of soy isoflavones on blood pressure: A meta-analysis of randomized controlled trials. *Nutrition, metabolism, and cardiovascular diseases : NMCD*. 2012;22:463-470
  117. Taku K, Lin N, Cai D, Hu J, Zhao X, Zhang Y, Wang P, Melby MK, Hooper L, Kurzer MS, Mizuno S, Ishimi Y, Watanabe S. Effects of soy isoflavone extract supplements on blood pressure in adult humans: Systematic review and meta-analysis of randomized placebo-controlled trials. *Journal of hypertension*. 2010;28:1971-1982
  118. Wong WW, Taylor AA, Smith EO, Barnes S, Hachey DL. Effect of soy isoflavone supplementation on nitric oxide metabolism and blood pressure in menopausal women. *The American journal of clinical nutrition*. 2012;95:1487-1494
  119. Li SH, Liu XX, Bai YY, Wang XJ, Sun K, Chen JZ, Hui RT. Effect of oral isoflavone supplementation on vascular endothelial function in postmenopausal women: A meta-analysis of randomized placebo-controlled trials. *The American journal of clinical nutrition*. 2010;91:480-486
  120. de Gaetano G, Costanzo S, Di Castelnuovo A, Badimon L, Bejko D, Alkerwi A, Chiva-Blanch G, Estruch R, La Vecchia C, Panico S, Pounis G, Sofi F, Stranges S, Trevisan M, Ursini F, Cerletti C, Donati MB, Iacoviello L. Effects of moderate beer consumption on health and disease: A consensus document. *Nutrition, metabolism, and cardiovascular diseases : NMCD*. 2016;26:443-467
  121. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA. Resveratrol improves health and survival of mice on a high-calorie diet. *Nature*. 2006;444:337-342
  122. Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, Tatar M, Sinclair D. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. *Nature*. 2004;430:686-689
  123. Ungvari Z, Bagi Z, Feher A, Recchia FA, Sonntag WE, Pearson K, de Cabo R, Csizsar A. Resveratrol confers endothelial protection via activation of the antioxidant transcription factor nrf2. *American journal of physiology. Heart and circulatory physiology*. 2010;299:H18-24
  124. Tsai SH, Lin-Shiau SY, Lin JK. Suppression of nitric oxide synthase and the down-regulation of the activation of nf-kappa-b in macrophages by resveratrol. *British journal of pharmacology*. 1999;126:673-680
  125. Morselli E, Maiuri MC, Markaki M, Megalou E, Pasparaki A, Palikaras K, Criollo A, Galluzzi L, Malik SA, Vitale I, Michaud M, Madeo F, Tavernarakis N, Kroemer G. Caloric restriction and resveratrol promote longevity through the sirtuin-1-dependent induction of autophagy. *Cell death & disease*. 2010;1:e10

126. Feige JN, Lagouge M, Canto C, Strehle A, Houten SM, Milne JC, Lambert PD, Matakaki C, Elliott PJ, Auwerx J. Specific sirt1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. *Cell metabolism*. 2008;8:347-358
127. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA. Small molecule activators of sirtuins extend *saccharomyces cerevisiae* lifespan. *Nature*. 2003;425:191-196
128. Menendez JA, Joven J, Aragones G, Barrajon-Catalan E, Beltran-Debon R, Borrás-Linares I, Camps J, Corominas-Faja B, Cufi S, Fernandez-Arroyo S, Garcia-Heredia A, Hernandez-Aguilera A, Herranz-Lopez M, Jimenez-Sanchez C, Lopez-Bonet E, Lozano-Sanchez J, Luciano-Mateo F, Martin-Castillo B, Martin-Paredero V, Perez-Sanchez A, Oliveras-Ferraro C, Riera-Borrull M, Rodriguez-Gallego E, Quirantes-Pine R, Rull A, Tomas-Menor L, Vazquez-Martin A, Alonso-Villaverde C, Micol V, Segura-Carretero A. Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: A new family of gerosuppressant agents. *Cell Cycle*. 2013;12:555-578
129. Bayram B, Ozcelik B, Grimm S, Roeder T, Schrader C, Ernst IM, Wagner AE, Grune T, Frank J, Rimbach G. A diet rich in olive oil phenolics reduces oxidative stress in the heart of *samp8* mice by induction of nrf2-dependent gene expression. *Rejuvenation research*. 2012;15:71-81
130. Chung S, Yao H, Caito S, Hwang JW, Arunachalam G, Rahman I. Regulation of sirt1 in cellular functions: Role of polyphenols. *Archives of biochemistry and biophysics*. 2010;501:79-90
131. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and reinfarction trial (dart). *Lancet*. 1989;2:757-761
132. McLennan PL, Abeywardena MY, Charnock JS. Reversal of the arrhythmogenic effects of long-term saturated fatty acid intake by dietary n-3 and n-6 polyunsaturated fatty acids. *The American journal of clinical nutrition*. 1990;51:53-58
133. Billman GE, Kang JX, Leaf A. Prevention of sudden cardiac death by dietary pure omega-3 polyunsaturated fatty acids in dogs. *Circulation*. 1999;99:2452-2457
134. Parratt JR, Coker SJ, Wainwright CL. Eicosanoids and susceptibility to ventricular arrhythmias during myocardial ischaemia and reperfusion. *Journal of molecular and cellular cardiology*. 1987;19 Suppl 5:55-66
135. Sellmayer A, Witzgall H, Lorenz RL, Weber PC. Effects of dietary fish oil on ventricular premature complexes. *The American journal of cardiology*. 1995;76:974-977
136. Christensen JH, Gustenhoff P, Korup E, Aaroe J, Toft E, Moller J, Rasmussen K, Dyerberg J, Schmidt EB. Effect of fish oil on heart rate variability in survivors of myocardial infarction: A double blind randomised controlled trial. *BMJ*. 1996;312:677-678
137. Christensen JH, Christensen MS, Dyerberg J, Schmidt EB. Heart rate variability and fatty acid content of blood cell membranes: A dose-response study with n-3 fatty acids. *The American journal of clinical nutrition*. 1999;70:331-337
138. Farrell TG, Bashir Y, Cripps T, Malik M, Poloniecki J, Bennett ED, Ward DE, Camm AJ. Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram. *Journal of the American College of Cardiology*. 1991;18:687-697



139. Siscovick DS, Raghunathan TE, King I, Weinmann S, Wicklund KG, Albright J, Bovbjerg V, Arbogast P, Smith H, Kushi LH, et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. *Jama*. 1995;274:1363-1367
140. Albert CM, Hennekens CH, O'Donnell CJ, Ajani UA, Carey VJ, Willett WC, Ruskin JN, Manson JE. Fish consumption and risk of sudden cardiac death. *Jama*. 1998;279:23-28
141. Leaf A, Albert CM, Josephson M, Steinhaus D, Kluger J, Kang JX, Cox B, Zhang H, Schoenfeld D. Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. *Circulation*. 2005;112:2762-2768
142. Raitt MH, Connor WE, Morris C, Kron J, Halperin B, Chugh SS, McClelland J, Cook J, MacMurdy K, Swenson R, Connor SL, Gerhard G, Kraemer DF, Oseran D, Marchant C, Calhoun D, Shnider R, McAnulty J. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: A randomized controlled trial. *Jama*. 2005;293:2884-2891
143. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin e after myocardial infarction: Results of the gissi-prevenzione trial. Gruppo italiano per lo studio della sopravvivenza nell'infarto miocardico. *Lancet*. 1999;354:447-455
144. Barzi F, Woodward M, Marfisi RM, Tavazzi L, Valagussa F, Marchioli R. Mediterranean diet and all-causes mortality after myocardial infarction: Results from the gissi-prevenzione trial. *European journal of clinical nutrition*. 2003;57:604-611
145. Di Minno MN, Tremoli E, Tufano A, Russolillo A, Lupoli R, Di Minno G. Exploring newer cardioprotective strategies: Omega-3 fatty acids in perspective. *Thrombosis and haemostasis*. 2010;104:664-680
146. Benova T, Knezl V, Viczenczova C, Bacova BS, Radosinska J, Tribulova N. Acute anti-fibrillating and defibrillating potential of atorvastatin, melatonin, eicosapentaenoic acid and docosahexaenoic acid demonstrated in isolated heart model. *Journal of physiology and pharmacology : an official journal of the Polish Physiological Society*. 2015;66:83-89
147. Mozaffarian D, Wu JH. (n-3) fatty acids and cardiovascular health: Are effects of epa and dha shared or complementary? *The Journal of nutrition*. 2012;142:614S-625S
148. Rupp H, Wagner D, Rupp T, Schulte LM, Maisch B. Risk stratification by the "epa+dha level" and the "epa/aa ratio" focus on anti-inflammatory and antiarrhythmogenic effects of long-chain omega-3 fatty acids. *Herz*. 2004;29:673-685
149. Weber C, Erl W, Pietsch A, Danesch U, Weber PC. Docosahexaenoic acid selectively attenuates induction of vascular cell adhesion molecule-1 and subsequent monocytic cell adhesion to human endothelial cells stimulated by tumor necrosis factor-alpha. *Arteriosclerosis, thrombosis, and vascular biology*. 1995;15:622-628
150. De Caterina R, Cybulsky MA, Clinton SK, Gimbrone MA, Jr., Libby P. Omega-3 fatty acids and endothelial leukocyte adhesion molecules. *Prostaglandins, leukotrienes, and essential fatty acids*. 1995;52:191-195
151. De Caterina R, Cybulsky MI, Clinton SK, Gimbrone MA, Jr., Libby P. The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells. *Arteriosclerosis and thrombosis : a journal of vascular biology*. 1994;14:1829-1836

152. Khalfoun B, Thibault F, Watier H, Bardos P, Lebranchu Y. Docosahexaenoic and eicosapentaenoic acids inhibit in vitro human endothelial cell production of interleukin-6. *Advances in experimental medicine and biology*. 1997;400B:589-597
153. Massaro M, Basta G, Lazzerini G, Carluccio MA, Bosetti F, Solaini G, Visioli F, Paolicchi A, De Caterina R. Quenching of intracellular ros generation as a mechanism for oleate-induced reduction of endothelial activation and early atherogenesis. *Thrombosis and haemostasis*. 2002;88:335-344
154. Matsumoto M, Sata M, Fukuda D, Tanaka K, Soma M, Hirata Y, Nagai R. Orally administered eicosapentaenoic acid reduces and stabilizes atherosclerotic lesions in apoe-deficient mice. *Atherosclerosis*. 2008;197:524-533
155. Massaro M, Habib A, Lubrano L, Del Turco S, Lazzerini G, Bourcier T, Weksler BB, De Caterina R. The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction through both nadp(h) oxidase and pkc epsilon inhibition. *Proceedings of the National Academy of Sciences of the United States of America*. 2006;103:15184-15189
156. Richard D, Kefi K, Barbe U, Bausero P, Visioli F. Polyunsaturated fatty acids as antioxidants. *Pharmacological research : the official journal of the Italian Pharmacological Society*. 2008;57:451-455
157. Massaro M, Scoditti E, Carluccio MA, De Caterina R. Basic mechanisms behind the effects of n-3 fatty acids on cardiovascular disease. *Prostaglandins, leukotrienes, and essential fatty acids*. 2008;79:109-115
158. Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP, Gallagher PJ, Calder PC, Grimble RF. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: A randomised controlled trial. *Lancet*. 2003;361:477-485
159. Pakala R, Sheng WL, Benedict CR. Eicosapentaenoic acid and docosahexaenoic acid block serotonin-induced smooth muscle cell proliferation. *Arteriosclerosis, thrombosis, and vascular biology*. 1999;19:2316-2322
160. Di Minno G, Spadarella G, Cafaro G, Petitto M, Lupoli R, Di Minno A, de Gaetano G, Tremoli E. Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. *Annals of medicine*. 2014;46:475-489
161. Arbustini E, Dal Bello B, Morbini P, Burke AP, Bocciarelli M, Specchia G, Virmani R. Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. *Heart*. 1999;82:269-272
162. Falk E, Shah PK, Fuster V. Coronary plaque disruption. *Circulation*. 1995;92:657-671
163. Drouet L. Atherothrombosis as a systemic disease. *Cerebrovasc Dis*. 2002;13 Suppl 1:1-6
164. Ness J, Aronow WS. Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice. *Journal of the American Geriatrics Society*. 1999;47:1255-1256
165. Schafer AI. Antiplatelet therapy. *The American journal of medicine*. 1996;101:199-209
166. European Heart Network. European cardiovascular disease statistics 2017
167. Odden MC, Coxson PG, Moran A, Lightwood JM, Goldman L, Bibbins-Domingo K. The impact of the aging population on coronary heart disease in the united states. *The American journal of medicine*. 2011;124:827-833 e825

168. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: A systematic analysis for the global burden of disease study 2015. *Lancet*. 2016;388:1459-1544
169. Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, Ahmed M, Aksut B, Alam T, Alam K, Alla F, Alvis-Guzman N, Amrock S, Ansari H, Arnlov J, Asayesh H, Atey TM, Avila-Burgos L, Awasthi A, Banerjee A, Barac A, Barnighausen T, Barregard L, Bedi N, Belay Ketema E, Bennett D, Berhe G, Bhutta Z, Bitew S, Carapetis J, Carrero JJ, Malta DC, Castaneda-Orjuela CA, Castillo-Rivas J, Catala-Lopez F, Choi JY, Christensen H, Cirillo M, Cooper L, Jr., Criqui M, Cundiff D, Damasceno A, Dandona L, Dandona R, Davletov K, Dharmaratne S, Dorairaj P, Dubey M, Ehrenkranz R, El Sayed Zaki M, Faraon EJA, Esteghamati A, Farid T, Farvid M, Feigin V, Ding EL, Fowkes G, Gebrehiwot T, Gillum R, Gold A, Gona P, Gupta R, Habtewold TD, Hafezi-Nejad N, Hailu T, Hailu GB, Hankey G, Hassen HY, Abate KH, Havmoeller R, Hay SI, Horino M, Hotez PJ, Jacobsen K, James S, Javanbakht M, Jeemon P, John D, Jonas J, Kalkonde Y, Karimkhani C, Kasaeian A, Khader Y, Khan A, Khang YH, Khera S, Khoja AT, Khubchandani J, Kim D, Kolte D, Kosen S, Krohn KJ, Kumar GA, Kwan GF, Lal DK, Larsson A, Linn S, Lopez A, Lotufo PA, El Razek HMA, Malekzadeh R, Mazidi M, Meier T, Meles KG, Mensah G, Meretoja A, Mezgebe H, Miller T, Mirrakhimov E, Mohammed S, Moran AE, Musa KI, Narula J, Neal B, Ngalesoni F, Nguyen G, Obermeyer CM, Owolabi M, Patton G, Pedro J, Qato D, Qorbani M, Rahimi K, Rai RK, Rawaf S, Ribeiro A, Safiri S, Salomon JA, Santos I, Santric Milicevic M, Sartorius B, Schutte A, Sepanlou S, Shaikh MA, Shin MJ, Shishehbor M, Shore H, Silva DAS, Sobngwi E, Stranges S, Swaminathan S, Tabares-Seisdedos R, Tadele Atnafu N, Tesfay F, Thakur JS, Thrift A, Topor-Madry R, Truelsen T, Tyrovolas S, Ukwaja KN, Uthman O, Vasankari T, Vlassov V, Vollset SE, Wakayo T, Watkins D, Weintraub R, Werdecker A, Westerman R, Wiysonge CS, Wolfe C, Workicho A, Xu G, Yano Y, Yip P, Yonemoto N, Younis M, Yu C, Vos T, Naghavi M, Murray C. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. *Journal of the American College of Cardiology*. 2017;70:1-25
170. Roth GA, Forouzanfar MH, Moran AE, Barber R, Nguyen G, Feigin VL, Naghavi M, Mensah GA, Murray CJ. Demographic and epidemiologic drivers of global cardiovascular mortality. *The New England journal of medicine*. 2015;372:1333-1341
171. Norheim OF, Jha P, Admasu K, Godal T, Hum RJ, Kruk ME, Gomez-Dantes O, Mathers CD, Pan H, Sepulveda J, Suraweera W, Verguet S, Woldemariam AT, Yamey G, Jamison DT, Peto R. Avoiding 40% of the premature deaths in each country, 2010-30: Review of national mortality trends to help quantify the un sustainable development goal for health. *Lancet*. 2015;385:239-252
172. Decline in deaths from heart disease and stroke--united states, 1900-1999. *MMWR. Morbidity and mortality weekly report*. 1999;48:649-656
173. World Health Organization. Who global ncd action plan 2013-2020. 2013
174. Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Flaxman A, Murray CJ, Naghavi M. The global burden of ischemic heart disease in 1990 and 2010: The global burden of disease 2010 study. *Circulation*. 2014;129:1493-1501
175. Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Murray CJ, Naghavi M. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: The global burden of disease 2010 study. *Circulation*. 2014;129:1483-1492
176. Roger VL. Epidemiology of heart failure. *Circulation research*. 2013;113:646-659

177. Dokainish H, Teo K, Zhu J, Roy A, AlHabib KF, ElSayed A, Palileo-Villaneuva L, Lopez-Jaramillo P, Karaye K, Yusoff K, Orlandini A, Sliwa K, Mondo C, Lanas F, Prabhakaran D, Badr A, Elmaghawry M, Damasceno A, Tibazarwa K, Belley-Cote E, Balasubramanian K, Islam S, Yacoub MH, Huffman MD, Harkness K, Grinvalds A, McKelvie R, Bangdiwala SI, Yusuf S. Global mortality variations in patients with heart failure: Results from the international congestive heart failure (inter-CHF) prospective cohort study. *The Lancet. Global health*. 2017;5:e665-e672
178. Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H, Rastogi V, Rohde LE, Samal UC, Shimokawa H, Budi Siswanto B, Sliwa K, Filippatos G. Heart failure: Preventing disease and death worldwide. *ESC heart failure*. 2014;1:4-25
179. Sato N. Epidemiology of heart failure in asia. *Heart failure clinics*. 2015;11:573-579
180. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH, Jr., Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJ. Worldwide epidemiology of atrial fibrillation: A global burden of disease 2010 study. *Circulation*. 2014;129:837-847
181. Zuhlke LJ, Steer AC. Estimates of the global burden of rheumatic heart disease. *Global heart*. 2013;8:189-195
182. Seckeler MD, Hoke TR. The worldwide epidemiology of acute rheumatic fever and rheumatic heart disease. *Clinical epidemiology*. 2011;3:67-84
183. Krishnamurthi RV, Feigin VL, Forouzanfar MH, Mensah GA, Connor M, Bennett DA, Moran AE, Sacco RL, Anderson LM, Truelsen T, O'Donnell M, Venketasubramanian N, Barker-Collo S, Lawes CM, Wang W, Shinohara Y, Witt E, Ezzati M, Naghavi M, Murray C. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010: Findings from the global burden of disease study 2010. *The Lancet. Global health*. 2013;1:e259-281
184. Chiu D, Peterson L, Elkind MS, Rosand J, Gerber LM, Silverstein MD. Comparison of outcomes after intracerebral hemorrhage and ischemic stroke. *Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association*. 2010;19:225-229
185. Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, Moran AE, Sacco RL, Anderson L, Truelsen T, O'Donnell M, Venketasubramanian N, Barker-Collo S, Lawes CM, Wang W, Shinohara Y, Witt E, Ezzati M, Naghavi M, Murray C. Global and regional burden of stroke during 1990-2010: Findings from the global burden of disease study 2010. *Lancet*. 2014;383:245-254
186. A classification and outline of cerebrovascular diseases. II. *Stroke; a journal of cerebral circulation*. 1975;6:564-616
187. Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, Hatsukami TS, Higashida RT, Johnston SC, Kidwell CS, Lutsep HL, Miller E, Sacco RL. Definition and evaluation of transient ischemic attack: A scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. *Stroke; a journal of cerebral circulation*. 2009;40:2276-2293
188. Edlow JA. Managing patients with transient ischemic attack. *Annals of emergency medicine*. 2017
189. Giles MF, Rothwell PM. Risk of stroke early after transient ischaemic attack: A systematic review and meta-analysis. *The Lancet. Neurology*. 2007;6:1063-1072

190. Amarenco P, Lavallee PC, Labreuche J, Albers GW, Bornstein NM, Canhao P, Caplan LR, Donnan GA, Ferro JM, Hennerici MG, Molina C, Rothwell PM, Sissani L, Skoloudik D, Steg PG, Touboul PJ, Uchiyama S, Vicaut E, Wong LK. One-year risk of stroke after transient ischemic attack or minor stroke. *The New England journal of medicine*. 2016;374:1533-1542
191. Stead LG, Bellolio MF, Suravaram S, Brown RD, Jr., Bhagra A, Gilmore RM, Boie ET, Decker WW. Evaluation of transient ischemic attack in an emergency department observation unit. *Neurocritical care*. 2009;10:204-208
192. Lavallee PC, Meseguer E, Abboud H, Cabrejo L, Olivot JM, Simon O, Mazighi M, Nifle C, Niclot P, Lapergue B, Klein IF, Brochet E, Steg PG, Leseche G, Labreuche J, Touboul PJ, Amarenco P. A transient ischaemic attack clinic with round-the-clock access (sos-tia): Feasibility and effects. *The Lancet. Neurology*. 2007;6:953-960
193. Rothwell PM, Giles MF, Chandratheva A, Marquardt L, Geraghty O, Redgrave JN, Lovelock CE, Binney LE, Bull LM, Cuthbertson FC, Welch SJ, Bosch S, Alexander FC, Silver LE, Gutnikov SA, Mehta Z. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (express study): A prospective population-based sequential comparison. *Lancet*. 2007;370:1432-1442
194. Rincon F, Rossenwasser RH, Dumont A. The epidemiology of admissions of nontraumatic subarachnoid hemorrhage in the united states. *Neurosurgery*. 2013;73:217-222; discussion 212-213
195. Johnston SC, Selvin S, Gress DR. The burden, trends, and demographics of mortality from subarachnoid hemorrhage. *Neurology*. 1998;50:1413-1418
196. Taufique Z, May T, Meyers E, Falo C, Mayer SA, Agarwal S, Park S, Connolly ES, Claassen J, Schmidt JM. Predictors of poor quality of life 1 year after subarachnoid hemorrhage. *Neurosurgery*. 2016;78:256-264
197. Elhadi AM, Zabramski JM, Almefty KK, Mendes GA, Nakaji P, McDougall CG, Albuquerque FC, Preul MC, Spetzler RF. Spontaneous subarachnoid hemorrhage of unknown origin: Hospital course and long-term clinical and angiographic follow-up. *Journal of neurosurgery*. 2015;122:663-670
198. Dormandy J, Mahir M, Ascady G, Balsano F, De Leeuw P, Blombery P, Bousser MG, Clement D, Coffman J, Deutshinoff A, et al. Fate of the patient with chronic leg ischaemia. A review article. *The Journal of cardiovascular surgery*. 1989;30:50-57
199. Davies MG. Critical limb ischemia: Epidemiology. *Methodist DeBakey cardiovascular journal*. 2012;8:10-14
200. Lambert MA, Belch JJ. Medical management of critical limb ischaemia: Where do we stand today? *Journal of internal medicine*. 2013;274:295-307
201. Hirsch AT, Haskal ZJ, Hertzner NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM, Jr., White CJ, White J, White RA, Antman EM, Smith SC, Jr., Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. Acc/aha 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): A collaborative report from the american association for vascular surgery/society for vascular surgery, society for cardiovascular angiography and interventions, society for vascular medicine and biology, society of interventional radiology, and the acc/aha task force on practice guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease): Endorsed by the american association of cardiovascular and pulmonary rehabilitation; national heart, lung, and blood

- institute; society for vascular nursing; transatlantic inter-society consensus; and vascular disease foundation. *Circulation*. 2006;113:e463-654
202. Meru AV, Mitra S, Thyagarajan B, Chugh A. Intermittent claudication: An overview. *Atherosclerosis*. 2006;187:221-237
  203. Leng GC, Fowkes FG, Lee AJ, Dunbar J, Housley E, Ruckley CV. Use of ankle brachial pressure index to predict cardiovascular events and death: A cohort study. *BMJ*. 1996;313:1440-1444
  204. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-society consensus for the management of peripheral arterial disease (tasc ii). *Journal of vascular surgery*. 2007;45 Suppl S:S5-67
  205. van der Meer IM, Bots ML, Hofman A, del Sol AI, van der Kuip DA, Witteman JC. Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: The rotterdam study. *Circulation*. 2004;109:1089-1094
  206. Resnick HE, Lindsay RS, McDermott MM, Devereux RB, Jones KL, Fabsitz RR, Howard BV. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: The strong heart study. *Circulation*. 2004;109:733-739
  207. Newman AB, Shemanski L, Manolio TA, Cushman M, Mittelmark M, Polak JF, Powe NR, Siscovick D. Ankle-arm index as a predictor of cardiovascular disease and mortality in the cardiovascular health study. The cardiovascular health study group. *Arteriosclerosis, thrombosis, and vascular biology*. 1999;19:538-545
  208. Ouriel K. Peripheral arterial disease. *Lancet*. 2001;358:1257-1264
  209. Criqui MH. Peripheral arterial disease--epidemiological aspects. *Vasc Med*. 2001;6:3-7
  210. Street TK. What the primary care provider needs to know for limb salvage. *Methodist DeBakey cardiovascular journal*. 2012;8:57-59
  211. O'Connell JB, Quinones-Baldrich WJ. Proper evaluation and management of acute embolic versus thrombotic limb ischemia. *Seminars in vascular surgery*. 2009;22:10-16
  212. Huppert P, Tacke J, Lawall H. [s3 guidelines for diagnostics and treatment of peripheral arterial occlusive disease]. *Der Radiologe*. 2010;50:7-15
  213. de Groot E, Hovingh GK, Wiegman A, Duriez P, Smit AJ, Fruchart JC, Kastelein JJ. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. *Circulation*. 2004;109:III33-38
  214. Bots ML, Grobbee DE. Intima media thickness as a surrogate marker for generalised atherosclerosis. *Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy*. 2002;16:341-351
  215. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK, Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular health study collaborative research group. *The New England journal of medicine*. 1999;340:14-22
  216. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, Clegg LX. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: The atherosclerosis risk in communities (aric) study, 1987-1993. *American journal of epidemiology*. 1997;146:483-494
  217. Belcaro G, Nicolaidis AN, Ramaswami G, Cesarone MR, De Sanctis M, Incandela L, Ferrari P, Geroulakos G, Barsotti A, Griffin M, Dhanjil S, Sabetai M, Bucci M, Martines G. Carotid and femoral ultrasound morphology screening and cardiovascular events in low risk subjects: A 10-year follow-up study (the cafes-cave study(1)). *Atherosclerosis*. 2001;156:379-387

218. Bauer M, Mohlenkamp S, Erbel R. [intima-media thickness as a surrogate for subclinical atherosclerosis]. *Herz*. 2007;32:372-378
219. Comerota AJ, Cranley JJ, Katz ML, Cook SE, Sippel PJ, Hayden WG, Fogarty TJ, Tyson RR. Real-time b-mode carotid imaging. A three-year multicenter experience. *Journal of vascular surgery*. 1984;1:84-95
220. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: A direct measurement with ultrasound imaging. *Circulation*. 1986;74:1399-1406
221. Ricotta JJ, Bryan FA, Bond MG, Kurtz A, O'Leary DH, Raines JK, Berson AS, Clouse ME, Calderon-Ortiz M, Toole JF, et al. Multicenter validation study of real-time (b-mode) ultrasound, arteriography, and pathologic examination. *Journal of vascular surgery*. 1987;6:512-520
222. Suurkula M, Agewall S, Fagerberg B, Wendelhag I, Widgren B, Wikstrand J. Ultrasound evaluation of atherosclerotic manifestations in the carotid artery in high-risk hypertensive patients. Risk intervention study (ris) group. *Arteriosclerosis and thrombosis : a journal of vascular biology*. 1994;14:1297-1304
223. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: The rotterdam study. *Circulation*. 1997;96:1432-1437
224. Riba U, Gillio S, Caruzzo C, Sechi A, Bonzano A. [correlations between risk factors and atherosclerotic disease of the carotid arteries. Investigation with the duplex scanner]. *Minerva cardioangiologica*. 1986;34:87-97
225. Kazmierski R, Watala C, Podsiadly E, Dorszewska J, Kozubski W. Association of atherosclerotic risk factors with carotid adventitial thickness assessed by ultrasonography. *J Clin Ultrasound*. 2009;37:333-341
226. Ferrieres J, Elias A, Ruidavets JB, Cantet C, Bongard V, Fauvel J, Boccalon H. Carotid intima-media thickness and coronary heart disease risk factors in a low-risk population. *Journal of hypertension*. 1999;17:743-748
227. Margitic SE, Bond MG, Crouse JR, Furberg CD, Probstfield JL. Progression and regression of carotid atherosclerosis in clinical trials. *Arteriosclerosis and thrombosis : a journal of vascular biology*. 1991;11:443-451
228. Allan PL, Mowbray PI, Lee AJ, Fowkes FG. Relationship between carotid intima-media thickness and symptomatic and asymptomatic peripheral arterial disease. The edinburgh artery study. *Stroke; a journal of cerebral circulation*. 1997;28:348-353
229. Burke GL, Evans GW, Riley WA, Sharrett AR, Howard G, Barnes RW, Rosamond W, Crow RS, Rautaharju PM, Heiss G. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The atherosclerosis risk in communities (aric) study. *Stroke; a journal of cerebral circulation*. 1995;26:386-391
230. Craven TE, Ryu JE, Espeland MA, Kahl FR, McKinney WM, Toole JF, McMahan MR, Thompson CJ, Heiss G, Crouse JR, 3rd. Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis. A case-control study. *Circulation*. 1990;82:1230-1242
231. Kato J, Aihara A, Kikuya M, Matsubara M, Ohta M, Ohkubo T, Tsuji I, Sekino H, Meguro T, Imai Y. Risk factors and predictors of coronary arterial lesions in japanese hypertensive patients. *Hypertens Res*. 2001;24:3-11
232. Wendelhag I, Wiklund O, Wikstrand J. Atherosclerotic changes in the femoral and carotid arteries in familial hypercholesterolemia. Ultrasonographic assessment of

- intima-media thickness and plaque occurrence. *Arteriosclerosis and thrombosis : a journal of vascular biology*. 1993;13:1404-1411
233. Ebrahim S, Papacosta O, Whincup P, Wannamethee G, Walker M, Nicolaides AN, Dhanjil S, Griffin M, Belcaro G, Rumley A, Lowe GD. Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women: The british regional heart study. *Stroke; a journal of cerebral circulation*. 1999;30:841-850
  234. Mannami T, Konishi M, Baba S, Nishi N, Terao A. Prevalence of asymptomatic carotid atherosclerotic lesions detected by high-resolution ultrasonography and its relation to cardiovascular risk factors in the general population of a japanese city: The suita study. *Stroke; a journal of cerebral circulation*. 1997;28:518-525
  235. Polak JF, O'Leary DH, Kronmal RA, Wolfson SK, Bond MG, Tracy RP, Gardin JM, Kittner SJ, Price TR, Savage PJ. Sonographic evaluation of carotid artery atherosclerosis in the elderly: Relationship of disease severity to stroke and transient ischemic attack. *Radiology*. 1993;188:363-370
  236. Salonen R, Tervahauta M, Salonen JT, Pekkanen J, Nissinen A, Karvonen MJ. Ultrasonographic manifestations of common carotid atherosclerosis in elderly eastern finnish men. Prevalence and associations with cardiovascular diseases and risk factors. *Arteriosclerosis and thrombosis : a journal of vascular biology*. 1994;14:1631-1640
  237. Simon A, Garipey J, Chironi G, Megnien JL, Levenson J. Intima-media thickness: A new tool for diagnosis and treatment of cardiovascular risk. *Journal of hypertension*. 2002;20:159-169
  238. Baldassarre D, Amato M, Bondioli A, Sirtori CR, Tremoli E. Carotid artery intima-media thickness measured by ultrasonography in normal clinical practice correlates well with atherosclerosis risk factors. *Stroke; a journal of cerebral circulation*. 2000;31:2426-2430
  239. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: A systematic review and meta-analysis. *Circulation*. 2007;115:459-467
  240. Tutta P. [the measurement by high resolution ultrasound of the intima-media thickness at the carotis comunis artery: Early marker of atherosclerosis]. *Praxis (Bern 1994)*. 2007;96:851-857
  241. Viskovic K, Rutherford GW, Sudario G, Stemberger L, Brnic Z, Begovac J. Ultrasound measurements of carotid intima-media thickness and plaque in hiv-infected patients on the mediterranean diet. *Croatian medical journal*. 2013;54:330-338
  242. Giannini C, D'Adamo E, Chiavaroli V, de Giorgis T, Di Iorio C, Chiarelli F, Mohn A. Influence of the mediterranean diet on carotid intima-media thickness in hypercholesterolaemic children: A 12-month intervention study. *Nutrition, metabolism, and cardiovascular diseases : NMCD*. 2014;24:75-82
  243. Shai I, Spence JD, Schwarzfuchs D, Henkin Y, Parraga G, Rudich A, Fenster A, Mallett C, Liel-Cohen N, Tirosh A, Bolotin A, Thiery J, Fiedler GM, Bluher M, Stumvoll M, Stampfer MJ. Dietary intervention to reverse carotid atherosclerosis. *Circulation*. 2010;121:1200-1208
  244. Giordano P, Scicchitano P, Locorotondo M, Mandurino C, Ricci G, Carbonara S, Gesualdo M, Zito A, Dachille A, Caputo P, Riccardi R, Frasso G, Lassandro G, Di Mauro A, Ciccone MM. Carotenoids and cardiovascular risk. *Current pharmaceutical design*. 2012;18:5577-5589



245. Petersen KS, Clifton PM, Keogh JB. The association between carotid intima media thickness and individual dietary components and patterns. *Nutrition, metabolism, and cardiovascular diseases : NMCD*. 2014;24:495-502
246. Amato M, Montorsi P, Ravani A, Oldani E, Galli S, Ravagnani PM, Tremoli E, Baldassarre D. Carotid intima-media thickness by b-mode ultrasound as surrogate of coronary atherosclerosis: Correlation with quantitative coronary angiography and coronary intravascular ultrasound findings. *European heart journal*. 2007;28:2094-2101
247. Baldassarre D, Nyyssonen K, Rauramaa R, de Faire U, Hamsten A, Smit AJ, Mannarino E, Humphries SE, Giral P, Grossi E, Veglia F, Paoletti R, Tremoli E. Cross-sectional analysis of baseline data to identify the major determinants of carotid intima-media thickness in a european population: The improve study. *European heart journal*. 2010;31:614-622
248. D'Agostino RB, Sr., Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: The framingham heart study. *Circulation*. 2008;117:743-753
249. Baldassarre D, Veglia F, Hamsten A, Humphries SE, Rauramaa R, de Faire U, Smit AJ, Giral P, Kurl S, Mannarino E, Grossi E, Paoletti R, Tremoli E. Progression of carotid intima-media thickness as predictor of vascular events: Results from the improve study. *Arteriosclerosis, thrombosis, and vascular biology*. 2013;33:2273-2279
250. Gardener H, Wright CB, Cabral D, Scarmeas N, Gu Y, Cheung K, Elkind MS, Sacco RL, Rundek T. Mediterranean diet and carotid atherosclerosis in the northern manhattan study. *Atherosclerosis*. 2014;234:303-310
251. Fung TT, Rexrode KM, Mantzoros CS, Manson JE, Willett WC, Hu FB. Mediterranean diet and incidence of and mortality from coronary heart disease and stroke in women. *Circulation*. 2009;119:1093-1100
252. Gardener H, Scarmeas N, Gu Y, Boden-Albala B, Elkind MS, Sacco RL, DeCarli C, Wright CB. Mediterranean diet and white matter hyperintensity volume in the northern manhattan study. *Archives of neurology*. 2012;69:251-256
253. Scarmeas N, Luchsinger JA, Stern Y, Gu Y, He J, DeCarli C, Brown T, Brickman AM. Mediterranean diet and magnetic resonance imaging-assessed cerebrovascular disease. *Annals of neurology*. 2011;69:257-268
254. Spence JD. Technology insight: Ultrasound measurement of carotid plaque--patient management, genetic research, and therapy evaluation. *Nature clinical practice. Neurology*. 2006;2:611-619
255. Spence JD, Eliasziw M, DiCicco M, Hackam DG, Galil R, Lohmann T. Carotid plaque area: A tool for targeting and evaluating vascular preventive therapy. *Stroke; a journal of cerebral circulation*. 2002;33:2916-2922
256. Brook RD, Bard RL, Patel S, Rubenfire M, Clarke NS, Kazerooni EA, Wakefield TW, Henke PK, Eagle KA. A negative carotid plaque area test is superior to other noninvasive atherosclerosis studies for reducing the likelihood of having underlying significant coronary artery disease. *Arteriosclerosis, thrombosis, and vascular biology*. 2006;26:656-662
257. Handa N, Matsumoto M, Maeda H, Hougaku H, Kamada T. Ischemic stroke events and carotid atherosclerosis. Results of the osaka follow-up study for ultrasonographic assessment of carotid atherosclerosis (the osaca study). *Stroke; a journal of cerebral circulation*. 1995;26:1781-1786
258. Barnett PA, Spence JD, Manuck SB, Jennings JR. Psychological stress and the progression of carotid artery disease. *Journal of hypertension*. 1997;15:49-55

259. Lydakis C, Stefanaki E, Stefanaki S, Thalassinos E, Kavousanaki M, Lydaki D. Correlation of blood pressure, obesity, and adherence to the mediterranean diet with indices of arterial stiffness in children. *European journal of pediatrics*. 2012;171:1373-1382
260. Papamichael CM, Karatzi KN, Papaioannou TG, Karatzis EN, Katsichti P, Sideris V, Zakopoulos N, Zampelas A, Lekakis JP. Acute combined effects of olive oil and wine on pressure wave reflections: Another beneficial influence of the mediterranean diet antioxidants? *Journal of hypertension*. 2008;26:223-229
261. Fargnoli JL, Fung TT, Olenczuk DM, Chamberland JP, Hu FB, Mantzoros CS. Adherence to healthy eating patterns is associated with higher circulating total and high-molecular-weight adiponectin and lower resistin concentrations in women from the nurses' health study. *The American journal of clinical nutrition*. 2008;88:1213-1224
262. Lau KK, Wong YK, Chan YH, Li OY, Lee PY, Yuen GG, Tong S, Wong D, Chan KH, Cheung RT, Siu CW, Ho SL, Tse HF. Mediterranean-style diet is associated with reduced blood pressure variability and subsequent stroke risk in patients with coronary artery disease. *American journal of hypertension*. 2015;28:501-507
263. Klonizakis M, Alkhatib A, Middleton G. Long-term effects of an exercise and mediterranean diet intervention in the vascular function of an older, healthy population. *Microvascular research*. 2014;95:103-107
264. Toobert DJ, Strycker LA, King DK, Barrera M, Jr., Osuna D, Glasgow RE. Long-term outcomes from a multiple-risk-factor diabetes trial for latinas: Inverted exclamation mark viva bien! *Translational behavioral medicine*. 2011;1:416-426
265. Itsiopoulos C, Brazionis L, Kaimakamis M, Cameron M, Best JD, O'Dea K, Rowley K. Can the mediterranean diet lower hba1c in type 2 diabetes? Results from a randomized cross-over study. *Nutrition, metabolism, and cardiovascular diseases : NMCD*. 2011;21:740-747
266. Elhayany A, Lustman A, Abel R, Attal-Singer J, Vinker S. A low carbohydrate mediterranean diet improves cardiovascular risk factors and diabetes control among overweight patients with type 2 diabetes mellitus: A 1-year prospective randomized intervention study. *Diabetes, obesity & metabolism*. 2010;12:204-209
267. Esposito K, Maiorino MI, Ciotola M, Di Palo C, Scognamiglio P, Gicchino M, Petrizzo M, Saccomanno F, Beneduce F, Ceriello A, Giugliano D. Effects of a mediterranean-style diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: A randomized trial. *Annals of internal medicine*. 2009;151:306-314
268. Shai I, Schwarzfuchs D, Henkin Y, Shahar DR, Witkow S, Greenberg I, Golan R, Fraser D, Bolotin A, Vardi H, Tangi-Rozental O, Zuk-Ramot R, Sarusi B, Brickner D, Schwartz Z, Sheiner E, Marko R, Katorza E, Thiery J, Fiedler GM, Bluher M, Stumvoll M, Stampfer MJ. Weight loss with a low-carbohydrate, mediterranean, or low-fat diet. *The New England journal of medicine*. 2008;359:229-241
269. Toobert DJ, Glasgow RE, Strycker LA, Barrera M, Jr., Radcliffe JL, Wander RC, Bagdade JD. Biologic and quality-of-life outcomes from the mediterranean lifestyle program: A randomized clinical trial. *Diabetes care*. 2003;26:2288-2293
270. Brehm BJ, Lattin BL, Summer SS, Boback JA, Gilchrist GM, Jandacek RJ, D'Alessio DA. One-year comparison of a high-monounsaturated fat diet with a high-carbohydrate diet in type 2 diabetes. *Diabetes care*. 2009;32:215-220
271. Karantonis HC, Fragopoulou E, Antonopoulou S, Rementzis J, Phenekos C, Demopoulos CA. Effect of fast-food mediterranean-type diet on type 2 diabetics

- and healthy human subjects' platelet aggregation. *Diabetes research and clinical practice*. 2006;72:33-41
272. Rodriguez-Villar C, Perez-Heras A, Mercade I, Casals E, Ros E. Comparison of a high-carbohydrate and a high-monounsaturated fat, olive oil-rich diet on the susceptibility of ldl to oxidative modification in subjects with type 2 diabetes mellitus. *Diabetic medicine : a journal of the British Diabetic Association*. 2004;21:142-149
  273. Huo R, Du T, Xu Y, Xu W, Chen X, Sun K, Yu X. Effects of mediterranean-style diet on glycemic control, weight loss and cardiovascular risk factors among type 2 diabetes individuals: A meta-analysis. *European journal of clinical nutrition*. 2015;69:1200-1208
  274. Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, Blackburn H, Buzina R, Dontas AS, Fidanza F, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. *Jama*. 1995;274:131-136
  275. Anderson TJ, Gregoire J, Hegele RA, Couture P, Mancini GB, McPherson R, Francis GA, Poirier P, Lau DC, Grover S, Genest J, Jr., Carpentier AC, Dufour R, Gupta M, Ward R, Leiter LA, Lonn E, Ng DS, Pearson GJ, Yates GM, Stone JA, Ur E. 2012 update of the canadian cardiovascular society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. *The Canadian journal of cardiology*. 2013;29:151-167
  276. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D. Esc/eas guidelines for the management of dyslipidaemias: The task force for the management of dyslipidaemias of the european society of cardiology (esc) and the european atherosclerosis society (eas). *European heart journal*. 2011;32:1769-1818
  277. Third report of the national cholesterol education program (ncep) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii) final report. *Circulation*. 2002;106:3143-3421
  278. Mikhailidis DP, Elisaf M, Rizzo M, Berneis K, Griffin B, Zambon A, Athyros V, de Graaf J, Marz W, Parhofer KG, Rini GB, Spinaz GA, Tomkin GH, Tselepis AD, Wierzbicki AS, Winkler K, Florentin M, Liberopoulos E. "European panel on low density lipoprotein (ldl) subclasses": A statement on the pathophysiology, atherogenicity and clinical significance of ldl subclasses. *Current vascular pharmacology*. 2011;9:533-571
  279. Ishigaki Y, Oka Y, Katagiri H. Circulating oxidized ldl: A biomarker and a pathogenic factor. *Current opinion in lipidology*. 2009;20:363-369
  280. Hoogeveen RC, Gaubatz JW, Sun W, Dodge RC, Crosby JR, Jiang J, Couper D, Virani SS, Kathiresan S, Boerwinkle E, Ballantyne CM. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: The atherosclerosis risk in communities (aric) study. *Arteriosclerosis, thrombosis, and vascular biology*. 2014;34:1069-1077
  281. Lamarche B, St-Pierre AC, Ruel IL, Cantin B, Dagenais GR, Despres JP. A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. *The Canadian journal of cardiology*. 2001;17:859-865
  282. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic

- heart disease in men. Prospective results from the quebec cardiovascular study. *Circulation*. 1997;95:69-75
283. Nigon F, Lesnik P, Rouis M, Chapman MJ. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular ldl receptor. *Journal of lipid research*. 1991;32:1741-1753
284. Camejo G, Hurt-Camejo E, Wiklund O, Bondjers G. Association of apo b lipoproteins with arterial proteoglycans: Pathological significance and molecular basis. *Atherosclerosis*. 1998;139:205-222
285. Bjornheden T, Babyi A, Bondjers G, Wiklund O. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. *Atherosclerosis*. 1996;123:43-56
286. de Graaf J, Hak-Lemmers HL, Hectors MP, Demacker PN, Hendriks JC, Stalenhoef AF. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. *Arteriosclerosis and thrombosis : a journal of vascular biology*. 1991;11:298-306
287. Mitra S, Goyal T, Mehta JL. Oxidized ldl, lox-1 and atherosclerosis. *Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy*. 2011;25:419-429
288. Vekic J, Zeljkovic A, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, Bogavac-Stanojevic N, Memon L, Spasic S. Small, dense ldl cholesterol and apolipoprotein b: Relationship with serum lipids and ldl size. *Atherosclerosis*. 2009;207:496-501
289. Miller AA, De Silva TM, Jackman KA, Sobey CG. Effect of gender and sex hormones on vascular oxidative stress. *Clinical and experimental pharmacology & physiology*. 2007;34:1037-1043
290. Wu T, Willett WC, Rifai N, Shai I, Manson JE, Rimm EB. Is plasma oxidized low-density lipoprotein, measured with the widely used antibody 4e6, an independent predictor of coronary heart disease among u.S. Men and women? *Journal of the American College of Cardiology*. 2006;48:973-979
291. Lemieux I, Pascot A, Lamarche B, Prud'homme D, Nadeau A, Bergeron J, Despres JP. Is the gender difference in ldl size explained by the metabolic complications of visceral obesity? *European journal of clinical investigation*. 2002;32:909-917
292. Li Z, McNamara JR, Fruchart JC, Luc G, Bard JM, Ordovas JM, Wilson PW, Schaefer EJ. Effects of gender and menopausal status on plasma lipoprotein subspecies and particle sizes. *Journal of lipid research*. 1996;37:1886-1896
293. Nikkila M, Pitkajarvi T, Koivula T, Solakivi T, Lehtimaki T, Laippala P, Jokela H, Lehtomaki E, Seppa K, Sillanauke P. Women have a larger and less atherogenic low density lipoprotein particle size than men. *Atherosclerosis*. 1996;119:181-190
294. Bedard A, Corneau L, Lamarche B, Dodin S, Lemieux S. Sex differences in the impact of the mediterranean diet on ldl particle size distribution and oxidation. *Nutrients*. 2015;7:3705-3723
295. Michas G, Micha R, Zampelas A. Dietary fats and cardiovascular disease: Putting together the pieces of a complicated puzzle. *Atherosclerosis*. 2014;234:320-328
296. Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to hdl cholesterol and on serum lipids and apolipoproteins: A meta-analysis of 60 controlled trials. *The American journal of clinical nutrition*. 2003;77:1146-1155
297. Ordovas JM, Corella D, Cupples LA, Demissie S, Kelleher A, Coltell O, Wilson PW, Schaefer EJ, Tucker K. Polyunsaturated fatty acids modulate the effects of the apoa1 g-a polymorphism on hdl-cholesterol concentrations in a sex-specific

- manner: The framingham study. *The American journal of clinical nutrition*. 2002;75:38-46
298. Barbagallo CM, Cavera G, Sapienza M, Noto D, Cefalu AB, Polizzi F, Onorato F, Rini G, Di Fede G, Pagano M, Montalto G, Rizzo M, Descovich G, Notarbartolo A, Averna MR. Nutritional characteristics of a rural southern italy population: The ventimiglia di sicilia project. *Journal of the American College of Nutrition*. 2002;21:523-529
  299. Noto D, Barbagallo CM, Cefalu AB, Falletta A, Sapienza M, Cavera G, Amato S, Pagano M, Maggiore M, Carroccio A, Notarbartolo A, Averna MR. The metabolic syndrome predicts cardiovascular events in subjects with normal fasting glucose: Results of a 15 years follow-up in a mediterranean population. *Atherosclerosis*. 2008;197:147-153
  300. Noto D, Fayer F, Cefalu AB, Altieri I, Palesano O, Spina R, Valenti V, Pitrone M, Pizzolanti G, Barbagallo CM, Giordano C, Averna MR. Myristic acid is associated to low plasma hdl cholesterol levels in a mediterranean population and increases hdl catabolism by enhancing hdl particles trapping to cell surface proteoglycans in a liver hepatoma cell model. *Atherosclerosis*. 2016;246:50-56
  301. Criqui MH, Heiss G, Cohn R, Cowan LD, Suchindran CM, Bangdiwala S, Kritchevsky S, Jacobs DR, Jr., O'Grady HK, Davis CE. Plasma triglyceride level and mortality from coronary heart disease. *The New England journal of medicine*. 1993;328:1220-1225
  302. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. *Jama*. 1996;276:882-888
  303. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. *Journal of cardiovascular risk*. 1996;3:213-219
  304. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. *Lancet*. 2014;384:626-635
  305. Boullart AC, de Graaf J, Stalenhoef AF. Serum triglycerides and risk of cardiovascular disease. *Biochim Biophys Acta*. 2012;1821:867-875
  306. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. *Jama*. 2007;298:309-316
  307. Wiesner P, Watson KE. Triglycerides: A reappraisal. *Trends in cardiovascular medicine*. 2017;27:428-432
  308. Estruch R, Martinez-Gonzalez MA, Corella D, Salas-Salvado J, Ruiz-Gutierrez V, Covas MI, Fiol M, Gomez-Gracia E, Lopez-Sabater MC, Vinyoles E, Aros F, Conde M, Lahoz C, Lapetra J, Saez G, Ros E. Effects of a mediterranean-style diet on cardiovascular risk factors: A randomized trial. *Annals of internal medicine*. 2006;145:1-11
  309. Vincent S, Gerber M, Bernard MC, Defoort C, Loundou A, Portugal H, Planells R, Juhan-Vague I, Charpiot P, Grolier P, Amiot-Carlin MJ, Vague P, Lairon D. The medi-rivage study (mediterranean diet, cardiovascular risks and gene polymorphisms): Rationale, recruitment, design, dietary intervention and baseline characteristics of participants. *Public health nutrition*. 2004;7:531-542
  310. Vardavas CI, Flouris AD, Tsatsakis A, Kafatos AG, Saris WH. Does adherence to the mediterranean diet have a protective effect against active and passive smoking? *Public health*. 2011;125:121-128

311. Perez-Martinez P, Garcia-Rios A, Delgado-Lista J, Perez-Jimenez F, Lopez-Miranda J. Mediterranean diet rich in olive oil and obesity, metabolic syndrome and diabetes mellitus. *Current pharmaceutical design*. 2011;17:769-777
312. Kris-Etherton PM. Aha science advisory. Monounsaturated fatty acids and risk of cardiovascular disease. American heart association. Nutrition committee. *Circulation*. 1999;100:1253-1258
313. Howard BV, Van Horn L, Hsia J, Manson JE, Stefanick ML, Wassertheil-Smoller S, Kuller LH, LaCroix AZ, Langer RD, Lasser NL, Lewis CE, Limacher MC, Margolis KL, Mysiw WJ, Ockene JK, Parker LM, Perri MG, Phillips L, Prentice RL, Robbins J, Rossouw JE, Sarto GE, Schatz IJ, Snetselaar LG, Stevens VJ, Tinker LF, Trevisan M, Vitolins MZ, Anderson GL, Assaf AR, Bassford T, Beresford SA, Black HR, Brunner RL, Brzyski RG, Caan B, Chlebowski RT, Gass M, Granek I, Greenland P, Hays J, Heber D, Heiss G, Hendrix SL, Hubbell FA, Johnson KC, Kotchen JM. Low-fat dietary pattern and risk of cardiovascular disease: The women's health initiative randomized controlled dietary modification trial. *Jama*. 2006;295:655-666
314. Halton TL, Willett WC, Liu S, Manson JE, Albert CM, Rexrode K, Hu FB. Low-carbohydrate-diet score and the risk of coronary heart disease in women. *The New England journal of medicine*. 2006;355:1991-2002
315. Mendez MA, Popkin BM, Jakszyn P, Berenguer A, Tormo MJ, Sanchez MJ, Quiros JR, Pera G, Navarro C, Martinez C, Larranaga N, Dorronsoro M, Chirlaque MD, Barricarte A, Ardanaz E, Amiano P, Agudo A, Gonzalez CA. Adherence to a mediterranean diet is associated with reduced 3-year incidence of obesity. *The Journal of nutrition*. 2006;136:2934-2938
316. Trichopoulou A, Naska A, Orfanos P, Trichopoulos D. Mediterranean diet in relation to body mass index and waist-to-hip ratio: The greek european prospective investigation into cancer and nutrition study. *The American journal of clinical nutrition*. 2005;82:935-940
317. Schroder H, Marrugat J, Vila J, Covas MI, Elosua R. Adherence to the traditional mediterranean diet is inversely associated with body mass index and obesity in a spanish population. *The Journal of nutrition*. 2004;134:3355-3361
318. Bes-Rastrollo M, Sanchez-Villegas A, de la Fuente C, de Irala J, Martinez JA, Martinez-Gonzalez MA. Olive oil consumption and weight change: The sun prospective cohort study. *Lipids*. 2006;41:249-256
319. Soriguer F, Almaraz MC, Ruiz-de-Adana MS, Esteve I, Linares F, Garcia-Almeida JM, Morcillo S, Garcia-Escobar E, Olveira-Fuster G, Rojo-Martinez G. Incidence of obesity is lower in persons who consume olive oil. *European journal of clinical nutrition*. 2009;63:1371-1374
320. Sofi F, Capalbo A, Pucci N, Giuliattini J, Condino F, Alessandri F, Abbate R, Gensini GF, Califano S. Cardiovascular evaluation, including resting and exercise electrocardiography, before participation in competitive sports: Cross sectional study. *BMJ*. 2008;337:a346
321. McManus K, Antinoro L, Sacks F. A randomized controlled trial of a moderate-fat, low-energy diet compared with a low fat, low-energy diet for weight loss in overweight adults. *International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity*. 2001;25:1503-1511
322. Schwartz GJ, Fu J, Astarita G, Li X, Gaetani S, Campolongo P, Cuomo V, Piomelli D. The lipid messenger oea links dietary fat intake to satiety. *Cell metabolism*. 2008;8:281-288

323. Romaguera D, Bamia C, Pons A, Tur JA, Trichopoulou A. Food patterns and mediterranean diet in western and eastern mediterranean islands. *Public health nutrition*. 2009;12:1174-1181
324. Romaguera D, Norat T, Vergnaud AC, Mouw T, May AM, Agudo A, Buckland G, Slimani N, Rinaldi S, Couto E, Clavel-Chapelon F, Boutron-Ruault MC, Cottet V, Rohrmann S, Teucher B, Bergmann M, Boeing H, Tjonneland A, Halkjaer J, Jakobsen MU, Dahm CC, Travier N, Rodriguez L, Sanchez MJ, Amiano P, Barricarte A, Huerta JM, Luan J, Wareham N, Key TJ, Spencer EA, Orfanos P, Naska A, Trichopoulou A, Palli D, Agnoli C, Mattiello A, Tumino R, Vineis P, Bueno-de-Mesquita HB, Buchner FL, Manjer J, Wirfalt E, Johansson I, Hellstrom V, Lund E, Braaten T, Engeset D, Odysseos A, Riboli E, Peeters PH. Mediterranean dietary patterns and prospective weight change in participants of the epic-panacea project. *The American journal of clinical nutrition*. 2010;92:912-921
325. Bedard A, Corneau L, Lamarche B, Dodin S, Lemieux S. Sex-related differences in the effects of the mediterranean diet on glucose and insulin homeostasis. *Journal of nutrition and metabolism*. 2014;2014:424130
326. Leblanc V, Begin C, Hudon AM, Royer MM, Corneau L, Dodin S, Lemieux S. Gender differences in the long-term effects of a nutritional intervention program promoting the mediterranean diet: Changes in dietary intakes, eating behaviors, anthropometric and metabolic variables. *Nutrition journal*. 2014;13:107
327. Battino M, Ferreiro MS. Ageing and the mediterranean diet: A review of the role of dietary fats. *Public health nutrition*. 2004;7:953-958
328. Visioli F, Bellomo G, Montedoro G, Galli C. Low density lipoprotein oxidation is inhibited in vitro by olive oil constituents. *Atherosclerosis*. 1995;117:25-32
329. Petroni A, Blasevich M, Salami M, Papini N, Montedoro GF, Galli C. Inhibition of platelet aggregation and eicosanoid production by phenolic components of olive oil. *Thrombosis research*. 1995;78:151-160
330. Grignaffini P, Roma P, Galli C, Catapano AL. Protection of low-density lipoprotein from oxidation by 3,4-dihydroxyphenylethanol. *Lancet*. 1994;343:1296-1297
331. Seiquer I, Manas M, Martinez-Victoria E, Huertas JR, Ballesta MC, Mataix FJ. Effects of adaptation to diets enriched with saturated, monounsaturated and polyunsaturated fats on lipid and serum fatty acid levels in miniature swine (sus scrofa). *Comparative biochemistry and physiology. Comparative physiology*. 1994;108:377-386
332. Periago JL, Suarez MD, Pita ML. Effect of dietary olive oil, corn oil and medium-chain triglycerides on the lipid composition of rat red blood cell membranes. *The Journal of nutrition*. 1990;120:986-994
333. Giron MD, Mataix FJ, Suarez MD. Changes in lipid composition and desaturase activities of duodenal mucosa induced by dietary fat. *Biochim Biophys Acta*. 1990;1045:69-73
334. Parthasarathy S, Khoo JC, Miller E, Barnett J, Witztum JL, Steinberg D. Low density lipoprotein rich in oleic acid is protected against oxidative modification: Implications for dietary prevention of atherosclerosis. *Proceedings of the National Academy of Sciences of the United States of America*. 1990;87:3894-3898
335. Kromhout D, Menotti A, Kesteloot H, Sans S. Prevention of coronary heart disease by diet and lifestyle: Evidence from prospective cross-cultural, cohort, and intervention studies. *Circulation*. 2002;105:893-898
336. Davis CR, Hodgson JM, Woodman R, Bryan J, Wilson C, Murphy KJ. A mediterranean diet lowers blood pressure and improves endothelial function:

- Results from the medley randomized intervention trial. *The American journal of clinical nutrition*. 2017;105:1305-1313
337. Tzima N, Pitsavos C, Panagiotakos DB, Skoumas J, Zampelas A, Chrysohoou C, Stefanadis C. Mediterranean diet and insulin sensitivity, lipid profile and blood pressure levels, in overweight and obese people; the attica study. *Lipids in health and disease*. 2007;6:22
  338. Carluccio MA, Ancora MA, Massaro M, Carluccio M, Scoditti E, Distante A, Storelli C, De Caterina R. Homocysteine induces vcam-1 gene expression through nf-kappab and nad(p)h oxidase activation: Protective role of mediterranean diet polyphenolic antioxidants. *American journal of physiology. Heart and circulatory physiology*. 2007;293:H2344-2354
  339. Esposito K, Ciotola M, Giugliano D. Mediterranean diet, endothelial function and vascular inflammatory markers. *Public health nutrition*. 2006;9:1073-1076
  340. Dedoussis GV, Panagiotakos DB, Chrysohoou C, Pitsavos C, Zampelas A, Choumerianou D, Stefanadis C. Effect of interaction between adherence to a mediterranean diet and the methylenetetrahydrofolate reductase 677c-->t mutation on homocysteine concentrations in healthy adults: The attica study. *The American journal of clinical nutrition*. 2004;80:849-854
  341. Molenberg FJ, de Goede J, Wanders AJ, Zock PL, Kromhout D, Geleijnse JM. Dietary fatty acid intake after myocardial infarction: A theoretical substitution analysis of the alpha omega cohort. *The American journal of clinical nutrition*. 2017
  342. Sacks FM, Lichtenstein AH, Wu JHY, Appel LJ, Creager MA, Kris-Etherton PM, Miller M, Rimm EB, Rudel LL, Robinson JG, Stone NJ, Van Horn LV. Dietary fats and cardiovascular disease: A presidential advisory from the american heart association. *Circulation*. 2017;136:e1-e23
  343. Wang DD, Hu FB. Dietary fat and risk of cardiovascular disease: Recent controversies and advances. *Annual review of nutrition*. 2017;37:423-446
  344. Fats and fatty acids in human nutrition. Proceedings of the joint fao/who expert consultation. November 10-14, 2008. Geneva, switzerland. *Annals of nutrition & metabolism*. 2009;55:5-300
  345. Mazidi M, Gao HK, Shivappa N, Wirth MD, Hebert JR, Kengne AP. The relationship of plasma trans fatty acids with dietary inflammatory index among us adults. *Lipids in health and disease*. 2017;16:147
  346. Capra V, Back M, Barbieri SS, Camera M, Tremoli E, Rovati GE. Eicosanoids and their drugs in cardiovascular diseases: Focus on atherosclerosis and stroke. *Med Res Rev*. 2013;33:364-438
  347. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Locher ML, Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM. [2016 european guidelines on cardiovascular disease prevention in clinical practice. The sixth joint task force of the european society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts. Developed with the special contribution of the european association for cardiovascular prevention & rehabilitation]. *G Ital Cardiol (Rome)*. 2017;18:547-612
  348. US Dep. of Health and Hum. Serv. UDA. 2015–2020 dietary guidelines for americans. <https://health.gov/dietaryguidelines/2015/guidelines/>. 2015



349. Chowdhury R, Warnakula S, Kunutsor S, Crowe F, Ward HA, Johnson L, Franco OH, Butterworth AS, Forouhi NG, Thompson SG, Khaw KT, Mozaffarian D, Danesh J, Di Angelantonio E. Association of dietary, circulating, and supplement fatty acids with coronary risk: A systematic review and meta-analysis. *Annals of internal medicine*. 2014;160:398-406
350. Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. *The American journal of clinical nutrition*. 2010;91:535-546
351. Jula A, Marniemi J, Ronnema T, Virtanen A, Huupponen R. Effects of diet and simvastatin on fatty acid composition in hypercholesterolemic men: A randomized controlled trial. *Arteriosclerosis, thrombosis, and vascular biology*. 2005;25:1952-1959
352. Imamura F, Lemaitre RN, King IB, Song X, Lichtenstein AH, Matthan NR, Herrington DM, Siscovick DS, Mozaffarian D. Novel circulating fatty acid patterns and risk of cardiovascular disease: The cardiovascular health study. *The American journal of clinical nutrition*. 2012;96:1252-1261
353. Clarke R, Shipley M, Armitage J, Collins R, Harris W. Plasma phospholipid fatty acids and chd in older men: Whitehall study of london civil servants. *The British journal of nutrition*. 2009;102:279-284
354. Itakura H, Yokoyama M, Matsuzaki M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y. Relationships between plasma fatty acid composition and coronary artery disease. *Journal of atherosclerosis and thrombosis*. 2011;18:99-107
355. Delgado GE, Marz W, Lorkowski S, von Schacky C, Kleber ME. Omega-6 fatty acids: Opposing associations with risk-the ludwigshafen risk and cardiovascular health study. *Journal of clinical lipidology*. 2017;11:1082-1090 e1014
356. Shearer GC, Pottala JV, Spertus JA, Harris WS. Red blood cell fatty acid patterns and acute coronary syndrome. *PLoS one*. 2009;4:e5444
357. Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, D'Armiento M, D'Andrea F, Giugliano D. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: A randomized trial. *Jama*. 2004;292:1440-1446
358. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. *The New England journal of medicine*. 2005;352:1685-1695
359. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. *Atherosclerosis*. 2003;170:191-203
360. Esposito K, Ciotola M, Giugliano F, De Sio M, Giugliano G, D'Armiento M, Giugliano D. Mediterranean diet improves erectile function in subjects with the metabolic syndrome. *International journal of impotence research*. 2006;18:405-410
361. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, Giugliano D. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: A randomized trial. *Jama*. 2003;289:1799-1804
362. Babior BM. NADPH oxidase: An update. *Blood*. 1999;93:1464-1476
363. Takaki A, Kawai D, Yamamoto K. Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH). *International journal of molecular sciences*. 2014;15:7352-7379
364. Muriel P. Role of free radicals in liver diseases. *Hepatology international*. 2009;3:526-536
365. Aw TY, Ookhtens M, Kaplowitz N. Inhibition of glutathione efflux from isolated rat hepatocytes by methionine. *J Biol Chem*. 1984;259:9355-9358

366. Adams JD, Jr., Lauterburg BH, Mitchell JR. Plasma glutathione and glutathione disulfide in the rat: Regulation and response to oxidative stress. *J Pharmacol Exp Ther.* 1983;227:749-754
367. Jones DP. Redox potential of gsh/gssg couple: Assay and biological significance. *Methods Enzymol.* 2002;348:93-112
368. Johnson F, Giulivi C. Superoxide dismutases and their impact upon human health. *Molecular aspects of medicine.* 2005;26:340-352
369. Jones DP. Extracellular redox state: Refining the definition of oxidative stress in aging. *Rejuvenation research.* 2006;9:169-181
370. Zalba G, Fortuno A, San Jose G, Moreno MU, Beloqui O, Diez J. Oxidative stress, endothelial dysfunction and cerebrovascular disease. *Cerebrovasc Dis.* 2007;24 Suppl 1:24-29
371. Yongvanit P, Pinlaor S, Bartsch H. Oxidative and nitrative DNA damage: Key events in opisthorchiasis-induced carcinogenesis. *Parasitology international.* 2012;61:130-135
372. Rosenblat M, Coleman R, Aviram M. Increased macrophage glutathione content reduces cell-mediated oxidation of ldl and atherosclerosis in apolipoprotein e-deficient mice. *Atherosclerosis.* 2002;163:17-28
373. Girotti AW. Lipid hydroperoxide generation, turnover, and effector action in biological systems. *Journal of lipid research.* 1998;39:1529-1542
374. Usal A, Acarturk E, Yuregir GT, Unlukurt I, Demirci C, Kurt HI, Birand A. Decreased glutathione levels in acute myocardial infarction. *Japanese heart journal.* 1996;37:177-182
375. Tsuru R, Hojo Y, Gama M, Mizuno O, Katsuki T, Shimada K. Redox imbalance in patients with coronary artery disease showing progression of atherosclerotic lesions. *Journal of cardiology.* 2006;48:183-191
376. Perez-Martinez P, Garcia-Quintana JM, Yubero-Serrano EM, Tasset-Cuevas I, Tunez I, Garcia-Rios A, Delgado-Lista J, Marin C, Perez-Jimenez F, Roche HM, Lopez-Miranda J. Postprandial oxidative stress is modified by dietary fat: Evidence from a human intervention study. *Clin Sci (Lond).* 2010;119:251-261
377. Perez-Martinez P, Moreno-Conde M, Cruz-Teno C, Ruano J, Fuentes F, Delgado-Lista J, Garcia-Rios A, Marin C, Gomez-Luna MJ, Perez-Jimenez F, Roche HM, Lopez-Miranda J. Dietary fat differentially influences regulatory endothelial function during the postprandial state in patients with metabolic syndrome: From the lipgene study. *Atherosclerosis.* 2010;209:533-538
378. Ruano J, Lopez-Miranda J, Fuentes F, Moreno JA, Bellido C, Perez-Martinez P, Lozano A, Gomez P, Jimenez Y, Perez Jimenez F. Phenolic content of virgin olive oil improves ischemic reactive hyperemia in hypercholesterolemic patients. *Journal of the American College of Cardiology.* 2005;46:1864-1868
379. Karatzi K, Papamichael C, Karatzis E, Papaioannou TG, Voidonikola PT, Vamvakou GD, Lekakis J, Zampelas A. Postprandial improvement of endothelial function by red wine and olive oil antioxidants: A synergistic effect of components of the mediterranean diet. *Journal of the American College of Nutrition.* 2008;27:448-453
380. Zrelli H, Matsuoka M, Kitazaki S, Araki M, Kusunoki M, Zarrouk M, Miyazaki H. Hydroxytyrosol induces proliferation and cytoprotection against oxidative injury in vascular endothelial cells: Role of nrf2 activation and ho-1 induction. *Journal of agricultural and food chemistry.* 2011;59:4473-4482

381. Schini-Kerth VB, Auger C, Etienne-Selloum N, Chataigneau T. Polyphenol-induced endothelium-dependent relaxations role of no and edhf. *Adv Pharmacol.* 2010;60:133-175
382. Keaney JF, Jr., Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, Massaro JM, Sutherland P, Vita JA, Benjamin EJ. Obesity and systemic oxidative stress: Clinical correlates of oxidative stress in the framingham study. *Arteriosclerosis, thrombosis, and vascular biology.* 2003;23:434-439
383. Meigs JB, Larson MG, Fox CS, Keaney JF, Jr., Vasan RS, Benjamin EJ. Association of oxidative stress, insulin resistance, and diabetes risk phenotypes: The framingham offspring study. *Diabetes care.* 2007;30:2529-2535
384. Heilbronn LK, de Jonge L, Frisard MI, DeLany JP, Larson-Meyer DE, Rood J, Nguyen T, Martin CK, Volaufova J, Most MM, Greenway FL, Smith SR, Deutsch WA, Williamson DA, Ravussin E. Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: A randomized controlled trial. *Jama.* 2006;295:1539-1548
385. Fito M, Guxens M, Corella D, Saez G, Estruch R, de la Torre R, Frances F, Cabezas C, Lopez-Sabater Mdel C, Marrugat J, Garcia-Arellano A, Aros F, Ruiz-Gutierrez V, Ros E, Salas-Salvado J, Fiol M, Sola R, Covas MI. Effect of a traditional mediterranean diet on lipoprotein oxidation: A randomized controlled trial. *Archives of internal medicine.* 2007;167:1195-1203
386. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. *The Journal of clinical endocrinology and metabolism.* 2001;86:1930-1935
387. Bodary PF, Eitzman DT. Adiponectin: Vascular protection from the fat? *Arteriosclerosis, thrombosis, and vascular biology.* 2006;26:235-236
388. Mantzoros CS, Williams CJ, Manson JE, Meigs JB, Hu FB. Adherence to the mediterranean dietary pattern is positively associated with plasma adiponectin concentrations in diabetic women. *The American journal of clinical nutrition.* 2006;84:328-335
389. Paniagua JA, Gallego de la Sacristana A, Romero I, Vidal-Puig A, Latre JM, Sanchez E, Perez-Martinez P, Lopez-Miranda J, Perez-Jimenez F. Monounsaturated fat-rich diet prevents central body fat distribution and decreases postprandial adiponectin expression induced by a carbohydrate-rich diet in insulin-resistant subjects. *Diabetes care.* 2007;30:1717-1723
390. Esposito K, Di Palo C, Maiorino MI, Petrizzo M, Bellastella G, Siniscalchi I, Giugliano D. Long-term effect of mediterranean-style diet and calorie restriction on biomarkers of longevity and oxidative stress in overweight men. *Cardiology research and practice.* 2011;2011:293916
391. Keys A. *Seven countries: A multivariate analysis of death and coronary heart disease.* Cambridge, MA: Harvard University Press; 1980.
392. Serra-Majem L, Roman B, Estruch R. Scientific evidence of interventions using the mediterranean diet: A systematic review. *Nutrition reviews.* 2006;64:S27-47
393. Sofi F, Cesari F, Abbate R, Gensini GF, Casini A. Adherence to mediterranean diet and health status: Meta-analysis. *BMJ.* 2008;337:a1344
394. Sofi F, Macchi C, Abbate R, Gensini GF, Casini A. Mediterranean diet and health status: An updated meta-analysis and a proposal for a literature-based adherence score. *Public health nutrition.* 2014;17:2769-2782
395. Feart C, Torres MJ, Samieri C, Jutand MA, Peuchant E, Simopoulos AP, Barberger-Gateau P. Adherence to a mediterranean diet and plasma fatty acids: Data from

- the bordeaux sample of the three-city study. *The British journal of nutrition*. 2011;106:149-158
396. Valenzuela R, Espinosa A, Gonzalez-Manan D, D'Espessailles A, Fernandez V, Videla LA, Tapia G. N-3 long-chain polyunsaturated fatty acid supplementation significantly reduces liver oxidative stress in high fat induced steatosis. *PLoS one*. 2012;7:e46400
397. Baldassarre D, Porta B, Camera M, Amato M, Arquati M, Brusoni B, Fiorentini C, Montorsi P, Romano S, Veglia F, Tremoli E, Cortellaro M. Markers of inflammation, thrombosis and endothelial activation correlate with carotid intima regression in stable coronary disease after atorvastatin treatment. *Nutrition, metabolism, and cardiovascular diseases : NMCD*. 2009;19:481-490
398. Baldassarre D, Hamsten A, Veglia F, de Faire U, Humphries SE, Smit AJ, Giral P, Kurl S, Rauramaa R, Mannarino E, Grossi E, Paoletti R, Tremoli E. Measurements of carotid intima-media thickness and of interadventitia common carotid diameter improve prediction of cardiovascular events: Results of the improve (carotid intima media thickness [imt] and intima-media regression as predictors of vascular events in a high risk european population) study. *Journal of the American College of Cardiology*. 2012;60:1489-1499
399. Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes care*. 2003;26 Suppl 1:S5-20
400. Sonka M, Liang W, Lauer RM. Automated analysis of brachial ultrasound image sequences: Early detection of cardiovascular disease via surrogates of endothelial function. *IEEE transactions on medical imaging*. 2002;21:1271-1279
401. Beux F, Carmassi S, Salvetti MV, Ghiadoni L, Huang Y, Taddei S, Salvetti A. Automatic evaluation of arterial diameter variation from vascular echographic images. *Ultrasound in medicine & biology*. 2001;27:1621-1629
402. Knoop KT, de Groot LC, Kromhout D, Perrin AE, Moreiras-Varela O, Menotti A, van Staveren WA. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly european men and women: The hale project. *Jama*. 2004;292:1433-1439
403. Agnoli C, Krogh V, Grioni S, Sieri S, Palli D, Masala G, Sacerdote C, Vineis P, Tumino R, Frasca G, Pala V, Berrino F, Chiodini P, Mattiello A, Panico S. A priori-defined dietary patterns are associated with reduced risk of stroke in a large italian cohort. *The Journal of nutrition*. 2011;141:1552-1558
404. Marangoni F, Colombo C, Galli C. A method for the direct evaluation of the fatty acid status in a drop of blood from a fingertip in humans: Applicability to nutritional and epidemiological studies. *Anal Biochem*. 2004;326:267-272
405. Squellerio I, Caruso D, Porro B, Veglia F, Tremoli E, Cavalca V. Direct glutathione quantification in human blood by lc-ms/ms: Comparison with hplc with electrochemical detection. *Journal of pharmaceutical and biomedical analysis*. 2012;71:111-118
406. Buscemi S, Nicolucci A, Mattina A, Rosafio G, Massenti FM, Lucisano G, Galvano F, Amodio E, Pellegrini F, Barile AM, Maniaci V, Grosso G, Verga S, Sprini D, Rini GB. Association of dietary patterns with insulin resistance and clinically silent carotid atherosclerosis in apparently healthy people. *European journal of clinical nutrition*. 2013;67:1284-1290
407. Mitrou PN, Kipnis V, Thiebaut AC, Reedy J, Subar AF, Wirfalt E, Flood A, Mouw T, Hollenbeck AR, Leitzmann MF, Schatzkin A. Mediterranean dietary pattern and prediction of all-cause mortality in a us population: Results from the nih-aarp diet and health study. *Archives of internal medicine*. 2007;167:2461-2468

408. Tognon G, Nilsson LM, Lissner L, Johansson I, Hallmans G, Lindahl B, Winkvist A. The mediterranean diet score and mortality are inversely associated in adults living in the subarctic region. *The Journal of nutrition*. 2012;142:1547-1553
409. Bifulco M. Mediterranean diet: The missing link between gut microbiota and inflammatory diseases. *European journal of clinical nutrition*. 2015
410. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, Biddinger SB, Dutton RJ, Turnbaugh PJ. Diet rapidly and reproducibly alters the human gut microbiome. *Nature*. 2014;505:559-563
411. Del Chierico F, Vernocchi P, Dallapiccola B, Putignani L. Mediterranean diet and health: Food effects on gut microbiota and disease control. *International journal of molecular sciences*. 2014;15:11678-11699
412. Panagiotakos DB, Georgousopoulou EN, Pitsavos C, Chrysohoou C, Skoumas I, Pitaraki E, Georgiopoulou GA, Ntertimani M, Christou A, Stefanadis C. Exploring the path of mediterranean diet on 10-year incidence of cardiovascular disease: The attica study (2002-2012). *Nutrition, metabolism, and cardiovascular diseases : NMCD*. 2015;25:327-335
413. Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, Gomez-Gracia E, Ruiz-Gutierrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pinto X, Basora J, Munoz MA, Sorli JV, Martinez JA, Martinez-Gonzalez MA. Primary prevention of cardiovascular disease with a mediterranean diet. *The New England journal of medicine*. 2013;368:1279-1290
414. Stricker MD, Onland-Moret NC, Boer JM, van der Schouw YT, Verschuren WM, May AM, Peeters PH, Beulens JW. Dietary patterns derived from principal component- and k-means cluster analysis: Long-term association with coronary heart disease and stroke. *Nutrition, metabolism, and cardiovascular diseases : NMCD*. 2013;23:250-256
415. Iqbal R, Anand S, Ounpuu S, Islam S, Zhang X, Rangarajan S, Chifamba J, Al-Hinai A, Keltai M, Yusuf S. Dietary patterns and the risk of acute myocardial infarction in 52 countries: Results of the interheart study. *Circulation*. 2008;118:1929-1937
416. Shikany JM, Safford MM, Newby PK, Durant RW, Brown TM, Judd SE. Southern dietary pattern is associated with hazard of acute coronary heart disease in the reasons for geographic and racial differences in stroke (regards) study. *Circulation*. 2015;132:804-814
417. Hu FB, Rimm EB, Stampfer MJ, Ascherio A, Spiegelman D, Willett WC. Prospective study of major dietary patterns and risk of coronary heart disease in men. *The American journal of clinical nutrition*. 2000;72:912-921
418. Fung TT, Willett WC, Stampfer MJ, Manson JE, Hu FB. Dietary patterns and the risk of coronary heart disease in women. *Archives of internal medicine*. 2001;161:1857-1862
419. Judd SE, Gutierrez OM, Newby PK, Howard G, Howard VJ, Locher JL, Kissela BM, Shikany JM. Dietary patterns are associated with incident stroke and contribute to excess risk of stroke in black americans. *Stroke; a journal of cerebral circulation*. 2013;44:3305-3311
420. Guo J, Li W, Wang Y, Chen T, Teo K, Liu LS, Yusuf S. Influence of dietary patterns on the risk of acute myocardial infarction in china population: The interheart china study. *Chinese medical journal*. 2013;126:464-470
421. Guallar-Castillon P, Rodriguez-Artalejo F, Lopez-Garcia E, Leon-Munoz LM, Amiano P, Ardanaz E, Arriola L, Barricarte A, Buckland G, Chirlaque MD, Dorronsoro M, Huerta JM, Larranaga N, Marin P, Martinez C, Molina E, Navarro C, Quiros JR,

- Rodriguez L, Sanchez MJ, Gonzalez CA, Moreno-Iribas C. Consumption of fried foods and risk of coronary heart disease: Spanish cohort of the european prospective investigation into cancer and nutrition study. *BMJ*. 2012;344:e363
422. Maruyama K, Iso H, Date C, Kikuchi S, Watanabe Y, Wada Y, Inaba Y, Tamakoshi A. Dietary patterns and risk of cardiovascular deaths among middle-aged japanese: Jacc study. *Nutrition, metabolism, and cardiovascular diseases : NMCD*. 2013;23:519-527
423. Brunner EJ, Mosdol A, Witte DR, Martikainen P, Stafford M, Shipley MJ, Marmot MG. Dietary patterns and 15-y risks of major coronary events, diabetes, and mortality. *The American journal of clinical nutrition*. 2008;87:1414-1421
424. Martinez-Ortiz JA, Fung TT, Baylin A, Hu FB, Campos H. Dietary patterns and risk of nonfatal acute myocardial infarction in costa rican adults. *European journal of clinical nutrition*. 2006;60:770-777
425. Osler M, Helms Andreasen A, Heitmann B, Hoidrup S, Gerdes U, Mørch Jørgensen L, Schroll M. Food intake patterns and risk of coronary heart disease: A prospective cohort study examining the use of traditional scoring techniques. *European journal of clinical nutrition*. 2002;56:568-574
426. Bhatt H, Safford M, Glasser S. Coronary heart disease risk factors and outcomes in the twenty-first century: Findings from the reasons for geographic and racial differences in stroke (regards) study. *Current hypertension reports*. 2015;17:541
427. Muntner P, Gutierrez OM, Zhao H, Fox CS, Wright NC, Curtis JR, McClellan W, Wang H, Kilgore M, Warnock DG, Bowling CB. Validation study of medicare claims to identify older us adults with ckd using the reasons for geographic and racial differences in stroke (regards) study. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2015;65:249-258
428. Roberts A. Risk factors: Insights from the regards study. *Nature reviews. Cardiology*. 2014;11:3
429. Vareiro D, Bach-Faig A, Raido Quintana B, Bertomeu I, Buckland G, Vaz de Almeida MD, Serra-Majem L. Availability of mediterranean and non-mediterranean foods during the last four decades: Comparison of several geographical areas. *Public health nutrition*. 2009;12:1667-1675
430. Regmi A, Ballenger N, Putnam J. Globalisation and income growth promote the mediterranean diet. *Public health nutrition*. 2004;7:977-983
431. Trichopoulou A, Naska A, Costacou T. Disparities in food habits across europe. *The Proceedings of the Nutrition Society*. 2002;61:553-558
432. Hupkens CL, Knibbe RA, Drop MJ. Alcohol consumption in the european community: Uniformity and diversity in drinking patterns. *Addiction*. 1993;88:1391-1404
433. Mackenbach JP, Kunst AE, Cavelaars AE, Groenhouf F, Geurts JJ. Socioeconomic inequalities in morbidity and mortality in western europe. The eu working group on socioeconomic inequalities in health. *Lancet*. 1997;349:1655-1659
434. Kunst AE, del Rios M, Groenhouf F, Mackenbach JP. Socioeconomic inequalities in stroke mortality among middle-aged men: An international overview. European union working group on socioeconomic inequalities in health. *Stroke; a journal of cerebral circulation*. 1998;29:2285-2291
435. van Rossum CT, van de Mheen H, Breteler MM, Grobbee DE, Mackenbach JP. Socioeconomic differences in stroke among dutch elderly women: The rotterdam study. *Stroke; a journal of cerebral circulation*. 1999;30:357-362
436. Franks PJ, Adamson C, Bulpitt PF, Bulpitt CJ. Stroke death and unemployment in london. *Journal of epidemiology and community health*. 1991;45:16-18

437. Maheswaran R, Elliott P, Strachan DP. Socioeconomic deprivation, ethnicity, and stroke mortality in greater london and south east england. *Journal of epidemiology and community health*. 1997;51:127-131
438. Freisling H, Fahey MT, Moskal A, Ocke MC, Ferrari P, Jenab M, Norat T, Naska A, Welch AA, Navarro C, Schulz M, Wirfalt E, Casagrande C, Amiano P, Ardanaz E, Parr C, Engeset D, Grioni S, Sera F, Bueno-de-Mesquita B, van der Schouw YT, Touvier M, Boutron-Ruault MC, Halkjaer J, Dahm CC, Khaw KT, Crowe F, Linseisen J, Kroger J, Huybrechts I, Deharveng G, Manjer J, Agren A, Trichopoulou A, Tsiotas K, Riboli E, Bingham S, Slimani N. Region-specific nutrient intake patterns exhibit a geographical gradient within and between european countries. *The Journal of nutrition*. 2010;140:1280-1286
439. Slimani N, Fahey M, Welch AA, Wirfalt E, Stripp C, Bergstrom E, Linseisen J, Schulze MB, Bamia C, Chloptsios Y, Veglia F, Panico S, Bueno-de-Mesquita HB, Ocke MC, Brustad M, Lund E, Gonzalez CA, Barcos A, Berglund G, Winkvist A, Mulligan A, Appleby P, Overvad K, Tjonneland A, Clavel-Chapelon F, Kesse E, Ferrari P, Van Staveren WA, Riboli E. Diversity of dietary patterns observed in the european prospective investigation into cancer and nutrition (epic) project. *Public health nutrition*. 2002;5:1311-1328
440. Naska A, Fouskakis D, Oikonomou E, Almeida MD, Berg MA, Gedrich K, Moreiras O, Nelson M, Trygg K, Turrini A, Remaut AM, Volatier JL, Trichopoulou A. Dietary patterns and their socio-demographic determinants in 10 european countries: Data from the dafne databank. *European journal of clinical nutrition*. 2006;60:181-190
441. Jenab M, Salvini S, van Gils CH, Brustad M, Shakya-Shrestha S, Buijsse B, Verhagen H, Touvier M, Biessy C, Wallstrom P, Bouckaert K, Lund E, Waaseth M, Roswall N, Joensen AM, Linseisen J, Boeing H, Vasilopoulou E, Dilis V, Sieri S, Sacerdote C, Ferrari P, Manjer J, Nilsson S, Welch AA, Travis R, Boutron-Ruault MC, Niravong M, Bueno-de-Mesquita HB, van der Schouw YT, Tormo MJ, Barricarte A, Riboli E, Bingham S, Slimani N. Dietary intakes of retinol, beta-carotene, vitamin d and vitamin e in the european prospective investigation into cancer and nutrition cohort. *European journal of clinical nutrition*. 2009;63 Suppl 4:S150-178
442. Cust AE, Skilton MR, van Bakel MM, Halkjaer J, Olsen A, Agnoli C, Psaltopoulou T, Buurma E, Sonestedt E, Chirlaque MD, Rinaldi S, Tjonneland A, Jensen MK, Clavel-Chapelon F, Boutron-Ruault MC, Kaaks R, Nothlings U, Chloptsios Y, Zylis D, Mattiello A, Caini S, Ocke MC, van der Schouw YT, Skeie G, Parr CL, Molina-Montes E, Manjer J, Johansson I, McTaggart A, Key TJ, Bingham S, Riboli E, Slimani N. Total dietary carbohydrate, sugar, starch and fibre intakes in the european prospective investigation into cancer and nutrition. *European journal of clinical nutrition*. 2009;63 Suppl 4:S37-60
443. Linseisen J, Welch AA, Ocke M, Amiano P, Agnoli C, Ferrari P, Sonestedt E, Chajes V, Bueno-de-Mesquita HB, Kaaks R, Weikert C, Dorransoro M, Rodriguez L, Ermini I, Mattiello A, van der Schouw YT, Manjer J, Nilsson S, Jenab M, Lund E, Brustad M, Halkjaer J, Jakobsen MU, Khaw KT, Crowe F, Georgila C, Misirli G, Niravong M, Touvier M, Bingham S, Riboli E, Slimani N. Dietary fat intake in the european prospective investigation into cancer and nutrition: Results from the 24-h dietary recalls. *European journal of clinical nutrition*. 2009;63 Suppl 4:S61-80
444. Slimani N, Deharveng G, Southgate DA, Biessy C, Chajes V, van Bakel MM, Boutron-Ruault MC, McTaggart A, Grioni S, Verkaik-Kloosterman J, Huybrechts I, Amiano P, Jenab M, Vignat J, Bouckaert K, Casagrande C, Ferrari P, Zourna P, Trichopoulou A, Wirfalt E, Johansson G, Rohrmann S, Illner AK, Barricarte A,

- Rodriguez L, Touvier M, Niravong M, Mulligan A, Crowe F, Ocke MC, van der Schouw YT, Bendinelli B, Lauria C, Brustad M, Hjartaker A, Tjonneland A, Jensen AM, Riboli E, Bingham S. Contribution of highly industrially processed foods to the nutrient intakes and patterns of middle-aged populations in the european prospective investigation into cancer and nutrition study. *European journal of clinical nutrition*. 2009;63 Suppl 4:S206-225
445. Jiang R, Jacobs DR, Jr., Mayer-Davis E, Szklo M, Herrington D, Jenny NS, Kronmal R, Barr RG. Nut and seed consumption and inflammatory markers in the multi-ethnic study of atherosclerosis. *American journal of epidemiology*. 2006;163:222-231
446. Dell'Agli M, Fagnani R, Mitro N, Scurati S, Masciadri M, Mussoni L, Galli GV, Bosisio E, Crestani M, De Fabiani E, Tremoli E, Caruso D. Minor components of olive oil modulate proatherogenic adhesion molecules involved in endothelial activation. *Journal of agricultural and food chemistry*. 2006;54:3259-3264
447. Fito M, Cladellas M, de la Torre R, Marti J, Munoz D, Schroder H, Alcantara M, Pujadas-Bastardes M, Marrugat J, Lopez-Sabater MC, Bruguera J, Covas MI. Anti-inflammatory effect of virgin olive oil in stable coronary disease patients: A randomized, crossover, controlled trial. *European journal of clinical nutrition*. 2008;62:570-574
448. Cortes B, Nunez I, Cofan M, Gilabert R, Perez-Heras A, Casals E, Deulofeu R, Ros E. Acute effects of high-fat meals enriched with walnuts or olive oil on postprandial endothelial function. *Journal of the American College of Cardiology*. 2006;48:1666-1671
449. Carluccio MA, Siculella L, Ancora MA, Massaro M, Scoditti E, Storelli C, Visioli F, Distante A, De Caterina R. Olive oil and red wine antioxidant polyphenols inhibit endothelial activation: Antiatherogenic properties of mediterranean diet phytochemicals. *Arteriosclerosis, thrombosis, and vascular biology*. 2003;23:622-629
450. Ros E, Nunez I, Perez-Heras A, Serra M, Gilabert R, Casals E, Deulofeu R. A walnut diet improves endothelial function in hypercholesterolemic subjects: A randomized crossover trial. *Circulation*. 2004;109:1609-1614
451. Salas-Salvado J, Garcia-Arellano A, Estruch R, Marquez-Sandoval F, Corella D, Fiol M, Gomez-Gracia E, Vinales E, Aros F, Herrera C, Lahoz C, Lapetra J, Perona JS, Munoz-Aguado D, Martinez-Gonzalez MA, Ros E. Components of the mediterranean-type food pattern and serum inflammatory markers among patients at high risk for cardiovascular disease. *European journal of clinical nutrition*. 2008;62:651-659
452. Chrysohoou C, Panagiotakos DB, Pitsavos C, Das UN, Stefanadis C. Adherence to the mediterranean diet attenuates inflammation and coagulation process in healthy adults: The attica study. *Journal of the American College of Cardiology*. 2004;44:152-158
453. Fung TT, McCullough ML, Newby PK, Manson JE, Meigs JB, Rifai N, Willett WC, Hu FB. Diet-quality scores and plasma concentrations of markers of inflammation and endothelial dysfunction. *The American journal of clinical nutrition*. 2005;82:163-173
454. Kouris-Blazos A, Gnardellis C, Wahlqvist ML, Trichopoulos D, Lukito W, Trichopoulou A. Are the advantages of the mediterranean diet transferable to other populations? A cohort study in melbourne, australia. *The British journal of nutrition*. 1999;82:57-61
455. Mena MP, Sacanella E, Vazquez-Agell M, Morales M, Fito M, Escoda R, Serrano-Martinez M, Salas-Salvado J, Benages N, Casas R, Lamuela-Raventos RM, Masanes



- F, Ros E, Estruch R. Inhibition of circulating immune cell activation: A molecular antiinflammatory effect of the mediterranean diet. *The American journal of clinical nutrition*. 2009;89:248-256
456. Estruch R. Anti-inflammatory effects of the mediterranean diet: The experience of the predimed study. *The Proceedings of the Nutrition Society*. 2010;69:333-340
457. Davis L, Stonehouse W, Loots du T, Mukuddem-Petersen J, van der Westhuizen FH, Hanekom SM, Jerling JC. The effects of high walnut and cashew nut diets on the antioxidant status of subjects with metabolic syndrome. *European journal of nutrition*. 2007;46:155-164
458. Alvarez P, Alvarado C, Mathieu F, Jimenez L, De la Fuente M. Diet supplementation for 5 weeks with polyphenol-rich cereals improves several functions and the redox state of mouse leucocytes. *European journal of nutrition*. 2006;45:428-438
459. Fang YZ, Yang S, Wu G. Free radicals, antioxidants, and nutrition. *Nutrition*. 2002;18:872-879
460. Fico A, Paglialunga F, Cigliano L, Abrescia P, Verde P, Martini G, Iaccarino I, Filosa S. Glucose-6-phosphate dehydrogenase plays a crucial role in protection from redox-stress-induced apoptosis. *Cell death and differentiation*. 2004;11:823-831
461. Rebrin I, Zicker S, Wedekind KJ, Paetau-Robinson I, Packer L, Sohal RS. Effect of antioxidant-enriched diets on glutathione redox status in tissue homogenates and mitochondria of the senescence-accelerated mouse. *Free Radic Biol Med*. 2005;39:549-557
462. Stachowska E, Wesolowska T, Olszewska M, Safranow K, Millo B, Domanski L, Jakubowska K, Ciechanowski K, Chlubek D. Elements of mediterranean diet improve oxidative status in blood of kidney graft recipients. *The British journal of nutrition*. 2005;93:345-352
463. Ambring A, Friberg P, Axelsen M, Laffrenzen M, Taskinen MR, Basu S, Johansson M. Effects of a mediterranean-inspired diet on blood lipids, vascular function and oxidative stress in healthy subjects. *Clin Sci (Lond)*. 2004;106:519-525
464. Hagfors L, Leanderson P, Skoldstam L, Andersson J, Johansson G. Antioxidant intake, plasma antioxidants and oxidative stress in a randomized, controlled, parallel, mediterranean dietary intervention study on patients with rheumatoid arthritis. *Nutrition journal*. 2003;2:5
465. Leighton F, Cuevas A, Guasch V, Perez DD, Strobel P, San Martin A, Urzua U, Diez MS, Foncea R, Castillo O, Mizon C, Espinoza MA, Urquiaga I, Rozowski J, Maiz A, Germain A. Plasma polyphenols and antioxidants, oxidative DNA damage and endothelial function in a diet and wine intervention study in humans. *Drugs under experimental and clinical research*. 1999;25:133-141
466. Girolì M, Laguzzi F, Amato M, Risé P, Vigo L, Bonomi A, Veglia F, Werba J, Tremoli E. Determinants of the fatty acid profile in patients with and without coronary heart disease. *JSM Nutr Disord*. 2017;1:1005
467. Keys A, Keys MH. *Eat well and stay well*. . Doubleday N.Y.; 1959
468. Keys A, Keys MH. *How to eat well and stay well the mediterranean way*. . Doubleday, N.Y.; 1975.
469. Yates LB, Djousse L, Kurth T, Buring JE, Gaziano JM. Exceptional longevity in men: Modifiable factors associated with survival and function to age 90 years. *Archives of internal medicine*. 2008;168:284-290
470. Beckman KB, Ames BN. The free radical theory of aging matures. *Physiological reviews*. 1998;78:547-581

471. Giugliano D, Ceriello A, Esposito K. The effects of diet on inflammation: Emphasis on the metabolic syndrome. *Journal of the American College of Cardiology*. 2006;48:677-685